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Abstract 
Hamza Mohammad Ali Abumansour 
Quantitative pharmacoproteomics investigation of anti-cancer drugs in mouse 
Development and optimisation of proteomics workflows for evaluating the 
effect of anti-cancer drugs on mouse liver 
Keywords: pharmacoproteomics, anti-cancer drugs, shotgun, cytochrome 
P450, mass spectrometry, drug toxicity, mouse liver, drug-induced liver injury, 
pheromone  
Minimizing anti-cancer drug toxicity is a major challenge for the 
pharmaceutical industry. Toxicity is most frequently due to either the direct 
interaction of the drug on previously unidentified targets or its conversion to 
metabolites by drug metabolizing enzymes (e.g. CYP450 enzymes) that cause 
cellular, tissue or organ damage. Pharmacoproteomics is beginning to take a 
central role in studying changes in protein expression corresponding to drug 
administration, the results of which, inform about the mode of action, toxicity, 
and resistance in pre-clinical and clinical stages of drug development. The 
main aim of this research is to apply comparative proteomics studies on livers 
from male and female mice xenograft models treated with major anti-cancer 
drugs (5-flourouracil, paclitaxel, cisplatin, and doxorubicin) and CYP inducer, 
TCPOBOP, to investigate their effect on protein expression profiles 
(proteome). Within this thesis, an attention is paid to optimise a highly 
validated proteomics workflow for biomarker identification. 
Proteins were extracted from liver microsomes of mice treated in two separate 
sets; Set A – male (5-fluoruracil, doxorubicin, cisplatin and untreated) or Set B 
– female (5-fluoruracil, paclitaxel, TCPOBOP and untreated) using cryo-
pulverization and sonication method. The extracts were digested with trypsin 
  ii 
and the resulting peptides labelled with 4-plex iTRAQ reagents. The labelled 
peptides were subjected for separation in two-dimensions by iso-electric 
focusing (IEF) and RP-HPLC techniques before analysis by mass 
spectrometry and database searching for protein identification. 
Set A and Set B resulted in identification and quantification of 1146 and 1743 
proteins, respectively. Moreover, Set A and Set B recovered 26 and 34 
cytochrome P450 isoforms, respectively. The microsomal changes after drug 
treatments were quite similar. However, more changes were observed in the 
male set. Up-regulation of MUPs showed the greatest distinction in the protein 
expression patterns in the treated samples comparing to the untreated 
controls. In Set A, 5-fluoruracil and cisplatin increased the expression of three 
isoforms (MUP1, 2, and 6), whereas doxorubicin has increased the expression 
of four isoforms (MUP1, 2, 3, and 6). On the other side, only TCPOBOP in Set 
B has increased the expression of two isoforms (MUP1 and 6). 
Our findings showed that the expression of MUP, normally involved in binding 
and excretion of pheromones, have drug- and sex-specific differences. The 
mechanism and significance of MUP up-regulation are ambiguous. Therefore, 
the impact of each therapeutic agent on MUP and xenobiotic enzymes will be 
discussed. 
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Chapter one: General introduction 
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1 General introduction 
1.1 Scope of pharmacology 
In general terms, pharmacology is a scientific field that plays a crucial role in 
linking various disciplines of biomedical sciences such as; biochemistry, cell 
biology, physiology, pathology, and genetics together in order to study the 
effects of the drug on living organism (Rang et al., 2014). It’s a basic science 
for medicine as well as for pharmacy, nursing, dentistry, and veterinary 
medicine in the study of drugs. According to the US FDA, a drug is defined as 
a chemical substance which has a physiological effect intended for use in 
diagnosis, cure, mitigation, treatment, or prevention of disease (Li, 2015). 
More so, a World Health Organisation scientific group defined the drug as “any 
substance or product that is used or intended to be used to modify or explore 
the physiological systems or pathological states for the benefit of recipient”. 
In spite of the various general definitions for pharmacology, pharmacological 
studies aim to deeply understand the mechanisms by which drugs interact with 
human systems to enable the rational use of pharmacological agents for 
treatment and diagnosis of disease (Brenner and Stevens, 2013). In other 
words, pharmacology looks at every aspect of the relationship of the drug with 
the body, starting from the time that a drug enters the body to the point of its 
excretion. This relationship is covered by the means of two important and 
interesting areas of pharmacology; pharmacokinetics and pharmacodynamics. 
Pharmacokinetics involves drug concentration changes over time in relation to 
the dose of the drug in one or more different parts of the body as a result of 
drug absorption, distribution, metabolism or excretion. On the other hand, 
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pharmacodynamics involves what the drug does to the body once it reaches 
its target and the consequential biological effects produced as a result of the 
interaction. However, as a distinctive science, pharmacology can be studied 
at all levels, starting from the molecules in the cell to the organ to the whole 
body. Genomics and proteomics are new approaches in pharmacology that 
can help in developing personalized medicine by exploring the character of 
genetic variability. Pharmacology can be further subdivided into: 
chemotherapy, pharmacogenomics, pharmacoeconomics, 
neuropharmacology, pharmacoepidemiology, and clinical pharmacology, as 
well as toxicology (Figure 1.1). 
A drug exerts its action once binds to its target site, and to achieve that, 
typically, the drug should first enter the body and distribute via the bloodstream 
to reach the target site. After that, the drug is eventually eliminated from the 
body after being modified/degraded by a set of specific metabolizing enzymes, 
where the metabolism process refers to “a chemical or structural 
biotransformation of endogenous and/or xenobiotics compounds like drugs”. 
Indeed, defined metabolizing enzymes are responsible for changing drugs into 
more water-soluble metabolites, thereby facilitating their excretion through 
urine or bile (Ioannides, 2008). However, some drugs are metabolised before 
they exert their action, others are metabolised subsequently after exerting their 
action, and still other drugs are not subjected to any of the metabolising 
processes.  
For those being metabolised, the resultant products can be either; inactive or 
more active than the parent drug in therapeutic activity or toxic. However, 
some drugs are designed to be inactive when being administrated to the 
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human body, where they are metabolised into active metabolites producing 
the desired therapeutic effect and are called prodrugs.  
 
 
 
 
 
 
 
 
Figure 1-1. Major branches of pharmacology. Pharmacotherapeutics concerns 
studying drug’s pharmacodynamics (systemic and cellular effects) and 
pharmacokinetic (absorption, distribution, metabolism, and excretion) properties. 
Systematic pharmacology such as; neuro-, cardio-, immuno- and other 
pharmacology. Clinical pharmacology concerns the aspects of drug efficacy and 
safety.      
 
The liver is the primary organ in the body responsible for the metabolism of 
endogenous and exogenous compounds via a large group of hepatic 
enzymes, collectively referred to as drug metabolizing enzymes (DMEs). 
DMEs are involved in the process of modifying a wide variety of exogenous 
(e.g. pharmaceutical agents, chemical carcinogens, lipophilic xenobiotics) and 
endogenous (e.g. steroids, fatty acids, prostaglandins, vitamin D3) molecules 
that are biologically active (Pelkonen et al., 2008). Generally, drug 
biotransformation reactions can be divided into two main phases (Phase I and 
Pharmacology 
Molecular 
pharmacology 
Chemotherapy 
Toxicology 
Clinical pharmacology 
Pharmacotherapeutics 
(PK/PD) 
Systematic 
pharmacology 
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Phase II) and each phase is accomplished by a unique set of metabolic 
enzymes. 
Cytochrome P450 family (CYP450) is the most significant family that belongs 
to Phase I family and is responsible for metabolizing more than 60% of 
clinically used drugs, resulting in polar metabolites that can be excreted in 
urine or undergo further conjugation reactions in Phase II (Kenaan et al., 
2010). However, some drugs might undergo either phase I only or just phase 
II metabolism pathway, but ordinarily, the drug undergoes phase I and then 
phase II sequentially. 
The level of CYP450 enzymes controls the rate at which many drugs are 
metabolised. They have limited capacity to metabolise drugs, so they can 
become overloaded when a high dose of the drug is given. Furthermore, many 
substances (e.g. drugs and foods) may affect the CYP450 enzymes 
expression level or activity. If these substances reduce the ability of these 
enzymes to metabolise a drug, then that drug's effects (including side effects) 
will increase. On the other hand, if the substances induce the ability of the 
enzymes to metabolise a drug, the drug's effects will decrease (Lim et al., 
2013). 
In conclusion, drug metabolizing enzymes activity may result in:  
(i) Bioactivation of inactive drug into reactive metabolites (positive 
activation, conversion of prodrug to drug). 
(ii) Potentiating the activity of drug by giving a highly reactive 
intermediate (metabolic activation). 
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(iii) Conversion of an active drug into equally active metabolites (no 
change activation). 
(iv) Inactivation of active drugs into inactive metabolite (negative 
activation). 
Examples of these biological conversions of Phases I and II are shown in 
Table 1.1. 
In the pharmaceutical “pipeline” of new drug development, studying DMEs is 
a cornerstone in the evaluation of drug efficacy and safety in experimental 
animals and humans. DMEs are important biomarkers in the occurrence of a 
number of drug interactions that may result in drug toxicities, pharmacological 
effect failure, and adverse drug reactions. Identifying whether a drug has the 
potential for inhibiting or inducing other DMEs, can minimise or even prevent 
clinically significant interactions from occurring (Cascorbi, 2012). 
Table 1-1. Examples of the different mechanism of Phases I and II metabolizing 
processes. 
 
 Sex-related differences are another potential issue, which highlights the 
importance of studying DMEs, in particular, the CYP450 family. Recent studies 
showed that the number of pharmacological responses that are sex-specific is 
Biological process Example 
Positive activation 
Conversion of cyclophosphamide to the pharmacologically 
active form (4-hydroxycyclophosphamide). 
Metabolic activation 
Production of N-acetyl-benzoquinonimine, the product of 
paracetamol metabolism. 
No change-activation Conversion of digitoxin to digoxin. 
Negative activation Inactivation of phenytoin to p-hydroxy-phenytoin. 
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more common than previously thought, which includes pharmacokinetics and 
pharmacodynamics, with more emphasis on the former. These differences led 
to individual variations in the toxicity and efficacy of the drug. However, the 
main consequence of sex-dependant pharmacokinetics is the sex-based 
variations in drug metabolism, which may be due to their hormonal effects on 
physiological processes. Concerning the differences in pharmacokinetics, 
Phase I and II subfamily enzymes exhibited marked sex variations in in vitro 
and animal studies. Moreover, the sex variation is not only at the enzyme 
expression level but also at the activity level of metabolizing enzymes (Chang 
et al., 2011). For example, CYP3A4 which is responsible for the metabolism 
of about 50% of clinically used drugs from almost all therapeutic categories 
including anti-cancer drugs showed significantly higher activity and expression 
level in female than the male of human liver (Lamba et al., 2010). 
The mechanistic basis for these differences has not been clarified yet, recent 
studies indicated that this may be due to the greater level of hormone-
dependent activation and nuclear translocation of hepatocyte nuclear factor-
4α (HNF-4α) and pregnane X receptor in female hepatocytes compared to 
male hepatocytes (Zanger and Schwab, 2013, Thangavel et al., 2011). On the 
other hand, there are some other factors that can lead to metabolizing 
enzymes variation, which may include but not limited to, exposure to 
xenobiotics, regulation by cytokines, hormones, during disease states, and 
age (Zanger and Schwab, 2013). 
Drugs have been investigated intensely for their effects on CYP450 enzymes 
expression and activity. It has been found that drugs, when administered 
internally, can modulate the expression of CYP450 enzymes and 
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subsequently, the activity of these enzymes through either inhibiting or 
inducing them. Enzyme inhibition signifies a decrease in the enzyme activity 
as result of the direct binding between drug and particular CYP enzyme either; 
reversibly (non-mechanism-based binding) or irreversibly (mechanism-based 
binding) (Pelkonen et al., 2008). Generally, the reversible inhibition can be 
competitive, non-competitive or uncompetitive. However, binding of the drug 
to a particular CYP450 enzyme to inhibit its activity is usually an artefact and 
occurs competitively (Ring et al., 2014). On the other hand, induction is to 
increase the amount of specific CYP450 enzymes (synthesis) and 
subsequently speed up the rate of metabolic elimination of drug itself or other 
concomitant drugs (Martikainen, 2012).  
Studying the changes in the expression and activity of membranous proteins 
such as CYP450 enzymes as a result of drug administration or disease status 
remains the main challenge. The low abundance of the CYP450 enzymes, 
their location, complex family profile, structure and physiochemical properties 
are all factors that provoke such challenges in this area of research (Donoghue 
et al., 2008, Golizeh and Sleno, 2013). 
Recently developed proteomics approaches have significantly increased the 
efficiency and applicability of mapping drug-protein interactions. The scope of 
proteomics is not limited to a list of proteins, but rather profiles every protein 
expressed in a target cell or tissue at any time in response to any stimulus 
such as exposure to a drug. Therefore, proteomics has been used in both, in 
vivo and in vitro studies for drug efficacy and safety (Barbosa et al., 2012).  
Pharmacoproteomics is a branch that deals with the application of proteomics 
in the field of drug discovery and development, in addition to the assessment 
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of drug administration (D’Alessandro and Zolla, 2010). It is known as a branch 
of proteomics, rather than a branch of pharmacology. It is used to understand 
the efficacious effects as well as side effects of drugs on organ proteome 
(D’Alessandro and Zolla, 2010). However, the proteome is defined as the 
complete set of proteins produced by a particular cell, tissue, or organ that 
might be affected as a result of drugs administration, pathophysiological 
condition or other (Bateson et al., 2011). Pharmacoproteomics aims to 
accelerate the drug development process, reduce costs, and provide tools for 
better management of diseases through understanding the effects of 
established drugs on protein expression in biological systems. In order to 
achieve that, proteomics in drug studies must be able to: (i) verify new drug 
targets, (ii) reveal the exact molecular mechanism of drug action including 
activity and toxicity, (iii) develop protein biomarkers and assays for 
assessment of drug efficacy, and (iv) identify consequences of toxicity for both 
preclinical and clinical applications (Lee et al., 2011).  
The liver proteome has been analysed in various comparative 
pharmacoproteomics studies to investigate whether drugs are able to change 
protein expression, particularly xenobiotic enzymes, and subsequently cause 
liver toxicity. Since 70% of blood supply reaches it by the portal vein, carrying 
the ingested xenobiotic from stomach and intestine, liver is a potential target 
organ for drug and toxin accumulation (ColemanM.D, 2010). Drug toxicity in 
the liver can be emphasized by drug-induced liver injury (DILI). Indeed, DILI is 
a serious matter for new drug candidates as well as for already marketed 
drugs.  
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1.2 Cancer 
The term cancer refers to a unique set of diseases in which cells divide 
uncontrollably by disregarding the normal rules of cells division, leading to the 
invasion of surrounding tissues and metastasizing to distant sites of the body, 
causing the death of the host at the end stage (Weinberg, 2013). Normally, 
cells grow and divide in a controlled and orderly way to produce more cells 
when the body needs them. However, sometimes cells overcome the rules of 
the division to become abnormal and keep dividing to form more cells without 
control or order, creating a mass of excess tissue called a tumour. Tumours 
can be benign or malignant. Contrary to the benign tumour, malignant can 
spread to surrounding cells and other parts of the body (metastasis) via the 
bloodstream or lymphatic system (Ruddon, 2007). 
Cancer treatment can take numerous approaches including surgery, 
radiotherapy, photodynamic therapy, chemotherapy, immunotherapy, and 
hormone therapy or a combination (e.g. radiosurgery). Cancer treatment 
strategy depends mainly on the nature of cancer and how far it has progressed 
(Makropoulou, 2016). 
Chemotherapy is a subdivision of pharmacology, which deals with the effects 
of drugs used to kill neoplastic cells. In oncology, chemotherapy is a preferred 
option due to the direct capability of targeting tumour cell death by necrosis or 
apoptosis, vascular damage leading to tissue ischemia and resultant target 
cell death, or immune modulation, or a combination of these (Ricci and Zong, 
2006). Anti-cancer drugs (ACDs) comprise a number of chemical agents that 
are used to halt the progression of cancer by interfering with either cell division 
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or DNA synthesis, usually causing severe side effects (Akhdar et al., 2012). 
Based on the mechanism of action, the traditional anti-cancer agents have 
been categorized into metalating-intercalating agents (cisplatin, 
cyclophosphamide), antimetabolite (5-fluorouracil, mercaptopurine), 
topoisomerase I inhibitors (topotecan), topoisomerase II inhibitors 
(anthracyclines; doxorubicin), alkaloid (taxol, vincristine), and others (Akhdar 
et al., 2012). 
Contrary to traditional therapies, modern anti-cancer agents have distinctive 
mechanisms of action against one or more pivotal cellular pathways involved 
in the cancer process (Giamas et al., 2010a). Therefore, their selectivity and 
efficacy are enhanced, where toxicity has reduced amongst others. The 
current targeted therapies include; immunotherapy, tyrosine kinase inhibitors, 
hormone therapy, etc. (Widmer et al., 2014). 
Immunotherapy or monoclonal antibody targets a specific host antigen such 
as prostatic acid phosphate (PAP) in prostate cancer by Sipuleucel-T and 
human epidermal growth factor receptor-2 (HER2) in breast cancer by 
trastuzumab (Kantoff et al., 2010, Hudis, 2007). Imatinib is a tyrosine kinase 
inhibitor which blocks the oncogenic signalling cascade causing the cells to 
die (Buchdunger et al., 2002). Other drugs are still in early stages of drug 
development such as drugs affecting histone-modifying enzymes (Giamas et 
al., 2010b, Razak et al., 2011).  
The effects of chemotherapies have been investigated intensively in preclinical 
and clinical phases of drug development on liver models for any possibility of 
drug-protein or drug-drug interactions. Such investigation has been of high 
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interest owing to the aggressive natures of both cancer disease and anti-
cancer drugs. Furthermore, since cancer is a heterogeneous and complex 
disease, it is typically managed with a combination of chemotherapies to 
overcome the problem of resistance. This results in increasing the chance of 
drug-drug interaction and subsequently liver injury. Besides, a number of 
important chemotherapeutic drugs such as cyclophosphamide, ifosfamide, 
tamoxifen or procarbazine are administered as prodrugs and have to be 
activated by defined CYP450 isoform (Preissner et al., 2012). 
1.3 Liver toxicity 
1.3.1 Liver and drug metabolizing enzymes 
The liver is one of the largest organs in the body, it plays an important role in 
different  biological processes such as homeostasis in the body, production of 
various plasma proteins, balancing blood sugar and pH, etc. (He, 2005). In 
pharmacology, the role of the liver is highly significant. It is the main organ in 
the body responsible for metabolizing various endogenous and exogenous 
compounds, even though other organs can participate in the metabolism 
process, such as; lungs, skin, kidney, and the gastrointestinal tract. The liver 
receives about 70% of the blood supply by the portal vein that carries the 
ingested xenobiotics, such as anti-cancer agents, from the stomach and 
intestine. As a result, liver is a potential organ for xenobiotic and toxin 
accumulation (Pelkonen et al., 2008). 
The majority of drugs are metabolised in the liver, particularly in the smooth 
endoplasmic reticulum (ER) of the hepatocytes. Once a drug is absorbed from 
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the GI tract, it may undergo a first-pass or systemic metabolism, where the 
liver or gut wall metabolises a large portion of the drug before it circulates in 
the blood. The first-pass metabolism can dramatically reduce the drug’s 
bioavailability (Gibson and Skett, 2001). 
Drug metabolism process involves a chemical or structural modification of drug 
by DMEs in order to change it into more water-soluble metabolites (Pelkonen 
et al., 2008). Generally, there are two metabolic pathways for drugs 
transformation in the liver: Phase I (oxidation, reduction, and hydrolysis) and 
Phase II (conjugation) (Pelkonen et al., 2008). 
Phase I reactions, which are preferably described as “functionalization 
reactions”, take place through either; introducing a new polar functional group 
like hydroxyl (-OH), amine (-NH2) or carboxylic (-COOH) to the parent drug 
(oxidation); or modifying an existing functional group in order to be more polar 
(reduction); or unmask existing polar functional group (hydrolysis). Resulted 
product is either inactive metabolite that can be easily excreted in urine or 
highly reactive intermediate metabolite that is conjugated with the endogenous 
compound in order to become water soluble (Phase II) (Guengerich and 
Shimada, 1991). Phase I includes different families of enzymes; cytochrome 
P450 (CYP450), flavin-containing monooxygenases (FMO), aldehyde 
dehydrogenases (ALD), monoamine oxidase (MAO), alcohol 
dehydrogenases, NADPH-quinone oxidoreductase (NQO) for quinones 
reduction and other (Puccinelli et al., 2011). 
Phase II metabolizing biotransformation enzymes conjugate highly polar 
endogenous substrate such as; glucuronic acid, sulphuric acid, acetic acid, or 
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glutathione to Phase I products (reactive intermediates), making them soluble 
in water, and thus, easily excreted in urine and/or bile. Sulphation (sulphuric 
acid), glucuronidation (glucuronic acid) and glutathione conjugation are the 
most common classes of phase II metabolism that may occur directly on the 
parent compounds converting them into more hydrophilic conjugates (Jancova 
et al., 2010). Phase II drug metabolizing enzymes include: UDP-
glucuronosyltransferases (UGTs), sulfotransferases (SULTs), N-
acetyltransferases (NATs), glutathione S-transferases (GSTs) and various 
methyltransferases (mainly; thiopurine S-methyl transferase (TPMT) and 
catechol-O-methyl transferase (COMT)) (Jancova et al., 2010). 
1.3.1.1 Cytochrome P450 enzymes 
Cytochrome P450 enzymes (CYP450’s) are examples of mixed-function 
oxidases of Phase I metabolizing enzymes, which have the ability to convert 
most of the drugs and other lipophilic xenobiotics to an inactive form 
(Ioannides, 2008). The functions of these enzymes have been found to be 
associated with initiation or prevention of carcinogenesis. Some CYPs are 
highly polymorphic enzymes that are regulated at various molecular levels. 
(Tamási et al., 2011). The human genome has a total of 115 CYP450 genes, 
among which 57 are putatively active genes and 58 are pseudogenes (Nelson 
et al., 2004). Although CYP450 enzymes in human are found in various tissues 
such as intestine, kidney, heart, lung, brain, adrenal glands, gonads, nasal and 
tracheal mucosa, the highest abundance and the largest number of individual 
CYP450 isoforms are predominantly located in the liver microsomes (Figure 
1.2) (Pelkonen et al., 2008, Ghosh et al., 2010).   
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CYP450 enzymes most commonly undertake oxidation reactions and, to a 
lesser extent; reduction, hydrolysis, hydration and isomerisation reactions 
(Johansson, 2011). Based on the similarity of amino acid sequence, human 
CYP450 enzymes are classified into 18 families with at least 40% sequence 
homology indicated by Arabic numerals (e.g. CYP3), and 44 subfamilies with 
at least 55% amino acid homology indicated by a letter (e.g. CYP3A) followed 
by an Arabic number to identify them individually (e.g. CYP3A4) (Wang et al., 
2008). CYP450s nomenclature and classification have been well described by 
David Nelson [http://drnelson.utmem.edu/CytochromeP450.html]. The 
CYP450 enzyme families 1–3 (2C9, 2C19, 2D6, and 3A4) are responsible for 
about 80% of all Phase I-dependent drug metabolisms as shown in Figure 1.2 
(Pelkonen et al., 2008).  
 
Figure 1-2. The relative abundance of CYP450 enzymes in the liver (pie chart A). 
Around 50 of functionally active CYP enzymes are classified into 18 families, among 
these enzyme isoforms, CYP3A showed the highest abundance. However, CYP 
3A4/5/7 and CYP 2D6 are responsible for metabolism the largest number of clinically 
used drugs (pie chart B). Modified from (Pelkonen et al., 2008, Zanger and Schwab, 
2013).  
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CYP450s oxidation reactions are NADPH-dependent, which enables their 
mono-oxygenase reaction to metabolise drugs (Figure 1.3), through coupling 
of the parent substrate (RH) with the active moiety of the CYP enzyme forming 
an oxidized complex (Fe3+-RH). NADPH oxidoreductase enzyme is a key 
cofactor that is responsible for transferring an electron and then reducing the 
heme of CYP450 (Fe3+) into ferrous (Fe2+). Moreover, and in the presence of 
O2, NADPH- oxidoreductase enzyme is also responsible for the formation of 
(Fe2+-OOH-RH) complex, which subsequently reacts with another proton, 
emitting water and yielding a ferric oxene complex ((FeO)3+-RH). However, 
cytochromeb5 is able to donate an electron and form (Fe2+-OOH-RH) complex. 
Lastly, the ferric oxene extracts a hydrogen atom from RH and hence gives off 
the metabolite ROH, returning the cycle to its starting point (De Montellano, 
2005, Sono et al., 1996). 
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Figure 1-3. The cytochrome P450 catalytic cycle. In this reaction, the active moiety of 
CYP binds with the parent substrate (RH), which results briefly at the beginning in 
donating a proton from RH to the substrate and ROH donates the final hydroxylated 
metabolite. Inducing a polar hydroxyl group (-OH) to the molecule transforms a 
nonpolar substrate into a polar metabolite (De Montellano, 2005). 
 
The expression of CYP isoform is controlled by a unique set of mechanisms 
and factors (Figure 1.4), including genetic polymorphisms, epigenetic and non-
genetic factors such as endogenous hormonal factors, sex, disease status, 
age as well as exposure to drugs and environmental chemicals (Zanger and 
Schwab, 2013). Awareness about the factors that influence the expression 
and activity of CYP450 enzyme is an important prerequisite to predict the 
pharmacokinetic parameters and subsequently the activity and safety profile 
of drugs that undergo metabolism by each particular enzyme. 
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Figure 1-4. Important variability factors influence the expression of a fraction of 
clinically used drugs metabolizing CYP450 isoforms (indicated by bold type). Arrow 
direction indicate the possible direction of influence (↑, increased activity; ↓, 
decreased activity; ↑↓, increased and decreased activity) (Zanger and Schwab, 2013). 
 
Genetic polymorphism of DMEs is the main cause of inter-individual variability 
in drug response since it has been estimated to affect about 20-25% of 
therapeutic drugs used clinically (Ingelman-Sundberg et al., 2007, Eichelbaum 
et al., 2006). However, sex differences have recently become a significant 
factor that can cause a remarkable variation, which is not limited to body 
weight and fat distribution, but also extends to include the liver blood 
transfusion, transporters, and DMEs (Gandhi et al., 2004). 
Pharmacokinetically, sex-based differences consider the variation in process 
of absorption, distribution, metabolism and excretion (ADME). However, 
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metabolism variation is thought to be the major factor that underlies sex 
differences in pharmacokinetics since they affect DMEs expression level in 
both Phases I (CYP450s) and Phase II (UGTs, SULTs, and GSTs) (Waxman 
and Holloway, 2009). Expression of specific individual CYP isoform based on 
sex was noticed in laboratory animal models such as mice, rat, and human. 
An early genomic study involving male and female human livers revealed more 
than 1300 genes, whose mRNA expression is sex-dependent, among these, 
40 genes were linked to ADME functions including: CYP1A2, CYP3A4 and 
CYP7A1 that show a female bias; and CYP3A5, CYP27B1, and UGT2B15 
showing male bias (Zhang et al., 2011). Further experiments, conducted in rat 
and mouse liver models, have resulted in the identification of more than 1000 
genes whose expression is significantly affected by sex (Waxman and 
Holloway, 2009). Proteomics approaches have also been used to involved 
evaluate sex-differences of CYP450 isoforms using rat and human liver 
microsomes (HLM) models (Nisar et al., 2004b, Shrivas et al., 2013a).   
Overall, males of human being show a higher rate of clearance of drugs 
compared to females and therefore, they are less likely to experience adverse 
drug effects. For example, paracetamol clearance rate is 22% higher in the 
former due to the high rate of glucuronidation (Miners et al., 1983). This 
despite some CYP isoforms being expressed in higher amounts or activities in 
females than occurred in males such as; the predominant CYP3A4 and 
CYP2A6 respectively (Zanger and Schwab, 2013). 
Despite the numerous interspecies variations in the expression, activities, and 
inducibility of CYP enzymes, mouse as an experimental model has been 
considered the most similar to human CYP profile (Guengerich, 1997). 
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However, more CYP450 gene superfamilies were sequenced in mouse (102 
genes) as compared to humans (57 genes) (Nelson et al., 2004). Importantly, 
36 orthologous pairs of CYP genes from various families (e.g. 1A, 1B, 2B, 2E, 
2C, 2D, 4B, and CYP27A) were identified as having the potential for similar or 
identical functions in both mice and humans. For instance, the selective 
CYP1A2 inhibitor, furafylline, demonstrated similarities in the inhibition profiles 
of mouse and human liver microsomes, which indicates a corresponding 
CYP1a2-metabolism in the mouse as in human (Bogaards et al., 2000). 
Cytochrome P450 isoform 1a2 and 2e1 in mouse have demonstrated the 
direct and meaningful species extrapolation to human. CYP2E1, for example, 
exists as a single isoform in both human and mouse exhibiting a significant 
similarity of catalytic specificity (Guengerich, 1997). The similarity of CYP1A2 
and CYP2E1 sequence between human and mouse (homologues) are shown 
in Figure 1.5, including the predicted specific-isoform unique peptides of each 
isoform.  
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Figure 1-5. Comparison of human and mouse CYP1A2 (A) and 2E1 (B) isoform 
sequences created by Clustal Omega tool. Predicted unique peptides (highlighted 
with red and green for mouse and human, respectively) were extracted from sequence 
editor (ProteinScape).    
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1.3.2 Drug toxicity in the liver  
Toxicity of drugs is the main reason of drug failing at various stages during 
drug development (clinical trials), regardless whether the drug is active or not. 
Moreover, drug toxicity is also responsible for drug withdrawal from the market 
(Hay et al., 2014). In general drugs might exert their toxicity due to:  
(i) Mechanism-based drug and target interaction ˝on-target˝, for 
example, drugs targeting the p38 MAP kinase in rheumatoid arthritis 
(Hammaker and Firestein, 2010)  
(ii) Unrelated drug-target interaction ˝off-target˝, where drug interacts 
with one or more unintended targets, resulting in adverse effects on 
the function of the organ. The main example on off-target is the 
induction of CYP3A4 and CYP2B6 by phenobarbital (Chu et al., 
2009).  
(iii) Biotransformation of drug into reactive intermediates “bioactivation” 
due to the activity of Phase I enzymes (such as CYP450’s) that are 
capable of attacking cellular macromolecules, such as those 
products of paracetamol metabolism.  
In addition, other reasons include hypersensitivity and immune response 
reaction (such as allergic reactions). For idiosyncratic reactions, it has been 
found that about 35% of known drugs were active against more than one target 
(Paolini et al., 2006).  
Toxicity from drugs or xenobiotics can be manifest in any organ. However, 
because the liver is the major site in the body responsible for the metabolism 
of drugs, it is particularly susceptible to toxic insult. Therefore, liver is a useful 
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organ to provide early indications of drugs toxicity. Drug toxicity may injure the 
liver causing what is known as drug-induced liver injury (DILI). The mechanism 
of DILI is complex and can be as a result of: 
(i) Drug itself (off-target), by affecting the expression level of drugs 
metabolizing enzymes, CYP450’s, through either inducing or suppressing 
them, which may lead to drug-drug interaction.  
(ii) Formation of highly reactive intermediates such as; Reactive oxygen 
species (ROS). Indeed, ROS attacks the cellular macromolecule components 
(DNA, proteins or lipids) causing liver injury (Srivastava et al., 2010, 
Dizdaroglu, 1998).  
DILI can be classified histologically as the following: (i) acute or chronic 
hepatitis/cholestasis, (ii) zonal or non-zonal primary hepatic necrosis, (iii) 
reversible hepatic changes such as steatosis, glycogen accumulation, or 
centrilobular hypertrophy due to CYP450 enzyme induction, (iv) pre-
neoplastic/neoplastic patterns of hepatic injury, (v) mixed histological patterns 
due to a combination of lesions, and (vi) non-specific changes that are 
secondary to other systemic and metabolic diseases (Ramaiah, 2007). 
1.3.2.1 Chemotherapy induces liver toxicity 
Although chemotherapeutic drugs are one of the best choices for killing cancer 
cells, they can target normal cells that are actively growing and dividing, 
causing unpleasant transient side effects such as; nausea, vomiting and hair 
loss (Debatin, 1997). Moreover, chemotherapy drugs may cause reversible 
and irreversible side effects such as liver injury. Chemotherapy-induced liver 
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injury (CILI) can be manifest in the changes of liver parenchyma such as; 
steatosis and chemotherapy induce steatohepatitis (CASH) (Ramadori and 
Cameron, 2010, Fong and Bentrem, 2006). Furthermore, CILI can result in 
chemotherapy treatment failure and culminate in serious liver damage and 
death. CILI may occur due to many causes including the anti-cancer drug itself 
“intrinsic” or for an idiosyncratic reason such as liver fibrosis prior long 
methotrexate administration (Fontana, 2014). However, the formation of ROS 
metabolites is thought to be the leading cause of CILI (Lim et al., 2010). 
Accumulation of toxins, like ROS in the liver, would lead to adding more stress 
on the liver’s filtering function. If toxins accumulate in the body at a higher rate 
than the liver capacity to process them, liver damage will result. Therefore, 
employing advanced laboratory methods such as quantitative proteomics on 
animal models of liver injury induced by chemotherapy can provide a predictive 
insight interpretation about the deleterious effects of chemotherapeutic drugs 
and the influence of DMEs on toxin formation in the liver (Van Summeren et 
al., 2011). 
1.3.3 Proteomics in drug analysis  
Proteomics has been involved in different aspects of drug studies, as the 
protein is the cellular functional unit that implements a response to any stimuli 
such as, drugs administration or environmental xenobiotics. Two major terms 
are contributed to the application of proteomics in drugs investigation: 
Toxicoproteomics and Pharmacoproteomics. 
Toxicoproteomics was first described by Wetmore (Wetmore and Merrick, 
2004), which specifically concerns understanding the undesired effects of 
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xenobiotics. The term “Toxicoproteomics” has been defined as using 
proteomics to identify critical proteins and pathways in biological systems that 
are affected by and respond to the toxic effects of xenobiotics (Ge et al., 2007). 
However, identifying the way that a drug interact with protein is a crucial point 
that may help in determining the mechanism of drug’s action and toxicity (Van 
Summeren et al., 2012). Nevertheless, toxicoproteomics is not limited to drugs 
analysis, as a matter of fact, many studies have been performed concerning 
chemical, metal and environmental toxins in acute or long-term exposures 
(Rabilloud and Lescuyer, 2015). For examples, investigating the molecular 
mechanisms of toxicity from exposure to polyfluorinated compounds using 
different toxicoproteomics approaches and quantitative toxicoproteomics to 
investigate the toxic/carcinogenic effect of the potent carcinogen, 
benzo[a]pyrene, using toxic and sub-toxic doses (Hansmeier et al., 2014, 
Kalkhof et al., 2014).   
On the other hand, pharmacoproteomics is a comprehensive term dealing 
principally with all aspects of drug administration. Thus, the eventual aims of 
pharmacoproteomics study include: (i) identification and verification of drug 
targets, (ii) illustration of efficacy and toxicity mechanism of action of drugs at 
molecular level and (iii) development of protein biomarkers and assay can be 
used for assessment of drug in pre-clinical and clinical stages (Zolla, 2008, 
Hess, 2013). 
In order to understand the molecular mechanisms of drug’s efficacy and 
toxicity, cells or organisms are exposed to either therapeutic or lethal dose of 
the drug, depending on the type of study, to induce a significant cellular 
response. By means of proteomics, the proteome of the exposed sample is 
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then compared to the control proteome to find out the regulated proteins 
(down-regulated or up-regulated) in the treated sample.  
Several pharmacoproteomics studies have been conducted to investigate and 
understand the mechanism of toxic effects of drugs in pre-clinical and clinical 
phases of drug development. However, proteomics approaches have also 
been applied for released drugs (i.e. drugs on the market). For examples, the 
hypoglycaemic drug; “troglitazone” was withdrawn from the market due to its 
unacceptable idiosyncratic hepatotoxicity (Lee et al., 2013b). Moreover, 
proteomics has been used to investigate the possible hepatotoxic 
mechanisms of acetaminophen, cyclosporine A and amiodarone (Van 
Summeren et al., 2013).  Despite the huge use of proteomics in drugs 
analyses, the reputation of proteomics was highlighted by studying the 
mechanism of resistance to anti-cancer drugs and the mechanism of their 
induced toxicity. The high importance of such studies is owing to the non-
selectivity of anticancer drugs, which might harm normal cells and the 
complexity of the molecular mechanisms of their toxicity. Examples of such 
pharmacoproteomics studies on anti-cancer drugs are shown in Table 1.2.   
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Table 1-2. Proteomics studies for some anti-cancer drugs. 
Drug Model Species Organ/cells 
Proteomics 
approach 
Reference 
Cisplatin 
In vitro Human Hela SILAC 
(Chavez et al., 
2011) 
In vitro Rat Hepatocytes Shotgun, free label 
(Cho et al., 
2012a) 
In vitro Human Ovary mitochondria 
Shotgun, spectral 
counts 
(Chappell et 
al., 2012) 
In vitro Human 
Neuroblastoma cell 
line 
2D-DIGE/ MALDI 
(D’Aguanno et 
al., 2010) 
Doxorubicin 
In vitro Human HepG2 2D-DIGE/MALDI 
(Hammer et 
al., 2010) 
In vitro Rat Isolated heart 2D-DIGE/ MALDI 
(Gratia et al., 
2012) 
Bortezomib In vitro Human Myeloma iTRAQ shotgun 
(Uttenweiler‐
Joseph et al., 
2013) 
5-fluorouracil In vitro Human 
Colon cancer cell 
line 
SILAC 
(Marin-Vicente 
et al., 2013) 
Vincristine In vivo Mouse Xenograft 2D-DIGE/MALDI 
(Verrills et al., 
2006) 
 
- Different proteomics approaches were used such as; 2D-DIGE: Proteins were 
separated by gel in two dimensions, then identified using PMF (peptide mass 
fingerprint) approach 
- Shotgun: Peptides were separated using chromatographic techniques then identified by 
suitable MS  
- iTRAQ: Isobaric tag for relative and absolute quantitation for digested peptides followed 
by MS-quantitative proteomics 
- SILAC: Stable isotope labelling by amino acids in cell culture followed by MS-
quantitative proteomics 
- Label-free: Proteins quantitation based on measurement of the ion current 
corresponding to their peptides 
- Spectral count: Proteins quantitation through the spectral counting of their independent 
peptides appearing in the MS/MS analysis. 
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1.3.4 Liver proteomics for studying CYP450s 
As stated before, liver is a pivotal organ that is responsible for many of critical 
functions like drugs metabolism and detoxification. Therefore, the Human 
Proteome Liver Project (HLPP) was initiated in 2002, to generate a 
comprehensive protein atlas of the human liver, which can help in 
understanding the molecular functions of liver proteins (He, 2005). Liver, as a 
model, has been considered for various drug investigation experiments, 
however, in pre-clinical drugs development, although, in vitro models reduce 
the number of animals used in pre-clinical trials, researchers don’t prefer 
employing it, as it lacks sensitivity and can generate false-negative results, 
additionally, in vitro models showed variation in DME expression and 
consequently different response to toxin compound450 (Suter et al., 2011, 
Hartung, 2009, Uetrecht, 2008).  
Currently, most of the available data concerning CYP450s expression were 
derived from DNA and mRNA-based experiments (Shrivas et al., 2013a). 
However, studying the DNA and mRNA provides insufficient information about 
the expression and activity level of individual CYP450 enzyme, since the 
correlation between mRNA level, protein levels and enzyme activity for 
membranous proteins in general and CYP450 isoforms, in particular, were 
poor or even negligible (Williamson et al., 2011). In the previous study by 
Ohtsuki and colleagues revealed a poor correlation between mRNA and 
protein levels of various drug-metabolizing enzymes (CYP450 and UGT) and 
transporters (Ohtsuki et al., 2012). Western blot (immunoblotting) is another 
approach used for CYP450 enzyme detection, although it is a very sensitive 
method, antibodies are not available for all CYP isoforms. In addition, as result 
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of highly sequence homology within CYP subfamilies, few of the available 
antibodies can distinguish between closely related isoforms (cross-reactivity). 
For example, neither polyclonal nor monoclonal antibodies can distinguish 
CYP2B1 and CYP2B2 (MacLeod et al., 2013). 
1.4 Proteomics 
1.4.1 Protein, proteome, proteomics 
Proteins are the functional units in the body, which are composed of amino 
acids connected together by peptide bonds. Proteins are pivotal molecules 
that play an important role in the formation of the cell architecture as well as in 
metabolic processes, cell motility, protein synthesis and mitosis. Proteins play 
a main role in disease progress and in response to stimuli, for example, drug 
administration and environmental xenobiotics (Mesri, 2014).  
The term “proteome” was first proposed in 1995 by Wilkins et al. (Wilkins et 
al., 1995) to describe that “PROTEin is complementary to the genOME”, 
meaning the complete set of the proteins expressed by the cell. Whereas 
Proteomics is the study of protein structure, function, expression, localization, 
and interactions (Bateson et al., 2011). Proteomics involves the integration of 
a number of technologies with the aim of identification and quantitation of the 
protein complement expressed by a biological system in response to various 
stimuli or to particular physiological or pathophysiological conditions. In 
general, a proteomics approach can be used for (i) protein profiling, (ii) 
comparative expression analysis of two or more protein samples (biomarkers 
identification), (iii) study the protein-protein or protein-drug interaction and (iv) 
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for the localization and identification of post-translational modifications (Figure 
1.6) (Chandramouli, 2009).  
 Figure 1-6. Disciplines of proteomics research, including the aspects of proteomics 
and their role in proteins analysis. (Wetmore and Merrick, 2004). 
 
Proteomics is a key technique that is able to correlate those proteins involved 
in the progress of diseases, since most diseases are expressed at the level of 
protein abundance or mutation, leading to the identification of new biomarkers 
that can be targeted for diagnosis or treatment of diseases. 
1.4.2 Proteomics vs. genomics 
Proteins are the active agents in the cells, tissues, and organs and have an 
essential role in determining the phenotype of an organism. Even if all the 
organisms have one unique genome, the proteome of the organism can vary 
and create different phenotypes for the organism (Diz et al., 2012). The 
challenge of proteomics versus genomics resides in the complexity of protein 
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chemistry and multiple potential post-translational functional modifications 
contrasting with the unique nucleotide complement and sequence upon which 
genomics relies (Smejkal, 2012). The human genome is estimated to be 
composed of approximately 21,000 protein-coding genes, which generate 
around 500,000 or more distinguishable functional proteins, where each single 
gene may encode for single or multiple proteins (Smejkal, 2012). This is due 
to the differential splicing and translation of many genes and numerous post-
translational modifications of proteins. Figure 1.7, illustrates the complexity of 
the cellular proteome. 
An advantage of analyzing the proteome rather than the genome is that 
proteomic changes are dynamic in contrast to genomic which are static; thus, 
proteomics can reflect the physiological and pathophysiological conditions 
much more accurately. This enables close monitoring of changes in the state 
of cells, tissues or organism over time. Another advantage is the dynamic 
range of concentrations of proteins since one cell can contain one to more 
than 100,000 copies of each protein, which is not reflected in genomic 
information (Chandramouli, 2009, Kolch et al., 2005). Furthermore, proteomics 
can identify the post-translational modifications of proteins which have 
profound effects on the biological function and their cellular localisation (Page 
et al., 1999, Parekh and Rohlff, 1997). In addition, protein functionality often 
demands specific protein-protein interactions forming functional protein 
complexes (Dziembowski and Séraphin, 2004). 
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Figure 1-7. The complexity of proteome is much more than its corresponding genome. 
As a result of the alternative splicing, one gene produces multiple pre-mature mRNA 
transcripts and thus generating multiple proteins. After translation step, a myriad of 
post-translational modifications can create additional distinctions in the number and 
natures of protein form. Many different forms can be produced due to post-
translational modifications, eight of which are shown. The figure is adapted from 
Peng et al, (Peng and Gygi, 2001).  
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1.4.3 Proteomics aspects 
Proteomics covers a number of different aspects of protein function, including: 
(i) structural proteomics that maps out the structure of proteins to help identify 
protein localization and the way they interact with the ligand. This is achieved 
using technologies such as X-ray crystallography and NMR spectroscopy. (ii) 
Expressional proteomics also called differential protein expression, which 
measures changes in protein expression in related samples, such as diseased 
versus healthy tissue. A protein found only in a diseased sample may 
represent a useful drug target or diagnostic marker. Proteins with similar 
expression profiles may also be functionally related. Technologies such as 2D-
gel electrophoresis and mass spectrometry are used for these studies. (iii) 
Functional proteomics is concerned with determining protein-protein 
interactions and their impact on protein function, both normal and abnormal. 
Technologies such as affinity purification, mass spectrometry, and the yeast 
two-hybrid system are particularly useful for these studies (Graves and 
Haystead, 2002, Ning et al., 2011). 
1.4.3.1 Proteomics in biomarker discovery 
A biomarker is defined as a characteristic and measurable indicator of normal 
biological process, particular pathophysiological or physiological conditions, or 
pharmacologic response to a therapeutic intervention (Atkinson et al., 2001). 
Biomarkers play an important role in drug discovery and development as well 
as in understanding the causes and progression of the disease.  
Mass spectrometry-based proteomics has been shown as a successful means 
for biomarker screening in clinical and pathological conditions. Nowadays, 
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proteomics is employed significantly in identification biomarkers for several 
diseases such as Alzheimer's, asthma, and chronic obstructive pulmonary 
disease (Galasko, 2005, Verrills et al., 2011). In oncology, proteomics has 
been applied to understand the pathology of cancer, implement tumor 
monitoring and identify novel targets for cancer therapy as well as for 
prognostic and diagnostic purpose. For examples, identification of  urinary 
S100A9 protein as a potential biomarker for early detection of hepatocellular 
carcinoma and PGAM1 proteins as a therapeutic potential target for urothelial 
bladder cancer (Huang et al., 2015, Peng et al., 2016). Certainly, identified 
biomarkers have to be validated to make sure that these biomarkers are 
confidently associated with the defined biological statistics and can be 
reproducibly performed (Issaq and Veenstra, 2008). 
1.5 Proteomics workflows 
There is more than one design for proteomics experiment workflow depending 
on the aim of the study. However, a typical quantitative proteomics workflow 
consists of biological sample preparation, protein extraction, protein 
separation, proteolytic degradation, peptide separation, mass spectrometer 
analysis and database analysis. All the methods used in different stages are 
linked very closely with each other, for example, a suitable MS analysis 
method should be considered based on the sample preparation and 
separation method. 
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1.5.1 Sample preparation  
The first step in proteomics workflow is sample preparation, which includes at 
least three steps: cell/tissue disruption, protein solubilisation, and removal of 
interfering substances. Extracting high quality and adequate amounts of 
proteins from sample for proteomics analysis should be as simple as possible 
to maximize reproducibility and reduce yield loss. Proteins can be extracted 
from many different sources, such as cultured cell lines, tissues, body fluids, 
etc.  
Protein extraction is achieved by three methods; mechanical, chemical and 
enzymatic, individually, more often in combinations. Chemical based 
extraction methods using detergents or organic solvents have become very 
popular, due to their ease of use, low cost and new protocols with proven 
efficiency. Detergent-based extraction methods involve cell membranes 
disruption, breaking lipid-protein interactions and solubilising proteins. 
However, detergents remain a significant challenge in MS-based proteomics 
study (section 3.1.1), as they generate background signals that may suppress 
peptide-derived signals or contaminate the MS source (Wiśniewski et al., 
2009). Therefore, detergent concentration needs to be optimised, or removed 
during protein preparation and before MS analysis. Examples of chemical 
methods are illustrated in Table 1.3. 
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Table 1-3. Different groups of chemical agents used for cell membrane disruption and 
proteins solubilisation with their applications 
Chemical method Materials Applications 
Detergent 
 Ionic: SDS 
 non-ionic: Triton X-100, 114 
 zwitter-ionic: CHAPS 
Bacterial cells, plants, animal 
tissues 
Organic solvents 
 Acetonitrile 
 Methanol 
 Isopropanol 
Bacterial cells, plants, animal 
tissues 
Organic acid  Formic acid Animal tissues 
 
Mechanical based extraction methods have shown a notable ability to disrupt 
the tissues or cells, allowing the rapid release of the intracellular proteins. 
These proteins are released into a harmless buffer that can keep the activity 
of the protein of interest (Carpentier et al., 2008). Mechanical methods (Table 
1.4), can be performed using many techniques varying from gentle to harsh, 
depending on the type of sample, the stability and cellular location of proteins 
required to be investigated (Carpentier et al., 2008). Mechanical methods 
include: 
1. The freeze-thaw method  
The freeze-thaw method is the simplest mechanical method that is used 
commonly to lyse cells from mammalian tissues and bacteria. The technique 
is based on freezing a suspension of cells and then thawing it back at room 
temperature. For freezing phase, liquid nitrogen or dry ice-ethanol bath can be 
used. During the freezing-thawing cycles, the cells size is increased where ice 
crystals are formed that eventually breakdown in the thawing phase. 
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Repeating the cycle is essential for efficient lysis, which lengthens the process 
time. However, the freeze-thaw method has been shown to efficiently release 
40%-90% of over-expressed recombinant protein located in the cytoplasm of 
Escherichia coli bacteria (Johnson and Hecht, 1994). 
2. Cryo-pulverization  
In this method, the sample is frozen in liquid nitrogen making it fragile and 
easily fractured. The sample is then crushed using a pre-chilled mortar and 
pestle to a fine powder. Cryo-pulverization is an effective method that has 
many advantages of enabling the fine powder to be recovered easily and 
extraction from large tissues or whole organs. Moreover, due to the extremely 
low temperature, the cryo-pulverization method is able to extract proteins 
preserving their activity (e.g. for enzyme activity assays) (Butt and Coorssen, 
2006, Ericsson et al., 2007). 
3. Sonication method 
Sonication is the most common process for cells disruption. Due to the 
difficulty in maintaining the low temperature and the long sonication time to 
achieve full lysis for cells, this method is preferably used for relatively small 
quantities. Sonication disrupts cells by using high-frequency sound waves, 
releasing proteins from tissue that has broken. A sonicator typically delivers 
sounds waves using a vibrating probe submerged in a liquid suspension of 
cells. Varying powers can be applied depending on the cell type. The 
sonication run is conducted in multiple short bursts using an ice bath for the 
sample in order to prevent excessive heating and protein damage. Sonication 
method is adaptable for different sample volume, which is used commonly for 
cells suspension (Goldberg, 2008, Vilkhu et al., 2011).  
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4. Liquid-based homogenization method 
Liquid-based homogenization is used mostly for small volume samples, 
usually cells and sections of tissue or whole organs in the buffer. It is based 
on sharing the forces between cells or tissue suspension through a narrow 
space of glass tube. Generally, there are different types of liquid homogenizers 
available come up with diverse sizes to adapt a range of sample volumes; 
moreover, they are inexpensive, easy to use, and clean (von Hagen, 2011). 
Dounce homogenizer is an example of the liquid homogenizer, which consists 
of a glass pestle shaped to fit a rounded glass tube. The sample suspension 
is added to the glass tube then gradually pressing the pestle on the sample 
manually. The number of strokes and the speed based on the size and type of 
sample (Simpson, 2010). However, the French press is another example on 
liquid homogenizer that applies high pressure automatically. It has been 
involved extensively in protein extraction from blood cell disruption and minced 
animal tissues (von Hagen, 2011).   
5. Electrical homogenizers or blenders 
Electrical homogenizer or blender is considered as the toughest method for 
protein extraction. Large solid tissues, such as liver and those organs with 
extensive fibrous connective tissues, are ground and dispersed by blades in 
electrical homogenizers which chilled on ice (Bodzon-Kulakowska et al., 
2007).  
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Table 1-4. Different groups of mechanical methods used for cell membrane disruption 
with their applications. 
Mechanical 
methods 
Materials Applications General procedures 
Freezing and 
thawing 
Liquid nitrogen 
Bacterial cells, plants, 
animal tissues 
Rapidly freeze cell 
suspension using liquid 
nitrogen and then thaw. 
Sonication 
 
Sonicator to 
produce ultrasonic 
waves 
Cell suspensions. 
Sonicate cell suspension in 
short bursts to avoid heating. 
Cool on ice between bursts. 
Grinding 
(pulverization) 
Pre-chilled mortar 
and pestle 
Solid tissues, 
microorganisms 
Tissue or cells are normally 
frozen with liquid nitrogen 
and ground down to a fine 
powder. 
Homogenizing 
 
Electrical 
homogenizer 
(blender) 
Solid tissues or Cell 
Rotating blades grind and 
disperse cells and tissues 
into small pieces using 
chilled buffer 
a liquid 
homogenizer 
(Dounce) 
Solid tissues or Cell 
Tissue suspensions are 
sheared by forcing them 
through a narrow space 
High pressure 
Chilled French 
press 
Microorganisms with 
cell walls 
Applying pressure on cell 
suspension 
 
In order to characterise the whole cell proteome, proteins must be solubilised 
during extraction. Proteins are often found in complexes with membranes, 
such as nucleic acids or other proteins. Some proteins form non-specific 
aggregates and precipitate when removed from their normal environment. 
Different treatments and conditions are required to solubilise different types of 
protein samples depending on the type of protein extraction, protein 
concentration and the solubilisation method (Pelkonen et al., 1974). For 
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example, detergents such as Triton X-100 and sodium deoxycholate can be 
used at low concentrations for membranous proteins solubilisation. 
During the process of protein extraction, cellular endogenous proteases are 
released, which may degrade cellular proteins rendering them unsuitable for 
subsequent analysis (von Hagen, 2011). In order to inactivate the enzymes, 
specific protease inhibitors (e.g., EDTA, chloromethyl ketone, or benzamidine) 
are added to prevent protein degradation. Moreover, samples are kept at low 
temperature, typically 4oC, to reduce proteolytic activity and since most 
mechanical methods release heat, affecting protein stability and activity. After 
protein extraction, contaminants such as; salts, nucleic acids, detergent, 
polysaccharides or lipids are removed by a desalting method such as dialysis 
or protein precipitation (Feist and Hummon, 2015).   
Extracted proteins are further reduced to cleave inter- and intra disulphide 
bonds crosslink within and between protein subunits and then alkylated to 
prevent reforming. The most common reducing agents are; beta-
mercaptoethanol, dithiothreitol (DTT), tributylphosphine (TBP) and tris-(2-
carboxyethyl)-phosphine (TCEP). Iodoacetamide, acrylamide derivatives, and 
vinyl pyridines are used as common alkylating reagents (Bai et al., 2005, 
Righetti, 2006, Darie et al., 2004). 
The final step in sample preparation is protein digestion. There are many 
chemicals and enzymes with different specificities available for protein 
digestion (further information on ExPASy; 
[au.expasy.org/tools/peptidecutter/peptidecutter_enzymes.html]. However, 
trypsin is the most commonly used protease since it has well-defined cleavage 
specificity at the C-terminal side of the basic amino acid residues lysine and 
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arginine unless the next residue is a proline (Olsen et al., 2004). The resulting 
peptides after trypsin digestion remain charged, which improves their 
ionization in the MS analysis, and for the most part are in the mass range 
suitable for MS/MS analysis and protein identification by database searching 
(Hustoft et al., 2012). 
In general, there are two approaches to converting proteins into peptides 
suitable for MS-based proteomics analysis; in-gel and in-solution methods, 
depending on the method of protein fractionation (Figure 1.8).  
 
Figure 1-8. Workflows of in-gel (left) and in-solution (right) digestion and subsequent 
LC-MS analysis of a protein sample. 
 
In the in-gel digestion method, the extracted proteins are first solubilised using 
detergent, and then separated in one or two dimensions (1D/2D) via SDS-
PAGE and finally the bands of interest with defined molecular weight are 
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excised and digested enzymatically with trypsin. On the other hand, in gel-free 
or in-solution digestion is followed by extensive separation of the resulting 
peptides using multi-dimensional chromatographic and/or electro-focusing 
methods, followed by MS analysis and protein identification (Yates et al., 
2009). 
1.5.2 Subcellular fractionation 
The presence of multiple forms of each gene product indicates the diversity 
generated by the alternative splicing of mRNA and the variety of post-
translational modifications that occur upon protein synthesis, altering the 
physical and chemical properties of proteins (Duan and Walther, 2015). In 
addition, cellular protein concentrations are extremely wide, ranging from 7 to 
10 orders of magnitude, making it difficult to detect the low abundance proteins 
(Dwane and Kiely, 2011). In order to improve the resolving power of 
proteomics, pre-fractionation strategies are used to reduce sample complexity 
and allow detection of less abundance protein. 
Since differential centrifugation separates cellular components based on their 
physical characteristics, it is considered the most effective approach and is 
compatible with analytical proteomics techniques (Huber et al., 2003).  
1.5.3 Proteomics approaches in proteins separation 
Protein identification traditionally follows one of two proteomics workflows, 
which differ based on the way extracted proteins are converted to peptides 
suitable for mass spectrometry (MS) analysis, as shown in Figure 1.8. 
Separations are performed prior to MS to simplify the complexity of protein 
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mixture and improve the information extracted from the proteome. Of the 
possible methods for proteome separation, gel electrophoresis (1D/2D-GE) 
and multidimensional liquid chromatography are the two most commonly used 
methods. 
1.5.3.1 One and two-dimensional polyacrylamide gel electrophoresis 
approach 
The gel electrophoresis-based technique was one of the original protein 
separation methods used in proteomics studies and can be performed in one- 
or two-dimensions depending on the complexity of the sample. One-
dimensional gel electrophoresis separates proteins based on their molecular 
weights. Chaotropes (e.g., urea and thiourea) and anionic detergent (e.g., 
sodium dodecyl sulphate (SDS)) are used in sample and gel preparation to 
unfold proteins, ensuring they are linearised and migrate based on their 
relative molecular weights (Laemmli, 1970). SDS-polyacrylamide gel 
electrophoresis (SDS-PAGE) is an excellent method to separate proteins and 
compare samples qualitatively throughout sample preparation and to assess 
the consistency of enriched fractions. However, it is also an effective low-
resolution preparative method for fractionating hundreds of proteins in a single 
gel (Thakur et al., 2011). It has been used very effectively as an enrichment 
step for isolation of cytochrome P450s, all of which have similar molecular 
weights (approximately 55 to 60kDa) from liver microsomes (Nisar et al., 
2004b, Sutton et al., 2010). SDS-PAGE can also be used in conjunction with 
blotting methods, for example, western blot or immunoblot, for specific protein 
detection using antibodies (Garfin, 2009).  
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Protein charge can also be used as the basis of separation using isoelectric-
focusing (IEF), which separates proteins based on their isoelectric points (pI). 
Two-dimensional gel-based separation (2D-PAGE) was first introduced by 
O’Farrell in 1975, for visually profiling total protein extracts, but it was not used 
until the advent of proteomics in the early 90’s that 2D gels proved their full 
potential as a two-step separation of proteomes prior to in-gel-trypsin digestion 
and mass spectrometric analysis (Figure 1.9) (O'Farrell, 1975). The resolution 
power of these two orthogonal separation techniques for proteins results in 
separating each protein isoform with specific pI and molecular weight 
coordinates, while the volume of the spot is correlated to the protein 
expression in the sample (Natale et al., 2012). 
1.5.3.2 In-gel visualisation and differential gel electrophoresis 
Once proteins have been separated by electrophoresis, staining techniques 
can be used to visualize proteins. Examples of staining dyes are: Coomassie 
blue (Neuhoff et al., 1988), silver stain (Winkler et al., 2007), zinc-imidazole 
stain (Fernandez‐Patron et al., 1998), or fluorescence staining or labelling 
such as, ruthenium bathophenanthroline disulfonate (Sypro Ruby) and Deep 
Purple (Lunardi, 2001, Bell and Karuso, 2003). Gel staining can be carried out 
with the aim of evaluating the efficiency of proteins separation and/or for in-gel 
digestion for peptide mass fingerprinting (PMF). In the case of PMF, spots of 
interest are identified, excised from the gel and trypsin digested for the MS 
analysis (Klose and Kobalz, 1995).   
Two-Dimensional Differential Gel Electrophoresis, (2D-DIGE) is a variation of 
2D-PAGE for differential mapping of two proteomes for comparative 
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proteomics analysis. Two or more protein samples are labelled with different 
fluorescent dyes (known as CyDyes: Cy2, Cy3, and Cy5) prior to 2D-PAGE 
(Marouga et al., 2005, Westermeier and Scheibe, 2008). The ultimate aim of 
using the fluorescent dyes is to identify those protein spots uniquely stained in 
each biological conditions (normal versus diseased or control versus treated) 
and then identify these protein expressions by in-gel digestion and peptide 
mass fingerprinting (Figure 1.9).  
 
Figure 1-9. Two-dimensional gel electrophoresis for proteins from hepatocellular 
carcinoma sample (Cy3, green) and  non-cancer sample (Cy5, red). Proteins (50 μg) 
were subjected first to IEF in an IPG strip (24 cm) 3-10 pH range, and then SDS-PAGE 
was performed on 12.5% polyacrylamide gel in 2D. Cyanine dye-labelled protein gel 
was fluorescently scanned directly for gel visualization (Lee et al., 2005). 
 
There are a number of advantages that made 2D-PAGE widely used in early 
proteomics studies. First, 2D-PAGE has the high-resolution power with the 
potential to visualize over 2000 spots corresponding to over 1,000 proteins 
(Rabilloud et al., 2010). Second, it is able to visualize the proteome map more 
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effectively than chromatography-based separation; enabling identification of 
protein isoforms and post-translational modifications such as glycosylation 
and phosphorylation (Lopez, 2007). 
However, 2D gel-based method has a number of disadvantages such as; 
inability to resolve proteins with very high or very low molecular weight and 
very acidic or very alkaline pIs (Koga, 2008), narrow dynamic range which 
limits sensitivity to detect low abundance proteins (Chevallet et al., 2008), 
limited capability to resolve membranous proteins (e.g. Cytochrome P450 
enzymes) (Kanaeva et al., 2005, Rabilloud, 2009), and poor reproducibility 
(Chevalier, 2010). Reducing the sample complexity through subcellular pre-
fractionation (Pasquali et al., 1999) or using narrow range of pI strips (IPGs) 
(Dépagne and Chevalier, 2012) can overcome dynamic range issues. 
1.5.3.3 Chromatography-based separation (multidimensional based 
proteins separation) 
Protein or peptide separation plays an important role in protein identification, 
where proteome coverage depends mainly on the extent of protein separation 
to resolve the complex protein mixture and low abundance proteins. 
Chromatography as a technique can also be used to reduce sample 
complexity. Here, proteins are usually digested enzymatically into peptides 
prior to their separation chromatographically. 
“Top-down” and “Bottom-up” approaches are two main analytical strategies for 
proteome separation and identification (Figure 1.10). ˝Top-down˝ approach is 
based on the separation of whole sample intact proteins directly by, for 
example, high performance liquid chromatography (HPLC) and subsequently 
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analysed directly by fragmenting the intact protein by mass spectrometry (MS), 
which provides valuable information about proteins at molecular level and 
detection of post-transitional modifications (PTMs) (Ryan et al., 2010). 
However, the ˝Top-down˝ approach has a limited resolution, requires pure 
proteins, and in practice is limited to proteins less than 500 amino acid 
residues (approximately 50 kDa) (McLafferty et al., 2007). Complementary to 
“Top-down”, the ˝Bottom-up˝ approach which also named by shotgun or 
MudPit strategy intends initially to digest proteins into peptides with specific 
proteases such as trypsin, then reduces their complexity by using multi-
dimensional chromatography techniques, such as two-dimensional HPLC (2D-
HPLC), prior to analysis by tandem MS (MS/MS). The advantage of the 
shotgun approach is to reduce the dynamic range of different physio-chemical 
proprieties of proteins, such as mass and charge, thereby simplifying the 
separation and identification by LC-MS system (Washburn et al., 2001a). 
However, similar to 2D-PAGE, protein inference can be a challenge in shotgun 
approach; where the identical peptide sequence can be detected in many 
different proteins or isoforms and cannot be specifically assigned (Zhang et 
al., 2010). Multi-dimensional proteomics abbreviated as MudPit, is an 
integration of two or more separation method coupled together to separate 
either proteins or peptides, which as a consequence enables automation 
reducing cost and time (Washburn et al., 2001b). Unlike gel-based technique, 
MudPit is a comprehensive approach able to identify the whole cellular 
proteome (Abdallah et al., 2012). In MudPit, the first dimension separation 
approach is used as a preliminary step to reduce the complexity of sample 
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which is then followed by the second dimension. Proteins/peptides throughout 
the 1D are resolved to depend mainly on their physio-chemical properties. 
 
Figure 1-10. In bottom-up MS approach (A), a protein is typically digested 
enzymatically (i.e. trypsin) into peptides either in-gel or -solution prior to peptides 
sequencing then protein identification and quantification take place. However, since 
this approach identifies protein via a small number of peptides (partial coverage), 
only one modification was determined. In Top-down MS approach, the intact protein 
(i.e. undigested) is analysed straightforward by MS, where fragmentation can take 
place for a distinctive protein to locate the modifications sites. However, more 
modifications (four modifications) were defined since a full coverage was achieved. 
The Figure is adapted from (Zhang and Ge, 2011). 
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1.5.3.3.1 Peptide chromatography 
Peptide separation plays a critical role in comprehensive proteome analysis 
strategies. It can substantially increase the number and confidence of 
identifiable components in a proteome. Chromatography-based methods such 
as ion exchange, hydrophilic interaction, affinity purification, and reverse 
phase–LC are normally engaged in shotgun proteomics strategy in tandem 
prior MS identification. 
Ion exchange chromatography (IEC) takes the advantages of the overall 
ionic charges of proteins/peptides for first dimension separation. In IEC, 
analytes with an opposite charge bind to charged functional groups of IEC 
media, thus, negatively charged proteins are bind to a positively charged group 
in anionic exchange (AX) chromatography. Conversely, in cationic exchange 
(CX) chromatography positively charged proteins bind to a negatively charged 
media. In order to get proteins eluted, a linear gradient of salt concentration 
buffers at fixed pH is used to competitively displace the anionic or cationic 
analytes of increasingly high charge states (Di Palma et al., 2012b). Typically, 
buffer used (such as; ammonium bicarbonate or ammonium formate) should 
have specific properties. For example, it has to be relatively volatile, with no 
effect on sample pH, able to elute analytes from the column, and finally MS 
compatible. The stationary phase in CX is composed of either strong or weak 
negatively charged residues that allow its binding to the positive moieties of 
analytes. In contrast, AX is packed with either strong or weak positively 
charged residues that can bind to the anionic moieties of analytes.  
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Strong cation exchange (SCX) is the most popular choice of IEX prior to RP-
LC in MudPit, although strong anion exchange (SAX) is indeed possible. 
Theoretically, about 29% of human peptides generated after trypsin digestion 
are not expected to be retained by SAX as they possess either neutral or basic 
net charge at pH less than 8.5 (Dai et al., 2009). Additionally, SCX is capable 
of working over a broad range of pH particularly as low as pH 3.0 without losing 
their negative charges (Di Palma et al., 2012b), since most of the peptides 
tend to have pIs around pH 4 (Cargile et al., 2004a). However, SAX has a bias 
to acidic peptides, such as phosphorylated peptides, which makes it superior 
in their separation and enrichment (Han et al., 2008).   
Affinity purification chromatography (APC) is a highly selective separation 
method that involves protein-ligand interactions. In this method, a protein of 
interest binds by virtue of its specific properties to a stationary phase with an 
appropriate ligand via reversible biological interactions due to electrostatic or 
hydrophobic interactions, van der Waals’ forces and/or hydrogen bonding 
(Ayyar et al., 2012). APC method is involved mainly for purification of definite 
proteins or class of proteins, such as antibody purification (Ayyar et al., 2012). 
However, in proteomics analysis, APC is used to enrich a particular class of 
proteins by depleting the high abundant proteins, such as removing albumins 
from blood serum (de Morais-Zani et al., 2011). 
Hydrophilic interaction liquid chromatography (HILIC) was suggested 
firstly by Alpert in 1990 (Alpert, 1990). HILIC is a normal phase liquid 
chromatography (NP-LC), where stationary phase is more polar than the 
mobile phase. HILIC separates proteins based on interactions of hydrophilic 
amino acid residues of the digested protein with hydrophilic groups on a resin. 
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Besides peptides, HILIC is frequently used in separating polar/basic 
compounds separation, such as drugs compounds and their metabolites 
(Hsieh, 2008). However, the main challenge of using this method is the polarity 
of the mobile phase that is commonly used to elute polar compounds. The 
resultant polar compounds can distort the shape of the peak and result in a 
mismatch between mobile solvent peak and compound solvent peaks (Fritz et 
al., 2009).  
Electrostatic repulsion-hydrophilic interaction chromatography (ERLIC) is a 
subset of HILIC which separates peptides on the basis of the simultaneous 
effect of electrostatic forces and hydrophilic interaction, by adjusting pH, salt 
component and concentration, and organic solvent compositions in the mobile 
phase. with elution in order of high to low pI and GRAVY values (Alpert, 2008). 
This affords convenient separations of highly charged peptides that cannot 
readily be resolved by IEC (i.e. SCX). In addition, phosphopeptides can be 
isolated selectively from a tryptic digest (Hao et al., 2011). 
In contrast with HILIC, Reversed-phase liquid chromatography (RP-LC) 
takes advantage of the hydrophobicity of peptides for separation, where 
stationary phase contains non-polar residues (Buszewski and Noga, 2012). 
Analytes such as peptides are separated on the column, by increasing the 
organic solvent in a linear gradient (Sandra et al., 2008). RP-LC generally is 
used as the single phase and as the last dimension of multi-dimensional 
separation prior to MS analysis (Fournier et al., 2007). Moreover, RP-LC is 
coupled directly to the MS, which gives high resolution, efficiency, 
reproducibility, and mobile phase compatibility with MS (Shen and Smith, 
2002). 
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Two dimensional-liquid chromatography (2D-LC) is an integration of two-
separation methods in tandem, which offers a great improvement in the 
resolving power over the conventional one dimension. The efficiency of the 2D 
separation strategy is determined by the alternative selectivity between the 
separation dimensions and the chromatographic power of the separation 
systems employed in the different dimensions (Dugo et al., 2008). The power 
of the orthogonal system of first dimension approach, such as IEC, and a 
second dimension (i.e. Reverse phase-LC) is being a successful approach that 
maximizes the extent of peptide dispersion and, thus, influences the number 
and confidence of identified proteins. SCX in conjugation with RP-LC is the 
most typical combination used in shotgun approach (Betancourt et al., 2013).  
Although 2D-LC approach has proven its ability to overcome sample 
complexity and the massive differences in protein concentration challenges in 
Bottom-up, separating abundant proteins from lower abundant proteins by 
fractionation of cellular proteins into the different compartment (i.e. subcellular 
fractionation) is another method to increase the proteome coverage analysed 
by MS. Also, employing a third dimension of liquid separation  (e.g. capillary 
electrophoresis (CE)) has been used recently in Bottom-up approach to 
achieve total proteome coverage (Zhang et al., 2007).  
1.5.4 Mass spectrometry  
Mass spectrometry (MS) is an analytical technique that intends to measure the 
masses of individual molecules after they are converted into ions. Since the 
first MS was constructed in 1912 (Dempster, 1918), it has been employed in 
several applications such as; proteomics field, drug discovery (identification of 
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drugs structure and their metabolites), clinical examination (biomarkers 
identifications), food safety assessment (food contamination), environmental 
analysis, space exploration and many others (De Carolis et al., 2014). The 
prominence of MS has been highlighted in proteins and peptides analysis, 
where it is capable of measuring molecular weights over 1 million Da, 
determine protein structure and performs amino acid sequencing. 
Traditionally, before biomolecular MS, proteins were identified using Edman 
degradation method that is based on sequencing proteins or peptides from the 
amino terminus. However, despite being very specific, it was time-consuming 
and relatively low sensitivity (Edman, 1950). 
The advancement of mass spectrometric ionization technology allowed the 
detection of thermally labile, polar and non-volatile protein/peptide analytes, 
becoming the dominant analytical method for proteome analysis (Yates et al., 
2009). Mass spectrometry nowadays is used routinely in proteome analysis to 
identify proteins, quantify their levels (relative or absolute) and to characterize 
protein post-translational modifications (Yates et al., 2009). 
Peptides analysis using MS can be conducted in various ways, depending on 
the MS instrumentation and the way of ionisation. In all cases, the peptide 
molecules must first be ionized using one of the soft ionizing techniques to 
produce charged ions (positive or negative) in a gaseous phase. Charged ions 
are then captured with a mass analyser to separate the ionized analytes 
according to their mass-to-charge ratio (m/z). The mass-to-charge ratio is then 
determined with a detector. However, typically, MS consists of three essential 
components: an ion source, a mass analyser and a detector as demonstrated 
in Figure 1.11. 
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Figure 1-11. The main stages of Mass spectrometric analysis for protein identification 
are shown. Proteins/peptides sample can be introduced to MS through different 
means including, HPLC, sample plate or by direct injection for analysis. The ion 
source is responsible for creating the ionized analytes such as peptides, which are 
the introduced into the mass analyzer and separated on basis of mass-to-charge 
(m/z). Ionized molecules are detected and counted at each mass-to-charge (m/z) 
value.   
1.5.4.1 Ion source 
Different techniques have been discovered for sample ionization, such as fast 
atom bombardment (FAB), chemical ionization (CI), atmospheric pressure CI, 
plasma desorption (PD), electrospray ionization (ESI) and matrix-assisted 
laser desorption/ionization (MALDI) (De Carolis et al., 2014). Depending on 
the nature of sample one of these methods is selected and the soft ionization 
techniques, with ESI and MALDI, are the ones most commonly used for protein 
and peptide analysis (Emonet et al., 2010). 
Even though both methods produce charged ions in a gaseous phase, each 
method is based on a very different principle. ESI changes the introduced 
liquid sample into very small droplets of solvent-containing analytes, through 
a combination of voltage, heat, and air (Yates et al., 2009). The continuous 
loss of solvent results in producing a constant stream of ions. On the other 
hand, MALDI uses a pulsed laser beam fired at the sample to get it ionized, 
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after mixing it with a suitable matrix, which is allowed to dry on a conductive 
surface (Table 1.5) (de Hoffmann and Stroobant, 2007). 
Table 1-5. A comparison between MALDI and ESI ionization methods. Table was 
adapted from (Cho, 2007, Yang et al., 2007, Seymour et al., 2010, Awad et al., 2015) 
Comparison MALDI ESI 
Sample status Solid (Co-crystal with matrix) Liquid (In solution) 
Charge states and 
adducts 
Usually single charge (M+H+) Multiple charges (M+nH)n+ 
Charge polarity Positive and negative mode Positive mode 
Method of ionization Laser Voltage, heat and gas (nebulization) 
Power of ionization Soft Soft (harsher than MALDI) 
Mass range For high mass, up to 500,000 Da For small molecules, up to 200,000 Da 
Common mass analyser Commonly coupled to TOF analyser 
Commonly coupled to quadrupole 
analysers 
LC-coupling Not compatible Compatible 
Pros 
- Very easy to operate 
- able to analyze proteins down 
to femtomole quantities 
- suitable for in-gel digestion 
approach 
- can tolerate small amounts of 
contaminants 
- more reliable in non-redundant 
peptides ionisation 
- highly reproducible 
- highly efficient and automated 
sample throughput 
- continue ions flow 
- More efficient in fragmentation 
(works in acidic pH) 
- Multiple proton-accepting sites 
generated 
Cons 
- Discontinue ions flow 
- Greatly affected by the quality 
of the sample, which can be 
contaminated. 
- Time consuming 
- Matrix produces background 
less than 800-900 m/z, 
problematic for small 
molecules analysis 
- Multiple fragmentations, 
complicates downstream analysis 
- Less suitable for non-basic, low-
polarity molecules 
- Ion suppression due to high 
concentration of non-volatile 
compounds 
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One of the main differences between MALDI and ESI is the generated 
fragments during MS/MS phase. MADLI produces more ions series of 1+ 
fragments including ammonium, a, b, y, x, d, v, and w ions. On the other side, 
ESI generates 2+ fragments or higher with only b and y ions (Figure 1.12), 
which might indicate more peptide sequence coverage by MALDI.   
 
Figure 1-12. Mass spectrum for a common peptide of CYP1a2 (IGSTPVVVLSGLNTIK) 
from mouse liver microsomes analysed in the current project using MALDI-TOF-TOF-
MS MS/MS (A) and previous project using ESI-Orbitrap Fusion MS-MS/MS (B).      
 
The matrix plays a key role in MALDI-MS by; (i) absorbing the laser energy 
and heating up the matrix to create a gas plume, (ii) being in excess, it protects 
the analytes from highly energy-laser source by absorbing most of the incident 
energy, (iii) separating the analyte molecules and thereby preventing the 
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formation of sample clusters that inhibit the appearance of molecular ions and 
(iv) serving as a proton donor and receptor, which is important for ionizing the 
analyte in both positive and negative ionization modes, respectively (Lewis et 
al., 2006, de Hoffmann and Stroobant, 2007). Such examples of compounds 
most frequently used as a matrix are α-cyano-4-hydroxycinnamic acid (CHCA) 
for peptides below 5 kDa, 2,5- dihydroxybenzoic acid (gentisic acid) for 
carbohydrates and trans-3,5-dimethoxy-4-hydroxycinnamic acid (sinapinic 
acid) used for protein analysis (de Hoffmann and Stroobant, 2007). 
1.5.4.2 Mass analyser 
The mass analyser is the part where gaseous ion separation takes place 
based on their mass-to-charge (m/z) ratio. Different types of mass analyser 
have developed, which vary in their physical principles and analytical 
performance capabilities including: mass range, analysis speed, resolution, 
sensitivity, ion transmission, and dynamic range (Seitz and Schumacher, 
2015). There are four different types of mass analysers which are commonly 
used for proteomics research: quadrupoles, ion trap (IT), time of flight (TOF), 
and Orbitraps (Balch and Yates, 2011). As an MALDI source produces short 
pulses of ions, it is preferably coupled to a very fast mass analyser such as 
TOF analyser, which measures the time taken by gas phase-ions to travel from 
ionization source to detector (m/z) (Yates et al., 2009). In contrast, ESI source 
produces a continuous current of ions; making it suitable to be coupled to a 
quadrupole, ion trap, and/or Orbitrap mass analyser. Since different mass 
analysers have strengths and weaknesses in their performance, which are 
characterized by the resolution, accuracy, sensitivity, mass range of detection 
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and cost, hybridizing two means of mass analyser for ionized analytes 
separation can provide greater experimental flexibility and reliability (Table 
1.6) (De Carolis et al., 2014, Domon and Aebersold, 2006). An example of 
such hybridization is combining LIT that has a low-resolution power but high 
sensitivity with Orbitrap which has relatively low sensitivity but excellent 
resolving power (Michalski et al., 2012). However, coupling mass analysers 
together is used primarily to perform tandem mass spectrometry (MS/MS) 
analysis, where specific peptides are isolated in the first analyser, fragmented 
by collision with a gas, before separation in the second mass analyser. 
1.5.4.3 Detector 
The detector converts an ion current into an electrical current, which is then 
digitized and delivered to the PC (de Hoffmann and Stroobant, 2007). 
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Table 1-6. Performance comparison of selective mass analyzers, showing the pros and cons for each analyzer. The table is adapted from 
(Yates et al., 2009, Lemière, 2001, Kromidas, 2016).  
Mass 
analyser 
Example Resolution 
Mass 
Accuracy 
Sensitivity 
Dynamic 
Range 
Advantages Disadvantages 
Scanning 
Time of flight 
(TOF) 
10,000 
 
2-5 ppm Femtomole 1x106 
 Good resolution and mass accuracy 
 Excellent mass range (m/z) 
 Simplest mass analyser. 
 Compact and easy to manipulate 
instrument 
 Easily adapted to MALDI 
 Low cost 
 Moderate to fast scan speed 
 Less adapted to ESI 
than MALDI. 
 Not quantitative 
Ion beam 
Triple 
quadrupole 
2000 100 ppm Attomole 
3x103 - 
4x103 
 Easily adapted to ESI 
 Good sensitivity 
 Low cost 
 Small size 
 Ease to switch between positive and 
negative ions 
 Fast scan speed 
 Quantitative 
 Limited mass range 
 Relative low mass 
accuracy and 
resolution. 
 Poor adaptability to 
MALDI 
Trapping 
 
Ion trap (IT): 
 
 3D ion 
trap (QIT) 
 Linear ion 
trap (LIT) 
 
2000 100 ppm Femtomole 
Up to 
1x106 
 Reasonable resolution 
 High sensitivity 
 Fast scan rate 
 Low cost 
 Small size 
 Excellent mass range 
 Limited resolution 
 Relatively low mass 
accuracy 
 
Orbitrap 500,000 2 ppm Attomole 
3x103 - 
4x103 
 Easily adapted to MALDI and ESI 
 Excellent resolution  
 Ease to switch between positive and 
negative ions 
 Low cost 
 Small size 
 Very fast scan speed 
 Limited mass range 
 Relative low mass 
accuracy and sensitivity  
Fourier 
transform-ion 
cyclotron 
resonance (FT-
ICR) 
500,000 <2 ppm Femtomole 
Up to 
1x104 
 Good mass range, up to 10,000 m/z 
 Excellent mass accuracy and resolution 
 Easily adapted to MALDI and ESI 
 Well suited to analyse complex mixtures 
 Slow scan speed 
 Expensive, require 
superconducting 
magnet 
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1.5.4.4 MALDI-TOF MS  
Proteomics Facility at the University of Bradford carried out their research 
using MALDI-TOF-TOF-MS, (Ultraflex II MALDI-TOF/TOF, Bruker Daltonics, 
Bremen, Germany). Schematically MALDI-TOF MS is composed of three main 
parts: source, where ions are produced and accelerated to a constant kinetic 
energy by means of electric fields; a drift region, which is a field-free region 
with a bounded extraction grid at ground potential; and a detector, where ions 
are colliding at the end, with the whole system under a high vacuum (Figure 
1.13).  
 
Figure 1-13. The schematic of Bruker Daltonics Ultraflex II MS consisted of target 
plate chamber, ion drift region and detectors. The target plate is introduced first into 
the ion source section at stage 1 (IS1) under vacuum. The laser beam hits the plate at 
the ground potential stage (P1). In the drift region, the precursor ion selector (PCIS) 
module is in charge to select for particular ion masses, which is then followed by the 
LIFT module to increase the kinetic energy of parent and fragment ions for detection. 
For better fragment ion detection, the parent ion signals can be deflected by using the 
post-LIFT metastable suppressor (PLMS) module. The signals are either measured in 
linear mode (MS mode) or reflected and detected by the reflector detector (de 
Hoffmann and Stroobant, 2007). 
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1.5.4.5 Instrumentation  
The first step involves the formation of co-crystals by mixing samples with 
excess matrix and loading it as spots on a metal plate. Upon complete 
evaporation of the sample’s solvents, the plate is placed in the source where 
the dried spot is fired by laser pulse beam, generating a short burst of ions in 
the gaseous phase as shown in Figure 1.14. 
 
 
Figure 1-14. Ionisation of analytes by MALDI. Sample co-crystallized first with the 
matrix. Then sample spot is irradiated by intense pulse laser beam, leading to 
sublimation and ionization of peptides. On the Ultraflex II MALDI-TOF MS, the sample 
is loaded onto a microtiter plate format MALDI target (metal plate for 384 sample 
spots) (de Hoffmann and Stroobant, 2007). 
 
Generated ions are then separated using time of flight (TOF) mass analyser. 
However, since not all ions are absorbed and ionized at the same time and 
place, ions of the same mass do not have the same kinetic energy after 
passing the acceleration field. Therefore, about 100-500 ns after the laser 
pulse, a strong acceleration field is switched on (delayed extraction) (GmbH, 
2006). Delayed extraction aims to impart a fixed kinetic energy to the ions 
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produced by MALDI process, ensuring that ions are accelerated and enter the 
drift region at the same time as illustrated in Figure 1.15.  
 
Figure 1-15. Schematic illustration of continuous (A) and delayed (B) extraction mode 
in a TOF. In continuous extraction mode, the electrical field is off, where; yellow, blue 
and red ions have the same mass with different kinetic energies (velocities) and so 
faster ion (red) hit before the slower one the detector. In delayed extraction mode, the 
electrical field is applied and a potential gradient accelerates slow ions more than fast 
ions resulting in those slow ions catch up with faster ones at the detector. Adapted 
from (Kovtoun et al., 2002).    
 
Throughout the flight tube, ions are reflected in a mirror called reflectron. It is 
basically an electrostatic reflector which reflects ions back through the flight 
tube till they reach the detector. The reflectron allows highly kinetic energy 
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ions to move more deeply into the reflector than ions with a lower energy 
(Figure 1.16). This compensates any differences in the initial energy and 
allows separating the ions with high resolutions on the basis of their mass-to- 
charge ratios.   
 
 
Figure 1-16. Schematic of a reflectron; ions (red and blue) have the same mass but 
not the same kinetic energies. Blue ion has much higher of kinetic energy compared 
to the red one, therefore it’s travel more deeply. However, after being reflected by the 
reflector, both ions will have the same kinetic energy and hence hit the detector at the 
same time (de Hoffmann and Stroobant, 2007).   
 
1.5.4.6 Tandem MS 
Tandem mass spectrometry (MS/MS) is a combination of multiple stages of 
mass analyser, in tandem, and in the same mass spectrometer. This can be 
useful in the detection of both parent and fragment ions and consequently 
identification of peptide sequences. In contrast to MS/MS, MS mode is able to 
detect only parent ions and not the fragmented ones.  
Bruker Daltonics Ultraflex II is an MALDI-TOF/TOF tandem mass 
spectrometer which, has two mass analysers making it an optimal technique 
for robotic MS and MS/MS throughout the identification of peptides and 
proteins (Figure 1.13). In MS/MS analysis, selected parent ions disintegrate 
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into fragments by means of collisionally induced dissociation (CID), and the 
fragments are analysed by TOF mass analyser. During the MS analysis, the 
feature of LIFT module is disabled and therefore only parent ions can be 
analysed and detected. When the LIFT device is used in MS/MS the kinetic 
energy of the selected parent and fragment ions is raised, allowing detection 
of fragments and parent ions. The LIFT module results in different kinetic 
energy for parent and fragment ions, where the level of difference between 
parent and smallest fragment does not exceed 30%. This difference allows for 
both parent and fragment ions to travel down the flight tube with the same 
velocity. Upon entering the reflectron the fragment ions have lower kinetic 
energy, so they do not travel as deep as parent ions do and are detected by 
the reflectron detector in a shorter flight time than the parent ions (GmbH, 
2006). 
The precursor ion selector (PCIS) is a mass filter that selects particular mass 
of parent ions and their related fragments to travel down a flight tube and then 
separates the selected ions from others for MS/MS analysis (Figure 1.17). It 
consists of deflector plates arranged in vertical layers below each other. 
Consecutive electrodes are coupled to a high voltage supply with alternating 
polarity. PCIS selects particular parent and fragment ion masses by altering 
the electrical fields during their entry into the deflector region to prevent 
deflection and allow ions to continue through the drift region (de Hoffmann and 
Stroobant, 2007).  
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Figure 1-17. A schematic of precursor ion selector (PCIS) and high voltage alteration. 
In the deflection region, the electrical field between the deflector layers is re-adjusted 
with aims to select particular parent and fragment ion masses. Thus, helps to prevent 
the deflection and allows them to move down the drift region (de Hoffmann and 
Stroobant, 2007). 
 
The detector converts an ion current into an electrical current, which is then 
digitized and delivered to the PC. Because small ions have a higher velocity 
than large ions, the detector detects and records the small ions earlier than 
large ions, producing the TOF spectrum.  
1.5.4.7 Peptide identifications  
Protein identification can be achieved by identifying the sequences of the 
peptides. Proteins are first digested enzymatically using a restriction enzyme 
such as; trypsin, into shorter length peptides. Each peptide produced from 
protein is made of a characteristic sequence of amino acids and thereby it has 
its particular mass and the detection of a number of peptides from a digested 
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protein constitutes a unique pattern; this is known as “Peptide Mass 
Fingerprint” (PMF) (Pappin et al., 1993b, Henzel et al., 2003). The PMF list is 
then compared, using a database search engine, with theoretical peptide 
molecular masses (in-silico database) generated using the same restriction 
enzyme to create a list of best matches (Liska and Shevchenko, 2003). 
The best-matched protein is most likely to be the correct protein, however, 
particular parameters such as scoring the quality of the match between the 
experimental and theoretical are used to validate the identified proteins by this 
method. Although PMF is a straightforward method that has been used widely 
in single purified protein identification, it is not feasible if the sample is a 
mixture of proteins or if there is an amino acid substitution or post-translational 
modifications (Liska and Shevchenko, 2003).  
The MS/MS approach can overcome these limitations. Fragmenting the 
peptide using CID breaks the peptide backbone during the fragmentation 
process. The resultant amino-acid specific daughter ions provide information 
about the constituent amino-acids of the peptide, which is used to identify the 
peptide. The cleavage of the peptide bond is based on the physio-chemical 
properties of amino acids within the peptide (Hubbard, 2010). After cleavage, 
the charge can be retained on daughter fragments at a different location. If the 
charge is possessed upon the N-terminus, then ions are known as, “a”, “b”, “c” 
will be formed; on the contrary, “x”, “y”, “z” is formed if the charge is possessed 
upon the C-terminus (Figure 1.18). However, b and y fragment ions are the 
most common formed for CID cleavage.   
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Figure 1-18. General product ion fragments generated upon fragmentation of from a 
peptide sequence in the mass spectrometer. The products (a, b, c) represent the N-
terminus, where (x, y, z) represent the C-terminus after the fragmentation. Collision 
induced dissociation (CID) fragmentation generates mostly b and y ion series adapted 
from (Hubbard, 2010).  
 
The identification of peptides forms MS/MS analysis can be achieved by 
matching the MS/MS spectra from experimentally trypsin-digested peptides to 
the theoretically determined fingerprints, again using database searching. 
Imported mass values are scored in a way that allows peptides or proteins 
which best matches the data to be identified. Several algorithms and computer 
programmes have been designed to search protein sequence databases and 
identify proteins (e.g., SEQUEST, Mascot, Comet, etc.). ‘Mascot’ is a search 
engine, which employs probability in proteins identification. The mascot is a 
development of the molecular weight search engine (MOWSE), which was 
developed by Darryl Pappin and Alan Bleasby in 1993 (Pappin et al., 1993a) 
for peptide mass fingerprint (PMF). The mascot can conduct three different 
types of searches, Peptide Mass Fingerprint; Sequence Queries; and MS/MS 
ion searches [http://www.matrixscience.com/]. Probability-based scoring is 
applied to search engines in order to establish the confidence of matching an 
‘unknown’ protein to the closest sequence homology on the database and 
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determine if it is significant or not, in order to reduce false positive results. In 
this approach, the probability of a match between the experimental data and 
theoretical mass values is calculated from candidate protein or protein 
sequence compared to a random event. A very low probability value is 
reported as the real match. Because the best match is usually a very small 
number, the Mascot score has been used instead of probability (P) which is 
equal to (-10 log10 (P)). Hence, the higher the MASCOT score, the more likely 
the peptide derives from the identified protein. In addition, the significance of 
the real match depends also on the size of the database. 
1.6 Aims and objectives  
The objective of the project is to investigate the influence of major anti-cancer 
drugs on mouse liver protein expression, in particular, the microsomal fraction, 
since the liver is considered as the primary organ in the body responsible for 
drugs metabolism and detoxification, and it has been involved in several drugs 
toxicity and safety profile studies.  
The expected outcomes of this work are: (i) demonstrating the optimised 
quantitative proteomics workflow to be used henceforth in liver microsomes 
investigation, (ii) identifying and validating potential biomarkers from treated 
liver microsomes in response to major anti-cancer drugs, (iii) better 
understanding of the influence of these drugs on the expression and activity 
of chief enzyme family exist mainly in liver microsomes (i.e. CYP450 subfamily 
enzymes) and, (iv) assessing the influence of sex variation affecting the 
expression and activity of pre-defined proteins. The approaches taken to 
accomplish these goals are outlined and the structure of this thesis is as 
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follows; the introductory chapter (Chapter 1) provides the background and 
motivation for the research, the research objectives and an overview of the 
research approach. Prior to this research, Chapter 2, describes the materials 
and methods common to much of the work contained within this thesis, more 
specific methods can be found within the chapter to which they pertain. 
Chapter 3 describes the optimisation of protein extraction by four different 
extraction methods followed by two key peptides-separation techniques. 
Hence, Chapter 4 investigates the impact of 5-flourouracil, doxorubicin, 
paclitaxel, cisplatin, and the CYP450s inducer, 1,4-Bis[2-(3,5-
dichloropyridyloxy)]benzene (TCPOBOP) on liver microsomes proteomes 
from mice. Chapters 3 and 4 aims were accomplished using quantitative 
proteomics approach (iTRAQ labelled), nano-reverse phase HPLC and 
MALDI-TOF-MS MS/MS. Identified proteins from Chapter 4 were validated in 
a new highly controlled study involved both sexes in Chapter 5, with definitive 
goals to confirm the regulated proteins in shotgun study (Chapter 4) using the 
advances of Western blotting technique and exploring the influence of sex 
variation in response to two anti-cancer drugs (Paclitaxel and Doxorubicin). 
Chapter 6 correlates the enzyme activity of two CYP450 isoforms (CYP1A2 
and CYP3A4) in response to drugs treatment using fluorescence assay (VIVID 
assay) with their expression level as indicated by Western blotting analysis in 
Chapter 5. The seventh and final chapter of the thesis gives a summary of the 
conclusions drawn from the presented research, and recommendations for 
future works.   
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Chapter two: General materials and method 
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2 General materials and method 
2.1 Materials  
2.1.1 Proteomics analysis 
The highest quality reagents were used throughout, from the following 
sources; α-cyano-4-hydroxy-cinnamic acid (CHCA), Peptide Calibration 
Standard II (components: angiotensin I, angiotensin II, substance P, 
bombesin, ACTH clip 1-17, ACTH clip 18-39, somatostatin 28, bradykinin 
fragment 1-7and renin substrate tetradecapeptide porcine; covered mass 
range ~700Da – 3200Da.) from Bruker Daltonics GmbH, Bremen, Germany; 
HPLC grade water, HPLC grade acetonitrile (ACN), HPLC grade methanol 
(MeOH), HPLC grade ethanol from Fisher Scientific, Leicestershire, England; 
trypsin (modified sequencing grade), complete mini EDTA-free protease 
inhibitor cocktail tablets (PIC) from Roche Diagnostics GmbH, Berlin, 
Germany; urea, sodium dodecyl sulphate (SDS), ammonium bicarbonate, 
phosphate buffered saline (PBS), acetone, iodoacetamide (IAA), dithiothreitol 
(DTT), trifluoroacetic acid (TFA), Bradford reagent, albumin from bovine serum 
(BSA), ammonium phosphate monobasic, potassium chloride (KCl), 
hydrochloric acid (HCl), sodium azide (NaAz), triethylammonium bicarbonate 
(TEAB) from Sigma-Aldrich, Poole, UK; potassium dihydrogen phosphate 
(Analar, Belgium); iTRAQ 4-plex reagent (AB Sciex UK Limited, Warrington, 
UK). OFF-GEL Kit (thiourea, dithiothreitol, glycerol and OFF-GEL buffer), 
Rehydration Solution and Mineral oil, pH 3-10, were from Agilent 
Technologies, CA, USA. 
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2.1.2 SDS-PAGE electrophoresis and Western blotting 
Acrylamide (30%) and tris-hydroxymethyl aminomethane (Tris) were 
purchased from Bio-Rad laboratories, Hercules CA, USA; Mouse anti-
CYP1A2 (ab22717), MUP1 recombinant protein (ab95193) and Rabbit anti-
CYP2E1 (ab151544), anti-CYP3A4 (ab135813), were purchased from Abcam, 
Cambridge, UK; Mouse anti-β actin (A2228), anti-mouse IgG (A4416), 
Coomassie Brilliant Blue stain, glycerol, glycine, sodium chloride, 
tetramethylethylenediamine (TEMED), Tween-20, ‘PhastGel Blue R’ 
Coomassie Brilliant Blue tablets and β-mercaptoethanol were purchased from 
Sigma-Aldrich, Poole, UK; Rabbit anti-MUP1 antibody was purchased from 
Santa Cruz, Texas, USA; Anti-Rabbit IgG-conjugated with HRP was 
purchased from Dako, Glostrup, Denmark; HPLC grade water, methanol and 
isobutanol and PageRuler™ Plus Prestained Protein Ladder (10 to 250 kDa) 
were purchased from Fisher Scientific UK Ltd, England; Amersham ECL-plus, 
Amersham hyperfilm™ ECL and ammonium persulphate (APS) were 
purchased from GE Healthcare, Buckinghamshire, UK; Multi-grade Rapid 
developer and fixer were purchased from ILFORD Imaging, Cheshire, UK; 
Skimmed milk from Marvel Premier Food, Manchester, UK. 
2.1.3 Enzyme activity assay 
VIVID CYP450 Reaction Buffer I, VIVID Assay Substrate, 0.1 mg of (7-
benzyloxy-methyloxy-3-cyanocoumarin, BOMCC for CYP3A4 or substrate 7-
ethoxymethoxy-3-cyanocoumarin, EOMCC for CYP1A2), baculosomes 
CYP3A4 (0.5 nmol) and CYP1A2 (0.5 nmol), 10mM Vivid NADP+, and VIVID 
regeneration system were purchased from Life Technologies, Carlsbad, CA. 
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2.2 Methods  
2.2.1 Proteomics analysis 
2.2.1.1 Tissue homogenization and protein extraction 
As a part of extraction protein optimization, four different mechanical extraction 
methods were evaluated and described in Chapter 3, section 3.2.2.1.  
2.2.1.2 Microsomal fraction preparation 
Liver microsomes were prepared from S9 fraction of liver extracts using a 
differential centrifugation method (Figure 2.1) as described previously (Sutton 
et al., 2010). Briefly, the supernatant (S9) was transferred to ultracentrifuge 
tubes and centrifuged at 100,000 g using the Beckman Optima TL100 
Ultracentrifuge (Beckman Coulter, UK) for 60 minutes at 4°C to sediment 
microsomes. The cytosolic supernatant was transferred to fresh tubes and 
stored at -80°C for future use. The microsomal pellet was then resuspended 
with 0.5 ml ammonium bicarbonate for protein concentration determination. 
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Figure 2-1. Flow diagram for Ultracentrifugation method 
 
2.2.1.3 Protein Assay 
Bradford assay was used to determine the initial protein concentrations in 
solution and ensure that the same amount of protein was used in further 
experiments (Bradford, 1976). A standard curve of absorbance versus serial 
concentrations of bovine serum albumin (BSA) was created starting from 
1mg/ml to 0.0625mg/ml (Figure 2.2). Absorbances were detected using a 
Multiskan Spectrum spectrophotometer (Thermo Scientific, Vantaa, Finland) 
at a wavelength of 595nm by adding 1.5 ml of Bradford reagent to 50 µl of 
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standards, and then standards were incubated for 15 minutes at room 
temperature. The samples were prepared in the same way, analysed in 
duplicate and the readings extrapolated to the standard curve to calculate 
samples concentrations. 
 
Figure 2-2. BSA standard curve represents the absorbance of serial dilutions of BSA. 
 
2.2.1.4 Protein Desalting and Concentration  
Briefly, pre-cooled acetone (1 ml) was added to a 10-fold excess of a sample 
containing approximately 50µg of extracted protein and the mixture stored at 
20°C overnight. Thereafter the mixture was centrifuged for 20 minutes, 13,000 
g at 4°C. The supernatant was discarded and the pellet was lyophilized and 
kept on ice for further analysis. 
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2.2.1.5 Protein digestion 
In order to convert proteins into peptides that can be used for tagging and 
identification, lyophilised protein pellets (equivalent to 50µg) were 
resuspended in 5 µl of 8M urea, 400mM ammonium bicarbonate. The 
resuspended pellet was reduced by 1 µl of 50mM dithiothreitol (DTT) and 
incubated in a water bath at 80°C for 20 minutes. The sample was cooled to 
room temperature and alkylated with 1 µl of 100mM iodoacetamide (IAA) for 
20 minutes in the dark. After that, 13 µl of 400mM ammonium bicarbonate and 
10% acetonitrile (ACN) were added to reduce the concentration of urea to 2M, 
before 2 µl of 1mg/ml trypsin was added and incubated at 37°C for 18-20 
hours. 
2.2.1.6 Digested proteins purification and desalting 
The digested samples were desalted using TELOS® C18 disposable columns 
(Kinesis Ltd., Cambridgeshire, England) to remove urea and other modifying 
reagents. Initially, the columns were wet with 1 ml of 100% methanol and then 
equilibrated with 2 ml of solvent A (2% v/v ACN and 0.05% TFA). A mixture of 
the digested sample (100 - 500 µl) and solvent A (2% v/v ACN and 0.05% 
TFA) was added to the column, with the total volume adjusted to 500 µl. The 
column was then washed with 2 ml of solvent A (2% v/v ACN and 0.05% TFA). 
The bound proteins were eluted using 1 ml of solvent B (80% v/v ACN and 
0.05% TFA) and collected in an Eppendorf tube. Finally, samples were 
centrifuged and lyophilized at 45°C to dryness for storage at -20°C. 
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2.2.1.7 iTRAQ peptide labelling 
Ethanol (70 µl) was used for iTRAQ 4-plex reagent resuspension, each vial 
contents were transferred to the relevant protein digested tubes. iTRAQ vials 
were rewashed with 10 µl ethanol, vortexed, then transferred to relevant 
sample tubes, vortexed and centrifuged at 14,100 g. The pH was tested and 
adjusted to pH 8.0 using 1M TEAB if required. After 2 hours of incubation at 
room temperature, the pH was retested and adjusted if needed. The contents 
of all the tubes were combined into one tube after adding 50 µl HPLC-water to 
stop the reaction. A further 25 µl of HPLC water was added to each tube, to 
wash out the sample, and combined with the remainder. The combined 
samples were lyophilized at 45°C and then stored at 4°C for further analysis. 
2.2.1.8 Peptides separation 
After protein digestion and labelling, peptides were separated in two 
dimensions, based on charge and then hydrophobic properties, to extend the 
coverage of identified proteins. However, for the first dimension separation; 
two charge-based techniques (strong cation exchange and isoelectric-
focusing) were compared to find the best resolving technique (Chapter 3). 
2.2.1.8.1 First-dimensional separation 
2.2.1.8.1.1 Strong cation Exchange 
The combined iTRAQ-labelled peptides were separated using ISOLUTE® 
column (ITS Ltd., England). Loading buffer (200 ml) was prepared using 10mM 
potassium dihydrogen phosphate in 25% (v/v) ACN and 0.01% (w/v) sodium 
azide (NaAz), and then adjusted at pH 3.0. The loading buffer was used to wet 
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the column and to resuspend the sample by using 2 ml and 0.6 ml, 
respectively. The resuspended sample was loaded onto the equilibrated 
column from which the first fraction (flow through 1) was collected by passive 
hydrostatic pressure. Then, the column was washed with 1 ml of loading buffer 
and collected as flow through-2 fraction. In order to elute the bounded 
peptides, 500 µl of a serial concentration of potassium chloride (30mM to 
1000mM) in loading buffer were applied and the resulting eluate collected as 
shown in Table 2.1. A total of 12 fractions were collected for second dimension 
separation of peptides. 
Table 2-1. Serial concentrations of potassium chloride used to elute bounded 
peptides. 
Fraction 
Volume loading 
buffer 
Concentration of KCl 
(mM) 
Amount of KCl for 
10ml (mg) 
E1 10 ml 30.0 22.4 
E2 10 ml 60.0 44.7 
E3 10 ml 90.0 67.1 
E4 10 ml 120.0 89.5 
E5 10 ml 150.0 111.8 
E6 10 ml 180.0 134.2 
E7 10 ml 250.0 186.4 
E8 10 ml 300.0 223.7 
E9 10 ml 350.0 260.9 
E10 10 ml 500.0 372.8 
E11 10 ml 700.0 521.9 
E12 10 ml 1000.0 745.5 
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Indeed, the eluted samples (fractions) were desalted as described before in 
(section 2.2.1.6), lyophilized at 45°C and kept at -20°C. 
2.2.1.8.1.2 Isoelectric-focusing  
Isoelectric-focusing (IEF) separation for iTRAQ labelled peptides was 
performed using the Agilent 3100 OFF-GEL Fractionator (Agilent 
Technologies) according to protein or peptide isoelectric point (pI), whereby 
the separated component was recovered in liquid fractions.  
Samples were resuspended in peptide OFF-GEL stock solution 1.25X. 
Immobilized pH gradient (IPG) strip gel 12 or 17 cm (Agilent Technologies) 
was placed on the tray well and the tray frame placed over the gel. The gel 
was rehydrated with 40 µl of IPG strip Rehydration solution per well and then 
150 µl of resuspended sample was loaded into each well. Mineral oil was used 
to cover the gel strip ends, after that the electrodes were fixed at both ends of 
the gel strips. Peptides were focused for 20 kV for 24 hours and the results 
were either 12 or 24 fractions based on the length of gel strip (12 or 17 cm). 
Fractions were collected and desalted in accordance with the procedure 
described in section 2.2.1.6. The lyophilized samples were kept at -20°C for 
the second dimension separation. 
2.2.1.8.2 Second-dimensional separation 
Throughout this project, the second dimension separation of peptides was 
carried out using a Nano-scale Reverse phase liquid Chromatography, LC 
Packings UltiMate 3000 capillary high-performance liquid chromatography 
system (Dionex, Surrey, UK). Utilising a PepMap100 C18 5μm, 5 cm guard 
column and a PepMap 100 C18 3μm, 15 cm analytical column (LC Packings, 
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Sunnyvale, USA). Lyophilised iTRAQ-labelled samples were resuspended in 
13 µl of 10% (v/v) ACN and 5 µl was injected onto the precolumn through the 
auto-sampler system. The sample was washed with mobile phase A, (2% v/v 
ACN, 0.05% v/v TFA) for 3.5 minutes at a flow rate of 0.3 µl/min on the pre-
column before being switched onto the analytical column. Six minutes after 
sample injection, the mobile phase B (80% v/v ACN, 0.05% v/v TFA) was 
increased to 15% and then increased with a linear gradient to 45% over 105 
minutes. At minutes 111.1 the mobile phase B was increased from 45% to 
100%. This mobile phase composition is maintained for 5 minutes and then 
changed to 100% mobile phase A ready for the next sample. During the 
analytical phase (16 to 112 minutes), a total of 384 fractions, at 75 nL for each, 
were collected onto an MTP Anchor Chip 800/384 target plate (Bruker 
Daltonics) using a Proteineer FC fraction collector (Bruker Daltonics). As each 
fraction was collected, 1.5 µl of a saturated α-cyano-4-hydroxycinnamic acid 
(CHCA) working matrix solution (1.056 ml ethanol: acetone, 120 µl saturated 
CHCA in 30% v/v ACN, 12 µl 100mM ammonium phosphate, 12 µl 45% v/v 
TFA) was automatically co-deposited by the fraction collector. The resultant 
droplets were allowed to air-dry and Peptide Calibration Standard II (Bruker 
Daltonics) was added manually using 0.4 µl Peptide II calibrant standards and 
1.5 µl CHCA working matrix solutions between each group of four fractions. 
2.2.1.9 MALDI - TOF/TOF MS analysis 
Mass spectrometric analysis of protein sample was performed using an 
Ultraflex II MALDI-TOF/TOF mass spectrometer (Bruker Daltonics). Prepared 
samples on the MTP AnchorChip 800/384 target plate were loaded into the 
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mass spectrometer (MS). A fully automated run was carried out using WarpLC 
software package version 1.3 (Bruker Daltonics). The laser power for calibrant, 
sample, and target teaching were manually adjusted and saved in relevant 
executable methods using FlexControl software version 3.4 (Bruker Daltonics) 
to be included in the automatic run. The MS data acquisition of each fraction 
was performed and parent peak signals identified between 700 and 4300 
Daltons using FlexControl-MS mode. WarpLC software creates a non-
redundant list of masses with signal-to-noise ratio ≥7:1, which are the subject 
of MS/MS analysis using FlexControl-LIFT mode. Mass peak lists were 
created for each compound which was transferred to ProteinScape software 
version 3.0 (Bruker Daltonics) for database searching against a SwissProt 
52.4 mouse protein database containing 16,765 sequences. The search 
standard parameters were set up in ProteinScape as follows; Mascot search 
engine, taxonomy Mus musculus species, trypsin digestion, fixed 
modifications (carbamidomethyl of cysteine residues, iTRAQ modification of 
lysine residues and iTRAQ modification of N-terminal residues), variable 
modification (oxidation of methionine residues), 2 partial digests allowed and 
100 parts per million (ppm) peptide mass tolerance for MS and 0.7 Daltons for 
MS/MS. For peptides acceptance, parameters were set for peptides as 
threshold score of 5, but proteins were only accepted if identified by at least 
one peptide with a score higher than 28 (a confidence level of 95% interval 
(p<0.05)). Only the ranked first peptides were accepted. 
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2.2.1.10 Data analysis  
ProteinScape Software version 3.0 (Bruker Daltonics) was used to generate a 
non-redundant protein list by combining all the fractions according to the 
previously mentioned parameters (section 2.2.1.9). The combined protein list 
was reprocessed manually, in which each single protein was investigated for 
a number of peptides; include replicate spectra for the same peptides, their 
Mascot scores and the inclusion of the only 1st ranked peptides.  
Proteins identified were deemed significant if they were identified by at least 
two peptides or multiple peptide spectrum matches (PSMs) and the Mascot 
score was greater than 28 for at least one of these peptides. However, for 
proteins with high degree of sequence homology, such as CYP450 members, 
proteins were considered significantly identified if two peptides minimum were 
detected; at least one of them was unique and has a Mascot score greater 
than 28 or one unique peptide with at least two spectra; one of them with 
Mascot score greater than 28.  
2.2.1.11 Protein quantifications 
For protein quantification, the unique peptide ratios were used relying on the 
relative intensities of the reporter ions of the corresponding peptides. Unique 
peptide list was generated from peptide redundant list by excluding the 
common peptides and any other peptide that has less than two iTRAQ ratios. 
Moreover, at least two unique peptides were required for determining the 
protein relative amount or a single peptide with multiple peptide spectrum 
matches (PSMs) with coefficient variation percentage (CV%) not more than 
25%. The p-value for each quantified protein was computed following the 
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permutation test as described by Nguyen and his colleagues (Nguyen et al., 
2012). The p-value computations have been done automatically using the 
Quantitative Proteomics p-value Calculator (QPPC), which is available online 
for free at [http://qppc.di.uq.edu.au/]. Briefly, an excel file contained 
normalised unique peptide ratios was uploaded to the QPPC website. A 
standard parameter set was used, which includes the number of computation 
repetitions (number of permutations) as 10000 (Chen et al., 2014). The 
resultant is an excel sheet having a list of proteins with their mean peptide 
ratios. 
For standard deviation determination and comparison between iTRAQ ratio 
datasets, data normalisation was performed for iTRAQ ratios by calculating 
the median protein value for each ratio (115/114, 116/114 and 117/114). Then, 
each protein value was divided by the average ratio to calculate the normalized 
ratio for each ratio (115/114, 116/114 and 117/114).  
2.2.1.12 Thresholds for significantly changed proteins  
Unique protein list was used for significant differentially expressed proteins 
were determined by applying two criterion as cutoffs for significantly altered 
proteins to reduce false positive. The first criterion was based on the 
normalised data as illustrated in Section 2.2.1.11. Briefly, the protein-
normalised ratios were first converted into log2 ratios and then standard 
deviation (SD) of log2 ratios was calculated for each ratio. Finally, up-regulated 
or down-regulated proteins were defined as those with ratios greater than 
+1SD and those with ratios less than -1SD, respectively. The second cutoff 
was the p-value (calculated in previous section 2.2.1.10), while proteins with 
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95% confidence (p-value <0.05) were considered as significantly regulated 
protein (either up- or down-regulated) based on the values of iTRAQ ratios.  
2.2.1.13 Bioinformatics analysis of identified proteins 
Protein annotations were obtained primarily from the Protein Analysis through 
Evolutionary Relationships (PANTHER) software tool, which is available on-
line at [http://www.pantherdb.org] (Stan et al., 2005). The protein analysis 
includes assigning the identified proteins to specific gene ontological 
definitions defined by cellular location, molecular function or biological 
process. Localization prediction of membrane proteins was determined based 
on the Gene Ontology (GO) information provided by UniProt database 7.0 
[http://www.uniprot.org/] (Consortium, 2014). The grand average of 
hydropathy (GRAVY) score was used to evaluate the hydrophobic status of 
proteins, indicate a hydrophobic protein, and suggest a membrane 
association. GRAVY index was determined using the GRAVY calculator 
[http://www.gravy-calculator.de/]. A calculated GRAVY score of up to –0.4 
indicates a hydrophobic protein (Kyte and Doolittle, 1982). 
For integral membrane proteins prediction, a combined transmembrane 
topology and signal peptide predictor (Phobius tool) was used. It is an online 
tool provided by the European Bioinformatics Institute (EMBL-EBI) that can be 
accessed by submitting the sequence of amino acids for a specific protein in 
FASTA format [http://www.ebi.ac.uk/Tools/pfa/phobius/]. Phobius gives a list 
of the location of the predicted transmembrane helices, the predicted location 
of the intervening loop regions and signal peptide (Käll et al., 2004).   
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Skyline Targeted Proteomics Environment (Skyline 3.5-64 bit) software tool, 
was used to provide possible theoretical digests from SwissProt database of 
close homologues isoforms in order to confirm whether the particular peptide 
is unique for matched isoform (MacLean et al., 2010).  
In additional, homology of closely related isoforms within subfamily was 
determined using multiple sequence alignment tools, CLUSTAL O (1.2.1), 
which is available on-line [http://www.ebi.ac.uk/Tools/msa/clustalo/] at the 
European Bioinformatics Institute (EMBL-EBI) website. 
For enrichment/depletion test, the Cytoscape plugin, Biological Networks 
Gene Ontology (BinGO), was used to classify proteins according to their 
cellular component, molecular function, and biological process and then find 
statistically enriched and depleted GO categories of the protein dataset. A list 
of regulated protein was compared to a list of reference protein (International 
Protein Index – IPI of the mouse). Only significant proteins were considered 
either over-represented (enriched) or under-represented (depleted) by 
calculation of p-values. P-value was computed following the hypergeometric 
statistic test. This statistical test displays the probability that the number of 
genes observed in this category occurred by chance (randomly), as compared 
with the reference list (IPI). Categories were only considered significantly 
enriched when (i) p-values were < 0.01 after correcting for a multiple term 
testing with a Benjamini and Hochberg false discovery rate and (ii) categories 
included more than one protein. 
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2.2.2 SDS-PAGE electrophoresis and Western blotting 
2.2.2.1 Gel preparation 
Fresh SDS polyacrylamide gel was prepared manually by pouring the 
resolving gel (12% acrylamide, 1% SDS, 1% APS, 0.04% TEMED in Tris-HCl 
buffer) into the casting glass plates. Plates were attached to the casting frame 
on the casting stand (Bio-Rad). After that, the top layer of gel was temporarily 
filled with isobutanol. Once the gel had polymerized, after approximately 45 
minutes, isobutanol was replaced by stacking gel (6% acrylamide, 1% SDS, 
1% APS, 0.08% TEMED in Tris-HCl buffer). The 1 mm comb was immediately 
inserted to create the wells for sample loading and the gel left to polymerize 
for approximately 20 minutes. Gels were removed from the casting stand and 
frames and immediately utilised for SDS-PAGE. 
2.2.2.2 Sample preparation 
A mixture of protein extracts (40µg) and 2X of SDS-reducing buffer (Laemmli 
buffer; 2% SDS, 25% glycerol, 5% β-mercaptoethanol, 0.004% bromophenol 
blue and 0.125 M Tris-HCl, pH approximately 6.8) were heated to 65 °C for 15 
minutes for protein denaturation.  
2.2.2.3 Gel Electrophoresis 
The fresh gel prepared (section 2.2.2.1) was inserted into the Mini-PROTEAN 
electrophoresis system (Bio-Rad) that contains electrophoresis running buffer 
(25mM Tris, 192mM glycine, and 0.1%SDS). After assembling the system, the 
denatured protein samples (20µl of each) were loaded into gel wells. A lane 
was reserved for Prestained Protein Ladder separation named by marker lane. 
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Manual gel separation involved an initial power pack setting of 20 minutes at 
80V followed by approximately 60 minutes at 150V (Bio-Rad). Then, the gel 
was used for either qualitative visual investigation by staining or for 
quantitative investigation by Western blotting technique. 
2.2.2.4 Coomassie Brilliant Blue staining 
After running the gel, the casting plates were disassembled, the gel removed 
and transferred into container containing distilled water to wash the gel from 
any excess SDS, after that, gel staining was done by immersing the gel in 
Coomassie Brilliant Blue stain solution (0.02% Coomassie Brilliant Blue R, 
50% MeOH and 10% glacial acetic acid) for 45-60 minutes with gentle 
agitation. The stain was then replaced with destaining solution (50% MeOH, 
5% acetic acid), which in turn was replenished several times with fresh destain 
solution until the background of the gel was fully removed. The destain solution 
was then replaced with distilled water to remove traces of stain and to 
rehydrate/expand the gel. Stained gels were stored in 10% MeOH at 4°C for 
further analysis. 
2.2.2.5 Western blotting 
As an alternative to Coomassie Blue staining, proteins separated in gels were 
transferred onto Hybond-P nitrocellulose membrane (GE Healthcare). A 
sandwich of the gel and nitrocellulose was immersed in a tank containing 
transfer buffer (48 mM Tris-base, 39 mM glycine, 0.04% SDS and 20% MeOH, 
pH8.3). Proteins were transferred on ice by electroblotting for two hours at 85 
mA in a Mini Trans-Blot Cell (Bio-Rad). Blocking buffer-TBST (5% w/v 
skimmed milk dissolved in Tris-buffered saline, 0.05% v/v Tween-20) was then 
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incubated with the recovered membrane for one hour at room temperature to 
block the non-specific binding sites. Following that, the blot was incubated with 
an appropriate primary antibody (Table 2.2) in blocking buffer overnight (16 
hours) at 4°C with constant agitation. The blot was then washed three times, 
5 minutes each, with fresh TBST to remove the excess primary antibody 
before incubation with the appropriate secondary antibody in blocking buffer 
for one hour at room temperature (Table 2.3). Lastly, the blot was washed 
three times, 15 minutes for each with fresh TBST. 
Table 2-2. A table of different primary antibodies that have been used thoroughly in 
the present project. The table shows information about the antibody including, 
supplier, the source of antibody, reactivity and specificity, and optimized 
concentrations used. TBST; Tris-buffered saline plus 0.05% v/v Tween-20. 
Name of 
primary 
antibody 
Species 
reactivity 
Developed 
animal 
Supplier Dilution 
Blocking 
buffer 
Clonality Epitope 
Anti-
Cytochrome 
P450 1A2 
antibody 
Mouse, Rat, 
Human 
Mouse 
Abcam 
(ab22717) 
1/2500 TBST monoclonal 
Full length of 
CYP4501A2 
(Rat) 
Anti-
Cytochrome 
P450 2E1 
antibody 
Mouse Rabbit 
Abcam 
(ab151544) 
1/2000 TBST monoclonal 
Full length of 
CYP4502E1 
(Rat) 
Anti-
Cytochrome 
P450 3A4 
antibody 
Human Rabbit 
Abcam 
(ab135813) 
1/500 TBST polyclonal 
Synthetic 
peptide 
corresponding to 
human CYP3A4 
(aa 234-264) 
Anti-Major 
urinary 
protein 1 
antibody 
Mouse Rabbit 
Santa Cruz 
(sc-66976) 
1/1000 TBST polyclonal 
Full-length 
protein of MUP1 
(Mouse) 
anti-β actin 
antibody 
Mouse, Rat, 
Human 
Mouse 
Sigma-
Aldrich 
(A2228) 
1/5000 TBST monoclonal 
N-terminal end 
of the β-isoform 
of actin (Human) 
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Table 2-3. A table of different secondary antibodies that have been used thoroughly in 
the present project. The table shows information about the antibody including, 
supplier, the source of antibody, reactivity and specificity, and optimized 
concentrations used. 
Name of primary 
antibody 
Species 
reactivity 
Developed 
animal 
Supplier Dilution Clonality 
Anti-mouse IgG 
conjugated with HRP 
Mouse Rabbit 
Sigma-
Aldrich 
(A4416) 
1/20000 polyclonal 
Anti-rabbit IgG 
conjugated with HRP 
Rabbit Goat 
Dako  
(P0448) 
1/5000 polyclonal 
 
Protein bands were visualised by the enhanced chemiluminescence (ECL) 
system (GE Healthcare) and according to the manufacturer’s guideline. 
Briefly, the blot was exposed to ECL reagents (A and B) for two minutes at RT 
before being enveloped in a hard plastic sheet. Then, in the dark room, the 
blot was exposed to hyper film ECL for a variable time ranging from 10 
seconds to 30 minutes depending on the antibody. Hyperfilm was developed 
using Multi-grade rapid developer solution (ILFORD) for up to three minutes, 
followed by distilled water to remove the excess developer solution and at the 
end, the blot was fixed using the Rapid film fixer for up to five minutes. 
2.2.1 Enzyme activity assay 
The VIVID CYP450 assay was conducted in accordance with the 
manufacturer’s instructions. All reactions were performed in black flat-
bottomed 96-well plates, Nunc™ (Thermo Fisher Scientific) with a final well 
volume of 100 µl. Concentrations were derived from the manufacturer’s 
handbook before being optimized during experiments (Table 2.4). 
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Table 2-4. Stock concentrations of main components of the VIVID assay.   
Cofactor 3A4 1A2 
CYP450 baculosomes 1000 pmol/ml = 1 µM 1000 pmol/ml = 1 µM 
VIVID Substrate BOMCC, 2mM EOMCC, 2mM 
NADP+ 10mM 10mM 
G6P/G6PD 333mM/30 U/ml 333mM/30 U/ml 
 
NADP+; Nicotinamide adenine dinucleotide phosphate, G6P/G6PD; Glucose-6-phosphate /Glucose-6-
phosphate dehydrogenase, BOMCC; 7-benzyloxy-methyloxy-3-cyanocoumarin, EOMCC; 7-
ethoxymethoxy-3-cyanocoumarin 
For BACULOSOME VIVID assays, A master pre-mix (100X) was created 
using 4850 µl of Reaction buffer I (200mM potassium phosphate buffer, pH 
8.0), 100 µl of Regeneration System (333mM Glucose-6-phosphate and 30 
U/ml Glucose-6-phosphate dehydrogenase in 100mM potassium phosphate 
buffer, pH 8.0) and 50 µl of either CYP3A4 or CYP1A2 baculosomes 
(baculovirus microsomes co-expressing human CYP450, NADPH-cytochrome 
P450 reductase and human cytochrome b5). A substrate mix (100X) 
comprised of 30 µl NADP+ and VIVID Assay Substrate, 25 µl of 2mM BOMCC 
or 15 µl of 2mM EOMCC for CYP3A4 and CYP1A2, respectively. The final 
volume for substrate mix was topped with reaction buffer I to 1000 µl.  
In order to measure the activity of CYP450, 90 µl of master pre-mix was mixed 
with 10 µl of the substrate mix in a well, the final concentrations were computed 
(Table 2.5). The plate was read using the Fluoroskan Ascent FL Microplate 
Fluorometer and Luminometer (Thermo Fisher Scientific, UK) continuously 
every minute for 60 minutes at 390 and 518nm emission and excitation 
wavelengths respectively.  
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Table 2-5. Final concentrations for main components of VIVID assay per reaction.   
Cofactor 3A4 1A2 
CYP450 baculosomes 5nM 5nM 
VIVID Substrate BOMCC, 10µM EOMCC, 3µM 
NADP+ 30µM 30µM 
G6P/G6PD 3.33mM/0.3 U/ml 3.33mM/0.3 U/ml 
NADP+; Nicotinamide adenine dinucleotide phosphate, G6P/G6PD; Glucose-6-phosphate /Glucose-6-
phosphate dehydrogenase, BOMCC; 7-benzyloxy-methyloxy-3-cyanocoumarin, EOMCC; 7-
ethoxymethoxy-3-cyanocoumarin 
For mouse liver microsomal activity, the VIVID assay was analogous to the 
baculosome VIVID assay. CYP1A2 or CYP3A4 was replaced initially with a 
serial dilution of microsomal proteins to determine the best concentration then 
the optimised one was used in further assays (protein content was determined 
as illustrated in section 2.2.1.3). The level of CYP450 activity was calculated 
by the change in relative fluorescent units (RFU) compared to a standard 
(Baculosome VIVID assays) with a known amount of CYP450 activity. All 
experiments were conducted in duplicate to confirm reproducibility. Statistical 
analysis was performed using GraphPad 7.0 software following either a 
Students’ t-test or ANOVA. Data were presented as means ± standard 
deviation (S.D.). Significance was noted at P<0.05. 
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Chapter three: Optimisation of protein extraction 
and peptides separation 
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3 Optimisation of protein extraction and peptides 
separation 
3.1 Introduction 
3.1.1 Proteins extraction approaches 
Proteomics aims to study the whole protein content of a specific biological 
sample regardless of the tremendous variation in their abundance and 
biophysical properties. However, proteomics data depends qualitatively and 
quantitatively on the proteome coverage which can be extended mainly by 
increasing the quality and quantity of extracted proteins as well as improving 
the resolving power of protein separation techniques.  
Protein extraction methods are a preliminary step in the proteomics workflow, 
which can be conducted for protein analysis such as protein quantitation 
and/or identification, as well as for studying protein functions. Indeed, the 
protein extraction process involves two key steps: cell or tissue disrupt and 
protein solubilisation. However, extracting the comprehensive protein 
populations from biological tissues, such as liver, can be particularly 
challenging due to their high degree of complexity and heterogeneity.  
In that respect, a number of extraction methods for proteins from soft tissues, 
such as the brain, liver, and kidney, however, have been developed and  
require relatively gentle techniques compared to hard tissues (e.g., skeletal 
and cardiac) which are more susceptible to harsh shear forces (Skehel, 2004). 
These methods range from the simplest (e.g., enzymatic digestion and 
osmotic shock) to the moderate (e.g., ultrasonication) and to the harsh (e.g., 
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mechanical blender and homogenizer) (Grabski, 2009). Generally, different 
extraction methods can result in extracting different classes of proteins when 
applied on the same sample. For example, methods in which detergents are 
omitted will primarily result in extracting the cytosolic proteins. (Burden, 
2012a).  
Choosing the appropriate extraction method depends mainly on the type of 
sample, cellular location of targeted proteins and the structure of desired 
proteins (intact vs denatured). For example, heat generating or protein 
denaturing methods must be avoided in studies concerning enzyme activity 
(Burden, 2012a).   
Chemical based extraction method tends to involve different kinds of 
detergents, organic buffer or organic acid for cellular membrane disruption, 
breaking lipid-protein interactions and solubilising the proteins, as shown in 
Table 1.3. (Shevchenko et al., 2012). Sodium dodecyl sulphate (SDS) is a 
common example of anionic detergents which nowadays are used extensively 
in proteins extraction and able to solubilise a wide range of proteins 
(Scheerlinck et al., 2015). However, although a detergent like SDS is relatively 
cheap, easy to use and has available proved and effective protocols, it can 
negatively affect the proteomics analysis at several levels such as; (i) digestion 
level by denaturing trypsin enzyme, (ii) the resolving power of RP-HPLC in 
peptides separations and (iii) the MS analysis level by suppressing peptides 
ionisation and masking peptide-derived signals by generating intense 
background signals (Lu and Zhu, 2005, Ernoult et al., 2008, Hustoft et al., 
2011, von Hagen, 2011). In addition, at a protein functional level, detergents 
can result in denaturing the three-dimensional structure of proteins causing 
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them to lose their activity (Shevchenko et al., 2012). Although Shevchenko 
and co-workers have found that detergents such as SDS can be cleaned up 
by filter-aided sample preparation (FASP) method, it has been suggested that 
FASP was not efficient enough to remove all SDS traces, in addition to being 
time-consuming (Shevchenko et al., 2012).           
On the other hand, mechanical-based extraction methods (Table 1.4) have 
proven their ability to extract a remarkable amount of proteins by applying 
shear forces to breakdown the cellular membrane and emancipate the inner 
cellular proteins to be dissolved subsequently with a suitable hypotonic buffer 
(Burden, 2012a). However, using mechanical-based methods have some 
challenges to be considered. For example, some of the mechanical systems 
are expensive, ponderous and variable in performance making protocols 
difficult to replicate (e.g. different fitting size of homogenization pestles). 
Another difficulty is the heat generation, which may cause proteins 
denaturation and aggregation though this can be overcome by pre-chilling the 
equipment as well as keeping the sample in ice throughout preparation 
(Burden, 2012a). 
3.1.2 Proteins separation approaches 
Shotgun proteomics approach is a powerful technique for biomarker 
candidates’ discovery that is based on combining two techniques for tryptic 
peptides separation in two dimensions’ format. Throughout proteomics study, 
protein separation is the most laborious task since it must cope with a myriad 
of various properties and characteristic to each protein, such as molecular 
weight and isoelectric point (pI).  
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One of the major limitations for proteomics is the low resolving power in the 
recovery of hydrophobic proteins. For example, membranous proteins cannot 
be negligible since they represent about 30% of the typical proteome, and 
since approximately 70% of the available drugs targeting proteins are active 
against this class of proteins (Perez-Reyes et al., 1990, Tan et al., 2008). 
Another limitation is the wide dynamic range of proteins concentration in 
tissues, extending from 7 and up to 10 orders of magnitude, which prevents 
identification of low abundant proteins (Dwane and Kiely, 2011). Therefore, it 
has been a necessity to develop separation techniques that allow a 
significantly higher proteome coverage in the sample, which will ensure the 
identification of the low abundant proteins and thus a comprehensive analysis 
of complex samples (Ernoult et al., 2008). 
Isoelectric-focusing was implemented as a first dimension separation 
technique for the first time in 2004 in shotgun proteomics using an OFF-GEL 
(OG) system (Cargile et al., 2004b). OG separates proteins/peptides 
depending on their isoelectric points (pIs). As a consequence of moving 
proteins and peptides over a pH gradient gel, their net charges will change till 
becoming null at a specific point and are no longer attracted by the electrical 
current. At this point, proteins/peptides become focused according to their pI 
within the pH gradient (Cargile et al., 2004b). However, IEF for protein 
separation is considered less suitable, compared to peptides, as proteins tend 
to precipitate at their pI, reducing protein recovery from the gel media (Wall et 
al., 2000). 
Currently, ion exchange chromatography and thus SCX is the traditional and 
the most commonly used approach for the first-dimensional separation 
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followed by RP-HPLC as the second dimension of separation (Puangpila et 
al., 2015). SCX is a well-established method that has proved its ability to work 
over a wide range of pH as well as to be coupled directly to RP-HPLC (on-line) 
in a shotgun approach due to the limited resolution (Dai et al., 2009, Di Palma 
et al., 2012a). However, It has been reported that using SCX as purification 
step has led to reducing ion suppression caused by detergents or chemicals 
from iTRAQ reagents (Kong et al., 2011). On the other hand, OG has been 
considered as the best alternative for SCX fractionation for first dimension 
separation in a shotgun approach due to its high reproducibility and resolving 
power, making it essential for membranous proteins analysis (Chick et al., 
2008). In addition, OG has been considered superior to other separation 
methods due to its great loading capacity (up to 5mg of proteins/peptides), and 
its ability to provide additional information that can be used as a filtration 
criterion to reduce false positive and false negative identifications. Therefore, 
this will improve confidence in protein and PTMs identifications (Millioni et al., 
2013, Krijgsveld et al., 2006). In contrast to SCX, OG has been considered as 
an efficient method that is capable to separate both basic and acidic peptides 
by using the advancement of focused immobilized pH gradient (IPGs) strips, 
which enables flexibility in selecting the preferred pH gradient, such as those 
peptides clustered at pH 3 (Krijgsveld et al., 2006, Eriksson et al., 2008). 
For quantitative proteomics experiments, IEF has proved its compatibility with 
peptide tagging reagents such as iTRAQ since the functional groups of tags 
are not charged and do not significantly influence focusing of tagged peptides 
(Lengqvist et al., 2007).  
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3.1.3 Aims of the chapter 
This chapter was conducted to optimise two elementary steps of shotgun 
proteomics workflow in two parts. The optimised methods from this chapter 
will be applied for subsequent proteomics experiments.    
a. Using total liver extracts, rather than the microsomal fraction, the first 
part of this chapter aims to determine: 
- The effect of freezing during storage, on the quantity of the extracted 
protein. 
- The most efficient mechanical method in protein extraction (cryo-
pulverization CP, cryo-pulverization and sonication CP+S, disperse 
homogenizing H and liquid Dounce homogenizing D) as determined 
by protein yield using the Bradford assay. 
- The effect of each mechanical method on mouse liver proteome, 
particularly on drug metabolizing enzymes (Phase I and II) by a 
shotgun proteomics approach.  
b. The second part of this chapter aims to determine: 
- The optimal peptides separation method using two well-established 
methods (OG and SCX)  
- The effect of each separation method on mouse liver proteome 
qualitatively and quantitatively, particularly on drug metabolizing 
enzymes (Phase I and II). 
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3.2 Animals and Method 
3.2.1 Animal Maintenance 
BALB\cOLaHsd –Foxn1nu immunodeficient nude mice (Harlan Laboratories, 
UK) aged 10 weeks were used. Mice received CRM diet (S.D.S., Witham, UK) 
and water ad libitum. Mice were kept in cages in an air-conditioned room with 
regular alternating light and dark cycles. All animal procedures were carried 
out under a project licence issued by the UK Home Office and following the 
UKCCCR guidelines (Workman et al., 1998). 
3.2.2 Sample Preparation 
3.2.2.1 Mouse Liver Protein Extraction 
Normal liver tissues were initially weighed and extracted by one of four 
mechanical methods, (Figure 3.1) using a freshly prepared phosphate 
buffered saline (PBS) containing complete mini EDTA-free protease inhibitor 
cocktail tablet (one tablet for 7 ml PBS) as a buffer. Tissues were kept in ice 
during protein extraction processes. 
3.2.2.1.1 Cryo-pulverization method (CP) 
The stainless steel Cell crushes Tissue Pulveriser (Cellcrusher, Cork, Ireland) 
consists of a two-component mortar with handles and a pestle, specifically 
designed for pulverizing 10 - 1000mg of tissue. Liver tissue homogenization 
was carried out as previously described (Toivonen et al., 2014, Lesseur et al., 
2014, Alhamdani et al., 2010). Briefly, after chilling the pulveriser and the liver 
sample in liquid nitrogen, the lead hammer was used on the mortar to 
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completely fracture the chilled sample. After that, the crushed sample was 
transferred to a 50 ml Falcon tube containing freshly prepared phosphate 
buffered saline (PBS) with a complete mini EDTA-free protease inhibitor 
cocktail tablet (one tablet for 10 ml PBS). The homogenate was then 
centrifuged for 30 minutes at 9,000 g at 4°C; the supernatant was collected 
and aliquoted into new Eppendorf tubes and kept at -20°C for further analysis. 
3.2.2.1.2 Combination of cryo-pulverization and Sonication method 
(CP+S) 
Optionally, after pulverizing the liver sample, sonication was carried out using 
Philip Harris Scientific Sonicating probe, (Scientific Laboratory Supplies Ltd, 
UK). The suspended sample was sonicated for 6 cycles, 5 seconds for each 
(tissue was cooled on ice for 20 seconds in between). Homogenates were 
centrifuged for 30 minutes at 9,000 g at 4°C. The supernatant was collected 
and stored at -20°C for further use as described above. 
3.2.2.1.3 Disperse homogenizer method (H) 
The liver sample was immersed in freshly prepared phosphate buffered saline 
(PBS) containing complete mini EDTA-free protease inhibitor cocktail tablet 
(one tablet for 10 ml PBS). The sample was homogenized whilst kept in ice for 
5 times, 30 seconds for each using a disperse Ultra-Turrax T25 homogeniser 
(Janke and Kunkel, IKA Labortecnik, Staufen, Germany) as described 
previously (Alhamdani et al., 2010). Homogenates were centrifuged for 30 
minutes at 9,000 g at 4°C. The supernatant was collected and kept at -20°C 
as described previously. 
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3.2.2.1.4 Liquid Dounce homogenizer method (D) 
According to a previous report (Burden, 2008), liver tissue was chopped into 
small pieces. Approximately 1 ml of freshly prepared phosphate buffered 
saline (PBS) containing complete mini EDTA-free protease inhibitor cocktail 
tablet (one tablet for 10 ml PBS) was mixed with small pieces of chopped 
tissue for homogenizing by Tenbroeck-Dounce Tissue Grinder (Wheaton, 
USA). Chopped tissue was broken up with 10 to 12 plunges until no large 
pieces remain. Homogenates were collected in 50 ml Falcon tube and 
centrifuged for 60 minutes at 9,000 g at 4°C. After that, the supernatant was 
collected and kept at -20°C as described previously. 
3.2.2.2 Protein digestion and iTRAQ Labelling 
Protein extracts from each method were quantified using Bradford method, 
then protein, equivalent to 50 µg, precipitated by chilled acetone (sections 
2.2.1.3-4). Samples were then digested by trypsin (section 2.2.1.5); the 
resultant peptides were purified and desalted prior iTRAQ labelling (section 
2.2.1.6-7). The iTRAQ was processed as shown in Table 3.1, with the 
homogenizing method (H) as the control.  
Table 3-1. 4-plex iTRAQ reagents used to label protease digests of mouse livers 
extracted with different mechanical extraction method. 
iTRAQ reagent 114 115 116 117 
Extraction method CP CP+S H D 
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3.2.2.1 Peptides separation and protein identification 
The combined iTRAQ sample was divided into two halves. Each half was 
separated in the first dimension using either SCX (12 flow-through and 
elution fractions) or OG (12 cm IPG strip, 12 Well Frame Set and 3-10 pH) 
method as described in Sections 2.2.1.8.1.1-2. Then, the resultant fractions 
(12 fractions for each method) were desalted and separated for their second 
dimension using RP-HPLC method (section 2.2.1.8.2). The MS analysis and 
proteins identifications were conducted as described in Sections 2.2.1.9.
 
Figure 3-1. Quantitative proteomics workflow shows the four mechanical extraction 
methods, iTRAQ labelling, the two-dimensional separation techniques, protein 
identifications by MALDI-MS and database searching. 
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3.3 Results 
3.3.1 Protein extraction optimisation by Bradford assay 
In order to optimise protein extraction by mechanical methods and determine 
the best one, frozen and fresh normal mouse liver tissues were subjected to 
protein extraction by four mechanical methods (cryo-pulverization - CP, cryo-
pulverization, and sonication - CP+S, disperse Homogenizing - H, and liquid 
Dounce homogenizing - D) in two duplicate experiments. The extracted protein 
concentration was determined using Bradford assay (section 2.2.1.3). 
Standard curves were created for frozen and fresh samples (Figure 3.2).  
 
Figure 3-2. Standard curves of BSA for proteins quantitation for (A) Frozen and (B) 
Fresh livers. 
The four extraction absorbance values were extrapolated to standard curves 
to determine the amount of total extracted proteins and then the protein-to-
tissue ratio, for frozen and fresh mouse livers (Table 3.2). 
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Table 3-2. Comparison of four mechanical methods for the extraction of the total 
proteins from frozen and fresh mouse liver 
Sample 
condition 
Method of 
extraction 
Mean relative yield 
(mg protein/mg tissue) 
Standard 
deviation 
Coefficient of 
variation 
(CV %) 
 
Frozen 
 
 
CP 0.116 0.029 24.7 
CP+S 0.223 0.025 11.0 
H 0.173 0.022 12.4 
D 0.138 0.005 3.7 
 
Fresh 
 
 
CP 0.125 0.007 5.6 
CP+S 0.247 0.007 2.8 
H 0.182 0.009 4.8 
D 0.158 0.017 10.5 
 
Furthermore, to explore whether there are any differences between frozen and 
fresh liver samples, the amount of protein in mg per mg of tissue for each 
extraction method was presented for frozen and fresh mouse livers as shown 
in Figure 3.3. 
The result demonstrated that there are no significant differences between 
frozen and fresh samples in the amount of extracted protein-to-tissue ratio for 
each extraction method. However, the results indicate that the CP+S method 
produced the highest yield of proteins.     
  105 
M e th o d  o f  E x t r a c t io n
M
e
a
n
 r
e
a
lt
iv
e
 y
ie
ld
 (
m
g
 p
r
o
t
e
in
/m
g
 t
is
s
u
e
)
C P C P + S H D
0 .0
0 .1
0 .2
0 .3
F ro z e n
F re s h
 
Figure 3-3. Comparison of the amount of extracted proteins (mg) to tissue (mg) 
between frozen and fresh mouse livers for each extraction method  
 
To confirm that CP+S was a significant improvement compared to the others 
a one-way ANOVA test was performed. The combination of cryo-pulverization 
and sonication method (CP+S) has generated the maximum yield of proteins 
with 0.223 and 0.247 (mg/mg protein-to-tissue ratio) for both frozen and fresh 
samples, respectively (Figure 3.4). Moreover, the results confirmed 
statistically that CP+S method is superior compared to CP, H and D methods 
for frozen and fresh samples apart from the comparison of CP+S and H 
extraction methods of the frozen liver. 
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Figure 3-4. Comparison the four extraction methods for their amount of extracted 
protein-to-tissue ratio within each sample condition. (a) Frozen sample and (b) Fresh 
sample. The significant difference between CP+S method and other methods is 
indicated with asterisks (p-value < 0.05).   
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3.3.2 Protein separation optimisation by quantitative proteomics 
Two first dimension separation techniques were evaluated: OFF-GEL (OG) 
and strong cation exchange (SCX), as part of a comparative proteomics study. 
Identified proteins and peptides were compared in order to determine which 
technique provides the highest performance for analysis of a complex mixture 
of tryptic peptides extracted from fresh mouse liver, by one of four mechanical 
methods (CP, CP+S, H, and D). An equal number of fractions (12 in each 
case) were collected by SCX chromatography using a serial concentration of 
elution buffer (30-1000 mM KCl) or by isoelectric-focusing (IEF) on OG (pH 3-
10, 12cm IPG strip). The second dimension was kept constant; i.e. reverse 
phase HPLC separation. The amount of sample used in each separation 
method was also kept constant. In addition, database searching was 
performed using the same parameters. 
3.3.2.1 Identified proteins analysis 
Data analysis indicated that a total of 6254 proteins and 9010 peptides were 
identified by OG method (Fractions 1 -12), with an average of 521 proteins per 
fraction (SD=149) and 751 peptides per fraction (SD=264). Whereas 4528 
total proteins and 7089 total peptides, average of 377 proteins per fraction 
(SD= 196) and 591 peptides per fraction (SD=366) were extracted from 12 
fractions by SCX. Peptides and proteins distribution is shown in Figures 3.5 
and 3.6, respectively. 
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Figure 3-5. The number of identified peptides for OG and SCX methods per each 
fraction. 
 
 
Figure 3-6. The number of identified proteins for OG and SCX methods per each 
fraction. 
 
For peptide identification, SCX showed greater variability across the 12 
fractions, with most of the peptides eluted in fractions number 6, 8, 9 and 10, 
demonstrating SCX was highly sensitive to pH differences. However, in OG 
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method, the identified peptides were distributed more evenly, since a wide pH 
strip was used. At the protein level, the same results were found regarding the 
distribution of the identified proteins by SCX and OG methods. 
Unambiguously identified proteins in each fraction were combined into a non-
redundant list as described in Section 2.2.1.10 for OG and SCX (Appendix AI 
and AII, respectively). There are 2265 peptides (2134 unique peptides) and 
2222 peptides (2069 unique peptides), resulting in 431 and 347 proteins 
identified by OG and SCX method, respectively. Of these, 1167 peptides and 
265 proteins were common between OG and SCX (identified by both 
methods) as summarized by Venn diagrams in Figure 3.7.  
 
Figure 3-7. Venn diagrams comparing the total and unique numbers of 
unambiguously identified (A) peptides and (B) proteins. 
 
For unique peptide identifications, the results demonstrate that 1167 peptides 
were confidently identified by both methods. However, OG resulted in the 
identification of more peptides (2134) in comparison to SCX (2069). At the 
protein level, 431 and 347 proteins were identified by OG and SCX 
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respectively, among which 265 proteins were detected in both methods 
representing 68.2% of all proteins detected by both methods when combined.  
Comparison between the theoretical isoelectric points (pI) for identified 
proteins from OG and SCX methods (Figure 3.8) revealed that both methods 
are able to identify proteins over a wide range of pH. However, in both 
methods, approximately 48% of identified proteins have pI equal to 7 or higher, 
indicating that these two methods can be used for detecting alkaline proteins, 
similar to the other traditional method 2D gel electrophoresis. But, proteins 
with pI higher than 10, which are not readily detected by 2D-PAGE, 
represented 10.4% and 8.9% of total proteins identified by OG and SCX, 
respectively.  
 
Figure 3-8. Distribution of identified proteins by OG and SCX over the isoelectric point 
(pI) values. 
 
Further classification of confidently identified proteins by gene ontology (GO) 
into different categories based on their molecular functions and biological 
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processes was also performed using PANTHER tool (section 2.2.1.13) (Figure 
3.9 and Figure 3.10, respectively). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-9. Gene ontology for identified proteins by SCX, n=347 (above) and OG, 
n=431 (below) based on their molecular function. Proteins were classified into 10 
groups, where the percent of each group represent the relative abundance. 
 
  112 
 
 
 
Figure 3-10. Gene ontology for identified proteins by SCX, n=347 (above) and OG, 
n=431 (below) based on their biological processes. Proteins were classified into 12 
groups, where the percent of each group represent the relative abundance. 
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GO analysis classified the identified proteins from SCX and OG into 10 groups 
based on their molecular functions (Figure 3.9), with the highest proportion 
being involved in a catalytic activity for both SCX (59.1%) and OG (59.3%) 
proteins, followed by binding and structural molecule activity. The results 
demonstrated that there was no significant variation in the relative abundance 
of each group of proteins for the molecular function between SCX and OG 
proteins.  
When classified by biological processes (Figure 3.10), 12 groups were 
identified with a major contribution representing the metabolic process for SCX 
(49%) and OG (50.5%). This provided clear evidence that liver is highly 
enriched in metabolic enzymes. However, it was seen that growth proteins 
(1%), which have a role in cell or organism proliferation (e.g. Epidermal growth 
factor receptor), and reproduction class (0.3%), which have a role in sexual 
reproduction such as spermatogenesis (e.g. Estradiol 17 beta-dehydrogenase 
5), were unique for SCX and OG, respectively. 
Moreover, it was seen that a slightly higher proportion of the SCX proteins 
were involved in cellular localization and response to stimulation processes, 
while more proteins were associated with metabolic processes from OG 
proteins. Many of these metabolic process proteins play an essential role in 
detoxification of xenobiotics, such as; glutathione S-transferase enzymes 
(GSTs), cytochrome P450 enzymes (CYP450s), major urinary proteins 
(MUPs), aldehyde dehydrogenase enzymes (ALDHs), and others. 
Next, in order to evaluate the power of OG and SCX methods in resolving the 
hydrophobic proteins (membranous proteins), a preliminary gene ontology 
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analysis (section 2.2.1.13) was conducted according to the reported 
annotation in the UniProt™ database and only protein annotated to a single 
membranous class was included (Figure 3.11).  
 
Figure 3-11. Venn diagram for proteins which are annotated as membrane proteins for 
OG and SCX method.  
 
A total of 125 and 96 proteins were annotated to the membranous fraction by 
OG (29.1%) and SCX (27.6%), respectively. Of the membranous proteins, 71 
proteins were identified by both methods, whereas 54 and 25 were uniquely 
detected using the OG and SCX methods, respectively. Findings indicated that 
OG method was superior in resolving membranous proteins.  
Moreover, the grand average of hydropathy (GRAVY) score was calculated 
for identified proteins in order to evaluate the hydrophobic status of proteins 
(section 2.2.1.13). 
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In the current comparison study, a total of 324 (75.2%) proteins and 240 
(69.2%) proteins identified from OG and SCX had GRAVY score of higher than 
(-0.4), suggesting membrane proteins (Figure 3.12).  
 
Figure 3-12. Distribution of identified proteins from OG and SCX over the GRAVY 
scores. The value (-0.4) is the threshold between cytosolic proteins and membrane 
proteins, therefore protein with a score higher than (-0.4) indicates a higher 
probability for membrane association (a more positive GRAVY score the more 
hydrophobic a protein).     
 
The results demonstrated that both methods were able to recover membrane 
proteins. However, GO analysis and GRAVY score indicated that OG is 
superior for hydrophobic proteins recovery from mouse liver extracts. Thought 
that GO analysis included only proteins with a single annotation to membrane 
class, which explains the differences in the percentage of membranous 
proteins between two methods. 
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3.3.2.2 Qualitative analysis of Cytochrome P450 enzymes extracted by 
OG and SCX 
Since CYP450 family is a key example of the membrane proteins in the liver 
and important in the metabolism of drugs, CYP450 subfamily enzymes were 
investigated qualitatively and quantitatively among the four mechanical 
methods (CP, CP+S, H, and D).  
Due to the high degree of sequence homology within the sub-families’ 
isoforms, CYP isoform was considered significantly identified according to 
criteria described previously in Section 2.2.1.12. Unique peptides identification 
and homology of closely related CYP isoforms determination were performed 
using (Skyline 3.5-64 bit) software and CLUSTAL O (1.2.1) tools (section 
2.2.1.13).  
An example of determining whether the peptide is unique or common with 
other close isoforms and subsequently deciding if that CYP isoform is 
significantly identified is shown in Figure 3.13. Based on these criteria, seven 
CYP450 enzymes (CYP1a2, 2c70, 2d9, 2d10, 2d26, 2e1, and 2f2) were 
identified by OG and four (CYP2c70, 2d9, 2d10 and 2e1) were identified by 
SCX (Table 3.3). The results demonstrated that OG was superior for 
Cytochrome P450 enzymes identification. Although SCX showed a slight 
improvement in unique peptides identified, as well as sequence coverage for 
CYP isoforms, it was unable to separate and detect CYP1a2 which is a highly 
abundant isoform.  
In conclusion, observing a higher number of CYP identifications than 
previously reported was not expected, since S9 fractions (whole liver extracts) 
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were used for this optimisation rather than microsomal fractions, which 
enables enrichment of metabolic enzymes. 
 
CYP isoform 
 
Sequence 
CP2DQ_MOUSE MGLLVGDDLWAVVIFTAIFLLLVDLVHRRQRWTACYPPGPVPFPGLGNLLQVDFENIPYS 
CP2D9_MOUSE MELLTGTDLWPVAIFTVIFILLVDLTHQRQRWTSRYPPGPVPWPVLGNLLQVDLGNMPYS 
CP2DA_MOUSE MELLTGAGLWSVAIFTVIFILLVDLMHRHQRWTSRYPPGPVPWPVLGNLLQVDLDNMPYS 
CP2DB_MOUSE MELLTGAGLWSVAIFTVIFILLVDLMHRHQHWTSRCPPGPVPWPVLGNLLQVDLGNMPYS 
 
 
CP2DQ_MOUSE FYKLQNRYGNVFSLQMAWKPVVVVNGLKAVRELLVTYGEDTSDRPLMPIYNHIGYGHKSK 
CP2D9_MOUSE LYKLQNRYGDVFSLQMAWKPMVVINGLKAMKEMLLTCGEDTADRPPVPIFEYLGVKPGSQ 
CP2DA_MOUSE LYKLQNRYGDVFSLQMGWKPMVVINGLKAMKEVLLTCGEDTADRPQVPIFEYLGVKPGSQ 
CP2DB_MOUSE LYKLQNRYGDVFSLQMGWKPMVVINGLKAMKEVLLTCGEDTADRPQVPIFEYLGVKPGSQ 
   
CP2DQ_MOUSE GVILAPYGPEWREQRRFSVSTLRDFGLGKKSLEQWVTEEAGHLCDAFTKEAEHPFNPSPL 
CP2D9_MOUSE GVVLAPYGPEWREQRRFSVSTLRNFGLGKKSLEDWVTKEANHLCDAFTAQAGQPINPNPM 
CP2DA_MOUSE GVVLAPYGPEWREQRRFSVSTLRNFGLGKKSLEDWVTKEARHLCDAFTAQAGQPINPNTM 
CP2DB_MOUSE GVVLAPYGPEWQEQRRFSVSTLRNFGLGKKSLEDWVTKEARHLCDAFTAQAGQSINPNTM 
   
CP2DQ_MOUSE LSKAVSNVIASLIYARRFEYEDPFFNRMLKTLKESLGEDTGFVGEVLNAIPMLLHIPGLP 
CP2D9_MOUSE LNKSTCNVIASLIFARRFEYEDPFLIRMLKVLEQSLTEVSGLIPEVLNAFPILLRIPRLA 
CP2DA_MOUSE LNNAVCNVIASLIFARRFEYEDPYLIRMQKVLEDSLTEISGLIPEVLNMFPILLRIPGLP 
CP2DB_MOUSE LNNAVCNVIASLIFARRFEYEDPYLIRMLKMLKECFTEISGFIPGVLNEFPIFLRIPGLA 
   
CP2DQ_MOUSE DKAFPKLNSFIALVNKMLIEHDLTWDPAQPPRDLTDAFLAEVEKAKGNPESSFNDKNLRI 
CP2D9_MOUSE DKALQGQKSFIAILDNLLTENRTTWDPVQAPRNLTDAFLAEIEKAKGNPESSFNDENLLM 
CP2DA_MOUSE GKVFQGQKSLLAIVENLLTENRNTWDPDQPPRNLTDAFLAEIEKVKGNAESSFNDENLRM 
CP2DB_MOUSE DMVFQGQKSFMAILDNLLTENRTTWDPDQPPRNLTDAFLAEIEKAKGNPESSFNDENLRM 
   
CP2DQ_MOUSE VVIDLFMAGMVTTSTTLSWALLLMILHPDVQRRVHQEIDEVIGHVRHPEMADQARMPYTN 
CP2D9_MOUSE VVRDLFGAGMLTTSTTLSWALMLMILHPDVQRRVQQEIDEVIGQVRHPEMADQAHMPYTN 
CP2DA_MOUSE VVLDLFTAGMVTTSTTLSWALLLMILHPDVQRRVQQEIDAVIGQVRHPEMADQARMPYTN 
CP2DB_MOUSE VVGDLFTAGMVTTSTTLSWALLLMILHPDVQRRVQQEIDAVIGQVQHPEMADQARMPYTN 
   
CP2DQ_MOUSE AVIHEVQRFADIVPTNLPHMTSRDIKFQDFFIPKGTTLIPNLSSVLKDETVWEKPLRFYP 
CP2D9_MOUSE AVIHEVQRFGDIVPVNLPRITSHDIEVQDFLIPKGTILLPNMSSMLKDESVWEKPLRFHP 
CP2DA_MOUSE AVIHEVQRFGDIAPLNLPRITSRDIEVQDFLIPKGSILIPNMSSVLKDETVWEKPLRFHP 
CP2DB_MOUSE AVIHEVQRFGDIAPLPLPRITSRDIEVQDFLVTKGSTLIPNMSSVLKDETVWEKPLRFHP 
   
CP2DQ_MOUSE EHFLDAQGHFVKHEAFMPFSAGRRSCLGEPLARMELFLFFTCLLQRFSFSVPDGQPRPSD 
CP2D9_MOUSE EHFLDAQGHFVKPEAFMPFSAGRRSCLGEALARMELFLFFTCLLQRFSFSVPDGQPQPSN 
CP2DA_MOUSE EHFLDAQGHFVKPEAFMPFSAGRRSCLGEPLARMELFLFFTCLLQHFSFSVPNGQPRPRN 
CP2DB_MOUSE EHFLDAQGHFVKPEAFMPFSAGHRSCLGEALARMELFLFFTCLLQRFSISVPDGQPQPSN 
   
CP2DQ_MOUSE YGIYTMPVTPEPYQLCAVAR---- 
CP2D9_MOUSE SGVYGILVAPSPYQLCAVVRDQGH 
CP2DA_MOUSE LGVFPFPVAPYPYQLCAVMREQGH 
CP2DB_MOUSE YRVHAIPVAPFPYQLCAVMREQGH 
Figure 3-13. An example of sequence alignment for a closely related subfamily CYP2D 
(CP2DQ = CYP2D26, CP2D9 = CYP2D9, CP2DA = CYP2D10, CP2DB = CYP2D11) 
identifying common and unique peptides determination. Red sequence indicates a 
unique peptide for a specific CYP, where blue sequence indicates a common peptide 
among the different isoforms. Sequence alignment was created by Clustal Omega 
tool.   
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Table 3-3. Cytochrome P450 enzymes unambiguously identified by OG and SCX, their average MASCOT score and the number of 
common and unique peptides. CYP isoforms were defined by at least one unique peptide with significant MASCOT score. ND indicated 
not detected for SCX method. 
M.Wt; molecular weight, SC%; percent of sequence coverage. 
 
 
 
OG 
 
 
SCX 
 
 
 
 
CYP isoform 
Uniprot/ 
accession 
number 
M.Wt 
(KDa) 
pI 
Total 
number 
of 
peptides 
Number 
of unique 
peptides 
Number of 
spectra for 
unique 
peptide 
Protein 
MASCOT 
score 
(SC %) 
Total 
number of 
peptides 
Number 
of unique 
peptides 
Number of 
spectra for 
unique 
peptide 
Protein 
MASCOT 
score 
(SC %) 
Theoretica
l unique 
peptides 
CYP 1a2 P00186 58.1 9.6 2 2 1 106.2 5.5 ND ND ND ND ND 27 
CYP 2c70 Q91W64 56 9.1 1 1 5 47.3 2.2 2 2 3 40.6 4.9 26 
CYP 2d9 P11714 56.9 5.9 3 2 6 95.3 5.4 4 2 4 184.5 8.9 14 
CYP 2d10 P24456 57.2 6.2 5 3 7 160.8 11.1 6 2 4 241.8 12.9 12 
CYP 2d26 Q8CIM7 56.9 6.2 4 3 2 137 10.6 ND ND ND ND ND 21 
CYP 2e1 Q05421 56.8 9.3 4 3 3 83.4 11.6 3 3 2 83.2 6.3 27 
CYP 2f2 P33267 55.9 8.8 1 1 1 35.2 2.4 ND ND ND ND ND 25 
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3.3.2.3 Quantitative analysis of Cytochrome P450 enzymes extracted by 
OG and SCX 
The four methods were compared by calculating the CYP450 iTRAQ ratios of 
three extraction methods (CP, CP+S, and D) relative to disperse 
homogenization (H). Two criteria were applied to determine the significantly 
altered CYP isoform as discussed previously in Section 2.2.1.12. The results 
indicated that the seven CYP450 enzymes identified by OG were within the 
normal range among the four extraction methods. On the other hand, CP 
method in SCX showed one CYP450 isoform (CYP2d9) below the normal 
range while the other three CYP450 isoforms (CYP2c70, 2d10m, and 2e1) 
were within the normal range (Table 3.4). Although not statistically significant, 
the p-value for the CP method from the OG data was also low, suggesting that 
this protein was specifically affected by the extraction method, relative to the 
H method. 
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Table 3-4. Identified cytochrome P450 isoforms by OG and SCX methods, with their mean iTRAQ ratios generated from unique peptides. * 
indicated the p-value for each method which has been computed following permutation test. ND indicated; not detected  
 Separation 
method 
OG SCX 
CYP isoforms Extraction method Mean iTRAQ ratios 
Number of unique 
peptides 
p-value* 
Mean iTRAQ 
ratios 
Number of unique 
peptides 
p-value* 
CYP 1a2 
CP/H 0.82 
3 
0.31 
 
 
ND 
ND 
ND 
CP+S/H 1.01 0.99 ND ND 
D/H 0.97 0.86 ND ND 
CYP 2c70 
CP/H 0.95 
5 
0.76 0.73 
 
4 
0.11 
CP+S/H 1.08 0.68 0.79 0.22 
D/H 0.90 0.53 0.86 0.40 
CYP 2d9 
CP/H 0.75 
7 
0.05 0.60 
6 
0.01 
CP+S/H 0.80 0.19 0.73 0.06 
D/H 0.94 0.64 0.83 0.23 
CYP 2d10 
CP/H 0.94 
9 
0.61 1.01 
8 
0.95 
CP+S/H 1.02 0.90 1.18 0.26 
D/H 1.10 0.45 1.19 0.21 
CYP 2d26 
CP/H 0.84 
5 
0.27 ND 
ND 
ND 
CP+S/H 1.00 0.98 ND ND 
D/H 0.87 0.37 ND ND 
CYP 2e1 
CP/H 0.91 
7 
0.52 0.94 
5 
0.72 
CP+S/H 0.95 0.75 1.05 0.764 
D/H 1.07 0.66 0.74 0.08 
CYP 2f2 
CP/H 0.75 
2 
0.23 ND 
ND 
ND 
CP+S/H 0.73 0.24 
 
ND ND 
D/H 0.73 0.19 ND ND 
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3.4 Discussion 
This chapter aimed to identify the best method for protein extraction from fresh 
and frozen mouse liver samples using four mechanical methods and to 
investigate the resolving power of two well-established peptide separation 
methods. The effect of freezing on total proteins content was evaluated as 
well. Several studies investigated the influence of freezing on protein stability 
from various organs such as liver from human, rats, and mice (Zeisler et al., 
1988, Prentø, 1997, Shabihkhani et al., 2014). Overall findings were not 
consistent and this may be because of variation in methods of freezing and 
temperature. However, global thoughts tend to propose that protein freezing, 
especially for the long duration of time, reduce total proteins content due to 
formation ice crystals inside the cells (Shabihkhani et al., 2014). For instance, 
an earlier study proposed that using a fresh sample is the best for subcellular 
proteomics analysis, as they recovered 13.5% and 14.6% more proteins from 
fresh liver compared to freshly froze liver or previously frozen liver, 
respectively (Song et al., 2006). Correspondingly, our results are to some 
extent in agreement with this finding, where (CP; 7.2%, CP+S; 9.7%, H; 5%, 
and D; 12.7%) marginally higher protein-to-tissue ratios were detected in fresh 
liver compared to frozen by the four extraction methods.  
The ultimate goal of protein extraction is to maximise the percentage of the 
recovery of proteins from any finite biological samples as proteins cannot be 
amplified artificially as in the case of DNA. An additional aim is to separate 
proteins from other cellular biomolecules, and thus can be detected and 
investigated in downstream analytical methods, such as 1D or 2D-PAGE, 
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Enzyme-linked immunosorbent assay (ELISA), Western blotting, MS, or other. 
In order to detect as wide a range of proteins as possible, optimal protein 
extraction must be determined experimentally depending on the nature of the 
sample and stability of proteins (Grabski, 2009). Thus, four mechanical 
extraction methods (P, CP+S, H, and D) were employed as a single-step or 
two-step protein extraction methods. Whereby, CP+S method gave a 
significantly higher yield using fresh and frozen samples of proteins compared 
to single methods (CP, H or D).  
Different approaches have been optimized for extraction and purification of 
total or specific group proteins from the liver. An earlier study investigated the 
toxic effect of acetaminophen on mice livers by 2D-GE approach homogenised 
mouse liver in lysis buffer using handheld homogenizer followed by sonication 
for a short while (30 seconds) (Albertini and Suter, 2000). The study proposed 
a significant improvement in the number and confident of protein identifications 
as result of combining these two-step extraction methods compared to a 
single-step method (i.e. sonication). Another study homogenized mouse liver 
by Dounce homogenizer (Song et al., 2006). According to the results, the study 
demonstrated 0.142 mg protein to mg tissue compared to 0.158 mg protein to 
mg tissue determined by our D method in this project. Moreover, authors 
showed organelles such as nuclei and vesicles were integrated (unbroken), 
proposing the importance of using advanced extraction method or two-step 
extraction method rather than using mild-method (i.e. Dounce) in liver protein 
extraction (Song et al., 2006). Moreover, a newly developed machine based 
on cycling pressure (Pressure-cycling technology - PCT, MicroPestle) was 
evaluated and compared to PCT-MicroCap by Shao et al, (Shao et al., 2016). 
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Mouse organs including liver with different weights were employed in this 
evaluation. A total of 0.11 mg protein to mg liver tissue was determined by 
PCT- MicroPestle. Comparing to our result, CP+S identified double ratio as 
PCT- MicroPestle determined (0.247 mg protein to mg tissue, fresh liver). 
In conclusion, cryo-pulverisation is a non-heating production method. 
Therefore, it is considered as a valuable technique for active enzyme 
extraction (Burden, 2008), although it was not the best single-step method for 
protein extraction. The combination of cryo-pulverization followed by 
sonication – CP+S is an efficient mechanical method that has been created 
and evaluated for the first time in liver protein extraction. A previous attempt 
on lactate dehydrogenase (LDH) enzyme extraction from muscle by various 
single-step and combined-step approaches, proved that combining cryo-
pulverization step with another step such as sonication resulted in the highest 
activity of LDH, thus highest amount. While sonication as a single step has 
shown the lowest activity, indicating poor efficiency as a single-step (Burden, 
2012b).   
OFF-GEL isoelectric focusing (OG) or Strong Cation Exchange 
chromatography (SCX)-based shotgun proteomics approaches were 
compared to determine which would be best suited for protein identifications 
for mouse tissues but in particular liver samples.  
Although whole liver extract (rather than microsomes) was used for this 
comparison, OG was found superior to SCX in identifying more proteins and 
enriching the number of hydrophobic “membrane” proteins (Figures 3.11-12). 
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Various studies were performed to evaluate the power of OG method over 
other separation methods like SCX. A previous attempt by Slebos and his 
group investigated whether OG (narrow pH, 3.5-4.5, 24 cm) or SCX was better 
for 10 or 100 µg of protein extract from human colon adenocarcinoma (RKO) 
cell or from 50 µg of protein from rectal adenocarcinoma biopsy specimen 
(Slebos et al., 2008). In contrast to our findings, the results determined that 
SCX generated more peptides and proteins using 10 and 50 µg compared to 
OG, while equal numbers of identifications were observed using 100 µg of 
protein. Though, Slebos et al employed a narrow range IGP strip in order to 
reduce bias toward highly redundant identifications of abundant proteins which 
excluded many peptides and subsequently proteins whereas SCX 
encompasses all peptides (Cargile et al., 2005). However, with 50 µg, they 
found that 77% of proteins identified using OG or SCX were common, which 
was similar to our observations of 68.2% common identities (Slebos et al., 
2008). In the same way, Mostovenko and his colleagues found that SCX (200 
µg) demonstrated better protein and peptide yields from Escherichia coli and 
human plasma extracts than OG (100 µg) even with wide range IPG strip (pH, 
3-10) (Mostovenko et al., 2013).   
 On the other hand, Slebos et al concluded that OG offered superior 
reproducibility and resolution for peptides separation from large (100 µg) and 
small (10 µg) protein samples, even though more peptides and proteins were 
identified by SCX and this was because three replicates were required for 
detection of 90% of medium abundance proteins (those detected with at least 
3-4 peptides) by OG. In contrast, the SCX required six replicates to detect the 
90% of medium abundance proteins (Slebos et al., 2008).  
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Furthermore, protein samples derived from testis of rat (Rattus norvegicus) 
demonstrated that OG, narrow pH range (3.5-4.5) was superior method in 
proteins separation comparing to SCX method using 1 mg of sample, since it 
produced 13% more identifications of protein than an optimized off-line SCX 
(Essader et al., 2005). Moreover, Schafer et al have evaluated the separation 
power of OG and SCX using mouse liver, in order to improve the sensitivity of 
selected reaction monitoring-based (SRM) quantitative proteomics workflows 
(Schäfer et al., 2012). They showed that applying separation of peptides by 
OG using a wide range of IPG (pH 3-10) was more efficient than SCX in 
increasing the number of quantifiable peptides and signal intensity as well as 
signal-to-noise ratios. Besides, OG was able to identify six membrane proteins 
with high signal intensity. In another experiment done by Elschenbroich and 
co-workers (Elschenbroich et al., 2009) to test the power of the OG method 
for membrane proteins recovery, using a membrane-enriched fraction from 
murine C2C12 myoblasts, they found that OG (12 fractions, pH 3-10) and SCX 
were effective, where the former showed a slight bias toward membrane 
proteins identification.    
Other experiments comparing OG and SCX (Bandhakavi et al., 2009, Tran et 
al., 2009, Waller et al., 2008, Barnea et al., 2005) were less clear, most likely 
due to inconsistent experimental conditions such as, sample complexity, 
starting amount, number of fraction produced, IPG strip length and pH range. 
However, inclusion of the OG method into shotgun proteomic workflow offers 
a number of advantages include: (i) determination of the pI of the peptides, 
which is a unique feature that is not provided by SCX and RP, (ii) loading 
capacity (up to 50 mg, compared to 250 µg for SCX). (iii) removal of detergents 
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and denaturants, if they have been used as part of the protein extraction 
protocol (iv) different pH range IPG strips are available for experimental design 
flexibility (Hörth et al., 2006). On the other hand, the main disadvantage of the 
OG is the limitation in selecting the number of fractions, besides, the 
predefined size and shape of wells. Moreover, OG focusing run time can be 
long dependent on the sample composition, taking up to 2–3 days. 
None of the previous comparative studies evaluate the separation power of 
OG and SCX quantitatively using liver in a comprehensive proteomics 
experiment. In this work, the digested peptides were labelled with (iTRAQ) to 
enable quantification. CYP450 family is highly expressed in liver and it is a 
good example of membranous bounded proteins, therefore CYP450 isoforms 
were compared amongst the four extraction methods and the two separation 
methods. OG detected almost the double of CYP450 enzymes observed with 
SCX. The 7 CYP450 enzymes identified by OG were within normal range 
among CP, CP+S, and D extraction methods. On the other hand, in SCX, only 
one CYP 2d9 was marginally decreased by CP. The number of those identified 
CYP450 isoforms will be evaluated intensively and compared to literature 
publications in next chapter (Chapter 4)  
In conclusion, pharmacoproteomics studies require a high resolution and 
reproducible first dimension separation method and OG proved to be the most 
appropriate for further application in the project.  
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Chapter four: Quantitative pharmacoproteomics for 
investigating the effect of major anti-cancer drugs 
on mouse liver  
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4 Quantitative pharmacoproteomics for 
investigating the effect of major anti-cancer drugs 
on mouse liver  
4.1 Introduction 
Drug toxicity (resulting in serious health problems) is one of the major 
complications leading to the withdrawal of approved drugs from the market 
(Hay et al., 2014). The liver is able to give accurate and sensitive indications 
of drugs induced-toxicity. Although, the pronounced advancements in proteins 
fractionation tools, such as; multidimensional proteomics (i.e. shotgun 
proteomics) reduce liver protein complexity and thus, identifying low 
abundance proteins, other approaches have been developed to enrich a set 
of interest proteins, such as those existing in specific intracellular 
compartments (Huber et al., 2003), biological complexes (Ho et al., 2002), or 
those modified proteins (e.g. phosphorylation, glycosylation, etc.). (Oda et al., 
2001).     
In subcellular fractionation, animal cells are divided into subcellular 
compartments named “organelles” include: mitochondrion, lysosome, 
phagosome, ER, Golgi, nucleus, nucleolus, and many others (Jung et al., 
2000). Each organelle comprises a characteristic set of proteins that are 
required to perform particular organelle functions. Some organelles can be 
isolated to enable understanding of the proteins present and how they enable 
the organelle to function (Peng et al., 2010).    
Liver microsomes are an example of an organelle derived from the ER, which 
is enriched with a myriad of membranous (e.g. CYP450s) and non-
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membranous proteins (e.g. NADH-ubiquinone oxidoreductase chain 1-5) 
(Golizeh et al., 2015). Liver microsomal proteins have major roles in the 
biosynthesis of lipid and cholesterol, formation of hormones and drug 
metabolism (Cederbaum, 2015). Therefore, liver microsomes provide an in-
depth insight into xenobiotics metabolism, lipid-protein interactions, the role of 
membranous enzymes, and drug-drug interactions. Furthermore, the 
synergistic effect of using liver microsomes with the new advanced techniques 
of proteins separation have extended the application of shotgun proteomics in 
the analysis of membranous proteins and helped in overcoming some of the 
challenges in studying these types of proteins.  
The main purpose of traditional anti-cancer agents is to stop the extensive cell 
division by interfering with their replication at one or more checkpoints in their 
cell cycle, however, this may result in serious side effects (Weinberg, 2013).  
Considering the heterogeneous properties of cancer, most subtypes of cancer 
are treated with combined-chemotherapeutics agents. An example of 
chemotherapy combination in treating advanced colorectal cancer is 5-
fluorouracil (5FU) with irinotecan or oxaliplatin which enhanced the response 
rates to 40–50% instead of 10-15% by 5FU alone (Kuehr et al., 2004, Zhang 
et al., 2008). However, this combination creates additional stress on the liver, 
as at least one CYP450 isoform (Table 4.1) metabolises most of the anti-
cancer drugs (ACDs). Generally, adverse side effects of ACDs occur since 
CYP450 enzymes have limited capacity and their level can be altered (induced 
or suppressed) because of the administration of concomitant drugs. For 
example, CYP3A4 plays a key role in metabolizing several ACDs (such as 
taxanes, vinca-alkaloids and new drugs such as imatinib, sorafenib, and 
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gefitinib), therefore, administering a potent CYP3A4 inhibitor such as, 
ketoconazole will lead to a decrease in the clearance rate of these ACDs with 
a subsequent increase in their levels in the body (Akhdar et al., 2012). The 
reduction in clearance of concomitant ACD, which may reach 49% as in the 
case of docetaxel, would result in a higher toxicity outcome of the drug (Engels 
et al., 2004b). Similarly, the low expression of CYP3A4 in breast tuomur tissue 
potentiates the response to CYP3A4-metaboilzed ACDs (Miyoshi et al., 2005). 
In addition, CYP450 enzymes are responsible for bioactivation of prodrugs into 
therapeutic active forms, such as cyclophosphamide, ifosfamide, dacarbazine, 
procarbazine, tegafur, thiotepa and 1,4-bis-([2-(dimethylamino-N-
oxide)ethyl]amino) 5,8-dihydroxy anthracene-9,10-dione (AQ4N) (Rodriguez-
Antona and Ingelman-Sundberg, 2006, Nishida et al., 2010). AQ4N is a 
bioreductive prodrug which can be activated by CYP2S1 and CYP2W1 in 
tumour tissues into a topoisomerase II inhibitor (Nishida et al., 2010). 
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Table 4-1. Major anti-cancer drugs with their mediated human metabolizing enzymes.  
Anti-cancer 
agent 
Cytochrome P450 isoform (CYP) References 
Cisplatin 2E1, 3A4 (Mašek et al., 2009) 
Cyclophosphamide 2B6, 2C9, 3A4 
(Boddy and Yule, 
2000, Huang et al., 
2000) 
Docetaxel 1B1, 3A4, 3A5 
(Engels et al., 2004a, 
Shou et al., 1998) 
Doxorubicin 2D6, 3A4 (Kivisto et al., 1995) 
Etoposide 1A2, 2E1, 3A4, 3A5 (Zhuo et al., 2004) 
Irinotecan 3A4, 3A5 (Santos et al., 2000) 
Paclitaxel 2C8, 3A4, 3A5 
(Shou et al., 1998, 
Monsarrat et al., 
1998) 
Procarbazine 1A1, 2B6 
(Rodriguez-Antona 
and Ingelman-
Sundberg, 2006) 
Tamoxifen 
1A1, 1A2, 1B1, 2B6, 2C9, 2C19, 2D6, 
2E1, 3A4, 3A5 
(Desta et al., 2004, 
Crewe et al., 1997) 
Topotecan 3A4 (Bai et al., 2003) 
Vincristine 3A4 (Zhou et al., 1993) 
Ifosfamide 
2A6, 2B1, 2B6, 2C9, 2C18, 2C19, 3A4, 
3A5 
(Huang et al., 2000) 
 
There are only a few published papers on pharmacoproteomics of ACDs, 
particularly on the liver proteome (Bryan, 2006, Cho et al., 2012b, van Swelm 
et al., 2013). However, identification of liver toxicity induced by chemotherapy 
agents is often difficult for the reasons of cross diagnosis with other liver 
disease symptoms.   
A few hepatocyte organelles can be involved in liver toxicity in response to 
ACDs, such as ER and mitochondria. ER is a dynamic intracellular organelle 
that plays a central role in the synthesis of all secreted proteins from cells, it 
also has a role in oxidative responsiveness (Coe and Michalak, 2009, Halperin 
et al., 2014). Disruption of ER homeostasis may lead to accumulation of 
unfolded proteins in the ER lumen, a condition referred to ER stress (Foufelle 
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and Fromenty, 2016). Mitochondria are well-recognized organelles that take 
part in a variety of cellular metabolism, ATP production and macromolecule 
biosynthesis (Weinberg and Chandel, 2015). The mitochondria have been 
attributed to produce abundant amounts of reactive oxygen species (ROS) 
that promote DNA damage and genetic instability (Murphy, 2009). 
Drug-induced hepatotoxicity can manifest by several processes including, 
necrosis, cholestasis, and steatosis. Generated reactive metabolites may 
cause excessive damage to mitochondria that can eventually result in cellular 
necrosis (Nelson, 1995). In other circumstances, impairment of bile-acid 
transportation proteins by ACDs and/or their metabolites leads to cholestasis 
(i.e. accumulation of bile salt) that trigger secondary injury to hepatocytes 
(Pauli‐Magnus and Meier, 2006). Steatosis originates by a disturbed fatty acid 
metabolism through, for example, hepatic β-oxidation pathway; this 
interruption may lead to intracellular accumulation of small lipid vesicles 
(Fromenty et al., 1990). 
This project has focused on studying the effect of major anti-cancer drugs from 
different classes, including 5-flourouracil (5FU), doxorubicin (DOX), cisplatin 
(CIS) and paclitaxel (PAX) on mouse liver, as represented by protein 
expression changes in the microsomes. 
5-Fluorouracil (5FU) is a drug that belongs to the fluoropyrimidines class and 
is used commonly for the treatment of many advanced solid types of tumour, 
such as; colon, rectal, breast, gastric, pancreatic, ovarian, bladder and liver 
cancer (Longley et al., 2003). 5FU has anti-metabolite activity by inhibiting 
thymidylate synthase (TS) enzyme, which later blocks the formation of 
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thymidylate, an essential precursor of DNA synthesis and replication (Longley 
et al., 2003).  
5FU has been shown to exhibit hepatotoxic effects, such as increased serum 
level of aminotransferases, lactate dehydrogenase and alkaline phosphatase, 
signifying liver injury (Ray et al., 2007). Several reports have demonstrated the 
hepatotoxic effect of 5FU since it is metabolised extensively in the liver (more 
than 80%) producing a toxic intermediates fluoro-beta-alanine (FBAL), beta-
ureidopropionase (UPB1), etc. (Al-Asmari et al., 2016a, Conklin, 2004, Al-
Asmari et al., 2016b, Ray et al., 2007, Ali, 2012). 5FU treatment results in 
accumulation of fat globules in the hepatocytes (hepatic steatosis) (Miyake et 
al., 2005). Subsequently, disrupts lipid metabolism via the β-oxidation pathway 
(Zorzi et al., 2007, McWhirter et al., 2013). However, none of the studies 
systemically investigated the influence of 5FU on liver. (Kaplowitz and DeLeve, 
2013). Although the capability of 5FU to modulate liver CYP has been 
investigated, the mechanism remains unclear (Stupans et al., 1995, 
Baumhäkel et al., 2001). Afsar and his co-workers have revealed that 5FU 
modulated the activities of CYP450 enzymes (CYP2c11 and CYP3a sub-
family members) in male rat liver. Furthermore, they elucidated that these 
alterations could be due to the changes at synthesis level (Afsar et al., 1996). 
Moreover, several case reports have demonstrated the interaction between 
5FU and co-administered drugs; warfarin and phenytoin. In this context, 
authors suggested that 5FU modulates the synthesis of CYP450s (Saif, 2005, 
Brickell et al., 2003, Aki et al., 2000). For instance, Aki et al suggested that 
5FU modulates the expression of CYP2C9, which is thought to be the key 
isoform of human liver participating in warfarin metabolism (Daly and King, 
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2003). Further, similar interaction has been observed with a 5FU prodrug, 
capecitabine which inhibits CYP2C9 synthesis, resulting in elevated warfarin 
activity (Copur et al., 2001, Yildirim et al., 2006). Conversely, an attempt by 
Park et al used human liver microsomes to investigate the inhibitory effect of 
5FU on 13 different CYP450s, including CYP2C9. By using drugs as 
substrates (e.g. phenacetin O-de-ethylation by CYP1A2, warfarin metabolism 
by CYP2C9, paclitaxel 6α-hydroxylation by CYP2C8, and midazolam 1-
hydroxylation by CYP3A4), they suggested that there was little or no impact 
(Park and Kim, 2003). 
Doxorubicin (DOX) is a member of the anthracycline antibiotics which induces 
cytotoxicity by; i) intercalating between DNA base pairs forming “doxorubicin-
DNA adducts” which inhibit the progression of the enzyme topoisomerase II, 
thus blocking the process of replication, ii) generation of free oxygen species, 
and iii) lipid peroxidation as well as binding to membrane lipids (Hammer et 
al., 2010, Yang et al., 2014). The end results of DOX administration are DNA 
synthesis inhibition, apoptotic activation, and death of rapidly dividing cells 
(Yang et al., 2014). DOX is a highly effective anti-neoplastic agent, used to 
treat several adult and paediatric tumours such as bladder, breast, lung, 
ovarian, stomach, thyroid cancers (Granados-Principal et al., 2010). Although 
DOX is an effective agent, it has shown serious side effects primarily on the 
heart as well as other organs such as liver, kidney, and brain (Tacar et al., 
2013). However, due to rigorous metabolism in the liver, several in vivo and in 
vitro studies on DOX reported hepatotoxicity induced by DOX (Wang et al., 
2009, Lee et al., 2002, Barraud et al., 2005, El-Sayyad et al., 2009, Lai et al., 
2009). DOX exhibits severe changes at histological, structural and 
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biochemical levels in tested liver, indicating DOX-induced hepatotoxicity (El-
Sayyad et al., 2009). The hepatotoxicity can manifest as necrosis, steatosis, 
fibrosis, cholestasis, and vascular injury (Ishak and Zimmerman, 1995). It is 
thought to result from DOX inducing oxidative stress, which in turn is 
responsible for mitochondrial dysfunction and apoptosis (Damodar et al., 
2014, Bulucu et al., 2009). Additionally, DOX induces inflammatory changes 
as measured by C-reactive protein and fibrinogen in the liver, as well as heart 
and kidney tissues of DOX-administered rats (Deepa and Varalakshmi, 2005).   
Few studies have reported the modulation of hepatic CYP450 enzymes by 
DOX administration. Zordeky et al investigated the ability of acute DOX toxicity 
in modulating the expression of different CYP450 enzymes using rat liver 
microsomes at both gene and protein expression levels. The results 
demonstrated that DOX altered the expression of four isoforms (CYP1B1, 2B1, 
2C11, and 4A). In addition, the study showed up-regulation in inflammatory 
mediators; interleukin 6 (IL-6), inducible nitric oxide synthase (iNOS), and 
tumour necrosis factor – (TNFα), proposing them as indicators of liver damage 
(Zordoky et al., 2011). 
Cisplatin (CIS) is a powerful anti-neoplastic drug belonging to alkylating agents 
group. CIS shows clinical activity against a wide variety of solid tumours such 
as the bladder, ovarian, head and neck, and cervical (Siddik, 2003). The 
mechanism of action is based on the formation of inter- or intra-strand cross-
links called adducts, causing an alteration in the structure and/or function of 
DNA and subsequent long-term damage for DNA (Siddik, 2003).  
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A recent study demonstrated that induction of the expression of unfolded 
response protein (URP) in response to ER stress is a possible mechanism of 
CIS-induced apoptosis (Mandic et al., 2003). Accordingly, and similar to 5FU, 
CIS caused hepatic steatosis, suggesting it to interfere mitochondrial and ER 
functions (Sharma et al., 2014). Hepatotoxicity of CIS recently became well 
characterised, where production of oxidative stress and depletion in 
glutathione levels are thought to play a pivotal role as one of the mechanisms 
(Lu and Cederbaum, 2007). Therefore, several studies have paid attention to 
identifying and analysing new compounds capable of protecting the liver from 
these reactive species, such as vitamin E and selenium (Nazıroǧlu et al., 
2004). A recent proteomics study revealed that CIS modulated the expression 
of three CYP450s (CYP2c13, CYP2d1, and CYP2d5) at the protein level and 
four CYP450s (CYP2c12, CYP2e1, CYP4a1, and CYP26b1) at the gene level 
in primary rat hepatocytes (Cho et al., 2012a). A further study investigated the 
platinum derivative, satraplatin (JM216), in modulating CYP450s using human 
microsomes, which indicated a strong but non-specific inhibitory effect (Ando 
et al., 1998).    
Paclitaxel (PAX) is a mitotic inhibitor originally derived from the bark of the 
Pacific yew tree, Taxus brevifolia (Stierle et al., 1993). PAX is commonly used 
in several types of solid cancer, however, it is the first line choice for advanced 
ovarian, non-small cell lung cancers and metastatic breast cancer (Khanna et 
al., 2015). Contrary to the microtubule destabilizing agents (e.g. vinca 
alkaloids), the primary mechanism of action of PAX is the prevention of 
cytoskeletal microtubule disassembly through its direct binding to microtubulin, 
resulting in suppression of cell mitosis and induction of apoptosis (Khanna et 
  137 
al., 2015, Walsh and Goodman, 2002). Similar to previous mentioned ACDs, 
PAX has shown significant degenerative and necrotic effects on mice liver 
tissues (Karaduman et al., 2010). PAX is extensively metabolised in the liver 
via CYP2C8 and CYP3A4; however, there is no evidence indicating that PAX 
modulated the expression of liver CYP450s. 
The compound 1,4-Bis[2-(3,5-dichloropyridyloxy)]benzene (TCPOBOP) is a 
well-established CYP450 enzymes inducing agent, it has been used as a 
control for CYP450s for both qualitative and quantitative analysis of liver 
microsomes in the animal model (Smith et al., 1993). The mechanism of 
inducing CYP450 genes is due to the activation of TCPOBOP for the 
constitutive androstane receptor (CAR). CAR plays a role in hepatic 
detoxiﬁcation pathways in response to xenobiotic or endogenous stimuli 
(Baskin-Bey et al., 2006). Although TCPOBOP is a CYP450 inducer, Lane et 
al, have observed down-regulation of four CYP isoforms (CYP2C40, 2E1, 
3A41, and 27A1) prior to a single dose of TCPOBOP administered (Lane et 
al., 2007).  
Traditional methods for CYP450 enzymes identification have been based on 
implicated specific inhibitors or substrates (Kobayashi et al., 2003), antibody-
based identifications (Shou et al., 2000) or measuring the corresponding 
mRNA level (Patterson and Murray, 2002). The disadvantages of traditional 
methods can be summarised by the lack of specificity and sensitivity due to 
the high degree of CYP450 enzymes sequence homology that was observed 
not only within one CYP450 family but also among various disparate isoforms. 
To overcome the limitations of these methods; highly validated and sensitive 
strategies were established by taking advantage of MS advancement. Since 
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all CYP450 molecular weights are located between 48-62 kDa range, SDS-
PAGE has been widely used for first dimension microsomal proteins’ 
separation, embracing detergents for microsomal purification prior to LC-MS 
protein identifications (Lane et al., 2004, Nisar et al., 2004a, Lisitsa et al., 2009, 
Shrivas et al., 2013b, Sutton et al., 2010).  
Galeva and his colleagues evaluated the efficiency of one and two-
dimensional gel electrophoresis (1D-PAGE, 2D-PAGE) for separation of 
hydrophobic membranous proteins, they demonstrated that 1D-GE is more 
applicable for CYP450 enzymes identifications than 2D-PAGE due to the 
aggregation of this proteins during first dimension separation of 2D-PAGE. In 
addition, 1D-PAGE resulted in identification of 7 CYP450 enzymes in livers 
from control and phenobarbital-treated mice (CYP 2a1, 2b1, 2b2, 2c11, 2d2, 
2d5 and 3a1), whereas 2D-PAGE identified only 2 isoforms (CYP2b1 and 2b2) 
(Galeva and Altermann, 2002). Applying in-gel digestion approach for 
CYP450s identification has been reported firstly by Nisar and co-workers 
(Nisar et al., 2004b). Using rat liver microsomes, they positively identified 24 
CYP450 isoforms. Another attempt by Sutton et al using an enhanced 1D-
PAGE approach for microsomal proteins separation identified 26 of highly 
homolog CYP450 isoforms from mouse (Sutton et al., 2010). A major 
drawback of using gel-based approach is the limited number of families that 
can be identified, low sensitivity, and lack of quantification. Conversely, gel-
free proteomics approach is commonly used nowadays for profiling the whole 
proteome, which raises a challenge to identify a high number of microsomal 
proteins including CYP450 enzymes. Due to the use of optimised proteomics 
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workflow (Chapter 3), a remarkable number of CYP450 isoforms were 
significantly identified and quantified in this Chapter.      
4.1.1 Aims of the chapter 
Work in this chapter has been conducted in two independent quantitative 
comparative experiments with the main aims to: 
a. Investigate the effect 5-flourouracil (5FU), doxorubicin (DOX), paclitaxel 
(PAX), cisplatin (CIS), and the CYP450s inducer, 1,4-Bis[2-(3,5-
dichloropyridyloxy)]benzene (TCPOBOP) on mouse liver microsomes 
by the means of proteomics technique.  
b. Identify potential biomarkers that may have role in drug disposition 
and/or liver toxicity 
c. Identify the changes in CYP450 expression, along with other xenobiotic 
enzymes as result of the application of these drugs.  
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4.2 Material and Method 
4.2.1 Reagents and chemicals 
5-fluorouracil (5FU), cisplatin (CIS), doxorubicin (DOX), paclitaxel (PAX), 1,4-
Bis [2-(3,5 dichloropyridyloxy)] benzene (TCPOBOP), Cremaphor-EL (CrEL), 
dimethyl sulphoxide (DMSO) and Arachis oil were purchased from Sigma-
Aldrich, UK. For information about other materials used in this chapter, refer 
to section 2.1.1.  
4.2.2 Animal treatment and xenograft preparation 
4.2.2.1 Animals 
Male and female BALB\cOLaHsd–Foxn1nu immunodeficient nude mice 
(Harlan Laboratories, UK) aged 10 weeks and 15 weeks, respectively, were 
used. All mice were kept and maintained as described previously (section 
3.2.1). 
4.2.2.2 Cell lines 
Human colon adenocarcinoma (DLD-1) and human pancreatic carcinoma 
(PANC-1) cell lines were purchased from ECACC (Porton Down, Wiltshire, 
UK). DLD-1 and PANC-1 were selected due to their good vascularisation when 
grown in vivo as subcutaneous xenograft tumours. Both cell lines were 
cultured in RPMI-1640 cell culture medium supplemented with 1mM sodium 
pyruvate, 2mM L-glutamine and 10% fetal bovine serum (Sigma-Aldrich, UK). 
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4.2.2.3 Tumour system 
Tumours were excised from a donor animal, placed in sterile physiological 
saline containing antibiotics and cut into small fragments of ~2 mm³. Under 
brief general inhalation anaesthesia, cell line fragments were implanted in both 
flanks of each mouse using a trocar. Once the tumours could accurately be 
measured by calipers, the mice were divided into groups of 8 by restricted 
randomisation in order to minimise group mean tumour size variation. 
4.2.2.4 Chemotherapy treatment  
Animal husbandry and tissue collection were carried out by Home Office-
certified expert Tricia Cooper, at the Institute of Cancer Therapeutics, 
University of Bradford. 5FU, CIS, DOX, PAX, and TCPOBOP were used to 
treat mice in two independent experiments. A colleague of the proteomics’ 
team had prepared the first set (Set A) previously. Male mice for Set A were 
treated with 5FU, CIS and DOX and female mice for Set B with 5FU, PAX, and 
TCPOBOP. In each case, Control mice were included receiving no treatment 
for Set A and normal saline for Set B. 5FU was included in both studies as an 
inter-experimental control (Table 4.2). Animals were sacrificed 24 hours after 
treatment. Heart, lung, liver, kidney, and tumour were recovered and stored at 
-80°C for proteomics analysis. Only the livers were used for subsequent 
experiments. 
Drugs doses (Table 4.2) which were used here were determined based on 
independent experiments prior to the present project on mice. The dose was 
measured as the maximum tolerated dose by mouse. Several toxic signs were 
considered in determining the dose; however, weight loss by maximum 15% 
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was the main indicator used for toxicity. Alongside the data from these 
experiments, the toxic dose used in the literature for these drugs, as well as 
the tolerated toxic effect of solvents were also taken into account.     
Table 4-2. Conditions of mice treatment and the type of drugs and tumours used 
Mice 
set 
Mice 
gender 
Drug 
Tumour 
type 
Dose 
(mg/kg) 
Route of drug 
administration 
Duration 
(hr.) 
Solvent 
system 
Set A Male 
Control PANC-1 0 Not given 24 Not given 
5FU PANC-1 100 IP 24 
Normal 
saline 
CIS PANC-1 10 IP 24 10% DMSO 
DOX PANC-1 10 IP 24 
Normal 
saline 
Set B Female 
Control DLD-1 0 IP 24 
Normal 
saline 
5FU DLD-1 100 IP 24 
Normal 
saline 
PAX DLD-1 20 IP 24 
CrEL, DMSO 
and Arachis 
oil 
TCPOBOP DLD-1 3 IP 24 
10% 
DMSO/Arach
is oil 
 
4.2.3 Sample preparation  
4.2.3.1 Protein extraction from mouse liver by cryo-pulverization 
and microsomes preparation 
The treated mouse livers were subject to quantitative proteomics as illustrated 
in Figure 4.1. Initially, mouse livers were weighed before dicing into small 
pieces and then protein extraction by sonication for Set A, where the optimised 
method (CP+S) was used for Set B as elucidated earlier (sections 3.2.2.1.1-
2). Next, the microsomal fraction was prepared for each sample as described 
in Section 2.2.1.1 in order to enrich drug-metabolizing proteins.  
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Figure 4-1. Flow diagram showing the steps of quantitative proteomics workflow that 
have been used. After drugs treatments, proteins were extracted by dicing followed 
by sonication method for Set A and the optimised method (CP+S) for Set B. iTRAQ 
labels were used for proteins quantification. Combined labelled proteins from both 
sets were subjected to Off-Gel (OG) and RP-HPLC separation techniques. The 
generated fractions were analysed using MALDI-TOF-TOF-MS for protein 
identifications by database searching and quantifications. 
  
4.2.3.2 iTRAQ peptide labelling 
Defined amounts (50µg) of each treated sample, calculated by Bradford assay 
(section 3.2.1.2) were, recovered and digested with acetone and trypsin 
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enzyme, respectively, (sections 3.2.1.4-6) prior to tagging with iTRAQ 4-plex 
reagent (section 3.2.1.7), in the two separated sets as shown in Table 4.3. 
 Table 4-3. 4-plex iTRAQ reagents was used to label tryptic digests of mouse livers 
treated with specific anti-cancer drugs or controls. 
iTRAQ 
reagent 
114 115 116 117 
Drug used 
Set A Control 5FU CIS DOX 
Set B Control 5FU PAX TCPOBOP 
 
4.2.3.3 Peptide separation and identification 
iTRAQ samples for each set were combined into one tube and then separated 
in two dimensions as shown in Figure 4.1. 
The optimised OG separation technique was used for first dimension 
separation, using a wide pH range IPG strip (3-10, 17cm) and 24 fractions 
were collected (section 3.2.1.7.1.2). The resulting fractions were desalted as 
described in Section 3.2.1.5 and separated for the second dimension using 
RP-HPLC technique (section 3.2.1.7.2). The MS analysis and protein 
identification were conducted as described in Sections 3.2.1.8-10.   
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4.3 Results 
4.3.1 Evaluation identified proteins from datasets A and B 
Two strategies were employed to extract liver microsomal proteins: a) 
extraction by dicing and sonication method for Set A (5FU, CIS and DOX); 
and, b) extraction by cryo-pulverization followed by sonication method for Set 
B (5FU, PAX, and TCPOBOP). Of collectively identified proteins, a total of 
1146 and 1743 proteins were obtained in Set A and Set B, respectively, with 
good qualitative data (at least two peptides identifying each protein) (Appendix 
BI and BII). Comparing the identified proteins by datasets A and B revealed 
that 952 proteins were common between the two sets (Figure 4.2), indicating 
that Set B identified approximately 83% of those proteins identified by Set A. 
 
Figure 4-2. Venn diagram showing the number of unique and common proteins 
between Set A and Set B.  
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Next, in order to evaluate the efficiency of the extraction methods of Set A and 
Set B in recovering microsomal proteins, two approaches were employed. 
Firstly, the grand average of hydropathy (GRAVY) algorithm (Figure 4.3) was 
used to determine the hydrophobic status of identified proteins as described 
earlier in Section 2.2.1.13. 
 
 
Figure 4-3. Distribution of identified proteins from Sets A and B over the GRAVY 
scores. The value (-0.4) is the threshold between cytosolic proteins and membrane 
proteins, therefore protein with score higher than (-0.4) indicates higher probability 
for membrane association (a more positive GRAVY score the more hydrophobic a 
protein) 
 
GRAVY results demonstrated that 726 proteins (63% of total identified proteins 
by Set A) and 1194 proteins (69% of total identified proteins by Set B) had 
GRAVY score of higher than (-0.4), suggesting a high proportion of membrane 
proteins.  
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Secondly, the identified proteins in datasets A and B were submitted to 
Phobius software for prediction of integral membrane proteins to determine 
protein’s hydrophobicity (section 2.2.1.13). Results demonstrated that 32% 
(368/1146) and 35% (608/1743) from Set A and Set B, respectively were 
predicted to be transmembrane proteins.  
Following this datasets of identified proteins from Set A (n = 1146) and Set B 
(n = 1743) were compared based on their cellular component, molecular 
function, and biological process (Appendix CI, CII, and CIII, respectively) 
using the Biological Networks Gene Ontology (BinGO) tools for ontology 
annotation (section 2.2.1.13). In addition, the identified proteins from Set A 
and Set B were compared to a reference protein list (RPL) provided by BinGO 
for enrichment and depletion analysis. A hypergeometric test with p < 0.01 as 
a cutoff was used to determine significant GO terms after correcting for a 
multiple term testing with a Benjamini and Hochberg false discovery rate. The 
enrichment factor was computed as the number of dataset proteins and 
reference proteins (i.e. entire international protein index-IPI of the mouse) 
annotated to each GO term divided by the number of dataset proteins and 
entire IPI proteins linked to at least one annotation term within the indicated 
GO terms. 
Analysis based on cellular locations, molecular functions, and biological 
processes did not show any significant differences between Set A and B. 
However, cytoplasmic associated proteins (CAPs), which are highly abundant 
in cells, were presented as the highest abundant fraction among Set A (33.3%) 
and Set B (25.7%). However, the analysis showed that CAPs were marginally 
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enriched in Set A (p-value, 0.016), and significantly depleted in Set B (p-value, 
5x108). 
Correspondingly, molecular function analysis of Set B demonstrated 
significant depletion in proteins involved in, 1) nucleotide, chromatin and DNA 
binding, 2) receptor binding, and 3) actin binding, indicating a reduction in 
nuclear, cytoplasmic and plasma membrane proteins, respectively. On the 
other side, RNA binding and lipid binding were significantly enriched, 
confirming more ribosomal proteins identified. Similarly, biological processes 
revealed that proteins are structurally and functionally linked to ER organelle 
(i.e. rough endoplasmic reticulum). 
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4.3.2 Validation of differentially expressed proteins 
For relative protein quantifications, minimum two unique peptides were 
required to generate a quantifiable protein list (section 2.2.1.12). Employing 
this strategy resulted in 1095 (96% of identified proteins) and 1726 (98% of 
identified proteins) accurately quantified proteins for Sets A and B, 
respectively. P-value was computed for each protein via permutation test as 
mentioned previously in Section 3.2.1.10. The distribution of quantified 
proteins (log2) against –log (p-value) of the ratio is presented using volcano 
plot for each drug treatment (Figure 4.4). 
For significantly altered proteins in each dataset, two criteria were applied as 
cutoffs for significantly altered proteins. The first cutoff was the protein p-value; 
thus proteins were considered significantly altered if their (p-value < 0.05). The 
second cutoff was the standard deviation (SD), proteins were considered as 
up-regulated if their log2 iTRAQ ratios were more than the cutoff (+1SD) and 
down-regulated if their log2 iTRAQ ratios were less than the cutoff (-1SD) 
(Figure 4.4). 
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Set A Set B 
1) 5FU 
 
1) 5FU 
 
2) CIS 
 
2) PAX 
 
3) DOX 
 
3) TCPOBOP 
 
Figure 4-4. Volcano plot of the complete iTRAQ proteomic dataset for Set A; 5FU, 
DOX, CIS (left column) and Set B; 5FU, PAX, TCPOBOP (right column) showing the 
fold change in protein expression between treated and control sample. For 
significantly altered proteins, 1SD was the first cutoff (the vertical two red dotted 
lines indicate the up- and down-regulated points). The second cutoff was the p-
value (the horizontal blue dotted line indicates the p-value threshold, p-value < 
0.05). Proteins were deemed significantly altered under the two criteria were 
colored with red.  
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Of the significantly regulated proteins in Set A, 67, 64, and 50 proteins were 
down-regulated and 28, 33, and 32 proteins were up-regulated in 5FU, CIS, 
and DOX, respectively. For Set B, a total of 113, 97, and 51 proteins were 
down-regulated and 51, 68, and 42 proteins were up-regulated in 5FU, PAX, 
and TCPOBOP, respectively (Figure 4.5) 
 
 
Figure 4-5. Bar charts showing the number of regulated proteins (up- or down-
regulated) as result of each drug, (A) for Set A and (B) for Set B. 
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4.3.3 Functional analysis of significantly regulated proteins 
4.3.3.1 Functional analysis of significantly regulated proteins by 
Set A 
The number of modulated proteins by each drug, including the unique and 
common proteins is shown in Venn diagrams (Figure 4.6). 
 
 
Figure 4-6. Venn diagrams depicting proteins regulated either down or up by 5FU, CIS 
and DOX-treatment in Set A. Proteins in the blue circle are regulated by 5FU, proteins 
in the yellow circle are regulated by CIS, and proteins in the green circle are regulated 
by the DOX treatment. 
 
4.3.3.1.1 Common differentially expressed proteins  
Among the differentially expressed proteins in Set A, six and nine proteins 
were significantly down-regulated (Table 4.4) and up-regulated (Table 4.5), 
respectively, by the three treatments; 5FU, CIS, and DOX.  
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Table 4-4. A list of down-regulated proteins by the three treatments for Set A 
Accessio
n 
Protein Name 
5FU/Cont CIS/Cont DOX/Cont 
iTRAQ 
ratio 
p-
value 
iTRAQ 
ratio 
p-
value 
iTRAQ 
ratio 
p-
value 
P16460 Argininosuccinate synthase 0.73 0.0001 0.65 0.0001 0.63 0.0001 
Q9Z2W0 Aspartyl aminopeptidase 0.70 0.0094 0.72 0.0286 0.72 0.0456 
Q8CGC7 
Bifunctional 
glutamate/proline--tRNA 
ligase 
0.66 0.0049 0.65 0.0072 0.61 0.0039 
P49312 
Heterogeneous nuclear 
ribonucleoprotein A1 
0.73 0.0292 0.65 0.0110 0.60 0.0106 
P53395 
Lipoamide acyltransferase 
component of branched-chain 
alpha-keto acid 
dehydrogenase complex, 
mitochondrial 
0.72 0.0063 0.58 0.0009 0.46 0.0001 
P12246 Serum amyloid P-component 0.36 0.0001 0.28 0.0001 0.21 0.0001 
 
Most of the down-regulated proteins have an important protective role in 
response to drugs administration, for example, argininosuccinate synthase 
(ASS) is an essential rate-limiting enzyme in arginine biosynthetic pathway 
that catalyses the synthesis of argininosuccinate from citrulline and aspartate. 
ASS is primarily located in the outer membrane of mitochondria inside the liver, 
it has been implicated in different types of cancer (e.g. hepatocellular 
carcinoma) and chemotherapy resistance (i.e. platinum anticancer drugs) 
(McAlpine et al., 2014a, Delage et al., 2010). Moreover, suppression of ASS 
showed a significant protection against CILI (Ming Leung et al., 2012). Aspartyl 
aminopeptidase (ASP) is a cytosolic abundant catalytic enzyme, which has 
specificity towards acidic peptide/ proteins, most commonly cleaving aspartic 
acid from the N-terminus and regulating bioactivation of peptides such as 
angiotensin II. Up-regulation of ASP mRNA level has been linked to the 
different type of cancer, such as colorectal cancer (Larrinaga et al., 2013). 
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Heterogeneous nuclear ribonucleoprotein A1; is an mRNA transporter from 
the nucleus to the cytoplasm. It has shown a significant role in hepatocellular 
carcinoma progression (Li et al., 2012). Furthermore, it has been considered 
as a potential target of  different anticancer drugs including, DOX (Mandili et 
al., 2012). Serum amyloid P-component is an apolipoprotein synthesized in 
the liver and its level increased in response to inflammation (e.g. drug 
administration) (Villapol et al., 2015). Lipoamide acyltransferase is a 
component of branched-chain alpha-keto acid dehydrogenase complex 
(BCKD) which is a mitochondrial enzyme that catalyses the conversion of 
alpha-keto acids into acyl-CoA. Suppression of BCKD results in accumulation 
of branched-chain amino acids (i.e. valine, leucine, and isoleucine), which 
appear capable of reducing oxidative stress effects, suggesting a protective 
route alongside liver injury (Tretter and Adam-Vizi, 2005). Previous studies 
demonstrated a reduction in BCKD level in response to the hepatotoxin, tienilic 
acid and it’s reactive metabolites (Koen et al., 2012). 
The up-regulated proteins are involved in lipid and glycogen metabolism 
(Table 4.5) including acetoacetyl-CoA synthetase (AACS) which activates 
acetoacetate to acetoacetyl-CoA that can be further utilized by ketone bodies 
for fatty acid synthesis (Tisdale, 1984). Up-regulation of AACS was observed 
in mice fed a high-fat diet as an indication of induction lipogenesis. In drug 
toxicity induction AACS is an indicator of high levels of free fatty acids (FFAs), 
thus liver injury (Kirpich et al., 2011). Fatty acid-binding protein (FABP1) is a 
cytoplasmic protein thought to have a role in binding and transporting lipophilic 
substrates such as fatty acid, indicating a hepatocellular protective mechanism 
against free radical products and liver steatosis (Gong et al., 2014). 
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Table 4-5. A list of up-regulated proteins by the three treatments for Set A 
Accessio
n 
Protein Name 
5FU/Cont CIS/Cont DOX/Cont 
iTRAQ 
ratio 
p-
value 
iTRAQ 
ratio 
p-
value 
iTRAQ 
ratio 
p-
value 
Q9D2R0 Acetoacetyl-CoA synthetase 2.45 0.01 2.43 0.02 2.70 0.01 
P12710 
Fatty acid-binding protein, 
liver 
1.37 0.04 1.56 0.00 1.51 0.07 
O35387 
HCLS1-associated protein X-
1 
2.53 0.01 2.10 0.04 3.40 0.00 
P11588 Major urinary protein 1 2.18 0.02 2.47 0.02 6.27 0.00 
P11589 Major urinary protein 2 1.81 0.01 2.04 0.01 2.78 0.00 
P02762 Major urinary protein 6 1.74 0.03 2.21 0.03 3.34 0.00 
Q99MR9 
Protein phosphatase 1 
regulatory subunit 3A 
3.17 0.00 3.47 0.00 5.26 0.00 
Q8R429 
Sarcoplasmic/endoplasmic 
reticulum calcium ATPase 1) 
3.00 0.00 2.07 0.01 1.65 0.04 
Q921T2 
Torsin-1A-interacting protein 
1 
2.05 0.04 2.70 0.01 2.18 0.03 
 
HCLS1-associated protein X-1 (HAX1) is a mitochondrial protein, which 
potentiates cell survival by various pathways such as promoting the clathrin-
mediated endocytosis pathway and has been described to be involved in 
cancer metastasis (Ramsay et al., 2007). HAX1 is up-regulated to counteract 
the delivery of free fatty acid and liver necrosis, thus promoting hepatocyte 
survival (Lam et al., 2015). Major urinary proteins (MUP1, 2, 6) are 
pheromone-binding proteins expressed largely in male mice (Flower, 1996). 
MUPs are believed to have a cellular protective mechanism and/or drug 
binding and excretion.  
4.3.3.1.2 Unique differentially expressed proteins  
A list of unique differentially expressed proteins in 5FU, CIS, and DOX 
compared with control are listed in the additional table (Appendix D; DI, DII 
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and DIII for 5FU, CIS and DOX, respectively). The unique differentially 
expressed proteins by 5FU, CIS and DOX were compared based on their 
cellular location and biological process to a reference protein list of complete 
mouse proteome (IPI mouse) that was provided by BinGO for enrichment 
study (section 2.2.1.13).  
The analysis did not show significant enrichment in regulated proteins by 5FU, 
CIS or DOX, however, 5FU has exhibited a bias in up-regulation of ER-stress 
proteins (7 proteins), which would explain the mechanism of 5FU inducing liver 
injury. CIS showed prominent down-regulation in mitochondrial proteins. This 
suppression may lead to ROS accumulation, DNA damage, and subsequently 
hepatocellular death. DOX resulted exclusively in down-regulation of proteins 
from ER, proteasomes complex and Golgi apparatus. The biological 
processes related to these particular groups of proteins were involved mainly 
metabolic energy generation via carbohydrate metabolism. Whilst, up-
regulated proteins play an important role in β-oxidation pathway, response to 
stress and cell division proteins. 
4.3.3.2 Functional analysis of significantly regulated proteins by 
Set B 
The number of modulated proteins for each treatment of Set B, including the 
unique and common proteins, is shown below in Venn diagrams (Figure 4.7). 
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Figure 4-7. Venn diagrams depicting proteins regulated either down or up by 5FU, 
PAX and TCPOBOP-treatment in Set B. Proteins in the blue circle are regulated by 
5FU, proteins in the yellow circle are regulated by PAX, and proteins in the green 
circle are regulated by the TCPOBOP treatment. 
 
4.3.3.2.1 Common differentially expressed proteins  
Among the differentially expressed proteins in Set B, six proteins were down-
regulated (Table 4.6) and three proteins were up-regulated (Table 4.7) by all 
three treatments; 5FU, PAX, and TCPOBOP, respectively.  
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Table 4-6. A list of down-regulated proteins by the three treatments for Set B 
Accessio
n 
Protein Name 
5FU/Cont CIS/Cont DOX/Cont 
iTRAQ 
ratio 
p-
value 
iTRAQ 
ratio 
p-
value 
iTRAQ 
ratio 
p-
value 
Q924Z4 Ceramide synthase 2 0.58 0.00 0.78 0.03 0.70 0.01 
P15392 Cytochrome P450 2A4 0.82 0.00 0.71 0.00 0.67 0.00 
Q9CR61 
NADH dehydrogenase 
[ubiquinone] 1 beta 
subcomplex subunit 7 
0.77 0.03 0.79 0.04 0.71 0.02 
Q7TNG8 
Probable D-lactate 
dehydrogenase, 
mitochondrial 
0.83 0.03 0.76 0.00 0.75 0.00 
Q9CQS8 
Protein transport protein 
Sec61 subunit beta 
0.54 0.00 0.63 0.00 0.73 0.04 
Q61136 
Serine/threonine-protein 
kinase PRP4 homolog 
0.74 0.02 0.74 0.01 0.72 0.02 
 
The majority of down-regulated proteins were linked to mitochondrial 
dysfunction. For example, ceramide synthase 2 is a key enzyme in 
sphingolipid biosynthesis (Reynolds et al., 2004). It has been reported that 
depletion in ceramide synthase 2 protein causes mitochondrial dysfunction 
due to ROS accumulation (Zigdon et al., 2013). CYP2A4 has a role in 
hydroxylation of several endogenous and exogenous compounds. Drugs 
causing steatosis such as tetracycline showed down-regulation in the 
expression of CYP2A4 (Yin et al., 2006). NADH dehydrogenase-1 beta 
subcomplex subunit 7 (NDUB7) is a member of mitochondrial membrane 
respiratory chain (complex I) that is responsible for electron transfer. The 
expression of NDUB7 was down-regulated in non-alcoholic fatty liver disease 
(NAFLD), suggesting liver injury in our study of ACDs (Wei et al., 2008). 
None of the up-regulated proteins have a role in response to drug toxicity or 
metabolism or liver injury (Table 4.7). 
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Table 4-7. A list of up-regulated proteins by the three treatments for Set B 
Accessio
n 
Protein Name 
5FU/Cont CIS/Cont DOX/Cont 
iTRAQ 
ratio 
p-
value 
iTRAQ 
ratio 
p-
value 
iTRAQ 
ratio 
p-
value 
Q8K1N1 
Calcium-independent 
phospholipase A2-gamma 
1.52 0.0034 1.47 0.0053 1.82 0.0006 
Q9CPQ3 
Mitochondrial import receptor 
subunit TOM22 homolog 
1.72 0.0063 1.63 0.0105 1.90 0.0041 
Q9Z2Y8 
Proline synthase co-
transcribed bacterial 
homolog protein 
1.38 0.0078 1.31 0.0160 1.46 0.0048 
 
4.3.3.2.2 Unique differentially expressed proteins  
The unique differentially expressed proteins in 5FU, PAX, and TCPOBOP 
compared with control are listed in additional tables (Appendix EI, EII, and EIII 
for 5FU, PAX, and TCPOBOP, respectively). Moreover, the enrichment 
analysis for unique differentially expressed proteins for each drug (5FU, PAX, 
and TCPOBOP) was performed as for Set A. The analysis of down-regulated 
proteins by 5FU showed significant enrichment in ribosomal proteins (14 
ribosomal proteins) that have a role in translation, ribosomal assembly, 
ribosomal subunit biogenesis and protein folding. For up-regulation, 
mitochondrial proteins were highly enriched, which showed a preference to 
fatty acid degradation. PAX significantly regulated proteins related mainly to 
ER-organelle (e.g. CYP450s and carboxylesterase enzyme), which have a 
major role in various types of metabolic processes such as, oxidation-
reduction process, and lipid, fatty acid, ketone, alcohol, and carboxylic acid 
metabolism. TCPOBOP showed a significant effect on microsomal proteins, 
especially drugs metabolizing enzymes. TCPOBOP affected bile acid, steroid 
metabolic process, and fatty acid metabolism. Furthermore, proteins 
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responding to stress were up-regulated in TCPOBOP, indicating protective 
role. 
4.3.4 Validation of the inter-experimental control (5FU) in 
quantitative proteomics study 
5-Fluorouracil (5FU) was used in both experiments as an inter-experimental 
control. A total of 925 proteins were confidently identified and quantified in both 
datasets of 5FU. 
Of the commonly identified proteins (925 proteins), 56 and 28 proteins were 
significantly changed by 5FU in Set A and Set B, respectively. Amongst these 
proteins, four were down-regulated and seven were up-regulated in both 
datasets (Table 4.8). The functional analysis of these proteins assigned them 
to ER and mitochondrion pathways, respectively. 
Table 4-8. The commonly regulated proteins by 5FU in the Sets A and B.  
Regulation Protein name Accession 
Set A  Set B 
iTRAQ 
ratio 
p-
value 
iTRAQ 
ratio 
p-
value 
Down-regulated 
in both Datasets 
 
Annexin A6 P14824 0.74 0.0391 0.83 0.0146 
Ferritin heavy chain P09528 0.71 0.0009 0.82 0.0001 
Protein disulfide-
isomerase A3 
P27773 0.74 0.0026 0.81 0.0001 
Protein disulfide-
isomerase A4 
P08003 0.71 0.0411 0.83 0.0001 
Up-regulated in 
both Datasets 
 
3-hydroxyacyl-CoA 
dehydrogenase type-2 
O08756 1.18 0.0489 1.29 0.0209 
Carbamoyl-phosphate 
synthase [ammonia], 
mitochondrial 
Q8C196 1.4 0.0009 1.27 0.0001 
Glycerol-3-phosphate 
acyltransferase 1, 
mitochondrial 
Q61586 1.39 0.0478 1.2 0.0146 
Carnitine O-
palmitoyltransferase 2, 
mitochondrial 
P52825 1.55 0.0124 1.21 0.0003 
Pyruvate carboxylase, 
mitochondrial 
Q05920 1.32 0.0036 1.21 0.0004 
Very long-chain acyl-
CoA synthetase 
O35488 1.3 0.0368 1.3 0.0124 
Fatty acid-binding 
protein, liver 
P12710 1.37 0.0378 1.43 0.0003 
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Down-regulated proteins in 5FU of both datasets in details are: i) Annexin A6; 
a calcium and phospholipid binding protein that plays an important role in 
regulating cholesterol transport, thus in hepatic lipid and glucose hemostasis 
(Qi et al., 2015). Moreover, it has shown a key role in mitochondrial 
morphogenesis and fidelity (Chlystun et al., 2013). ii) Ferritin heavy chain; an 
iron ion binding protein, is located mainly in the cytoplasm and has a role in 
storing iron as well as protecting cells from oxidative stress (Aung et al., 2007). 
Down-regulation of this protein in liver and up-regulation in serum is indicative 
of liver damage (Kell and Pretorius, 2014). iii) Protein disulfide isomerases 
(PDIs) A3 and A4 are ER-marker proteins that act as molecular chaperones. 
Suppressing the expression of PDIs led to unfolded proteins accumulating and 
thus ER stress, which in consequence activated the apoptotic pathways (Grek 
and Townsend, 2014). 
Of the up-regulated proteins in both datasets, 3-hydroxyacyl-CoA 
dehydrogenase type-2 catalyses the third reaction of the mitochondrial β-
oxidation cascade, playing a role in beta-oxidation pathway. Carbamoyl-
phosphate synthase (CPS1) is an intramitochondrial enzyme; it is involved in 
the formation of carbamoyl phosphate, the first committed step of the urea 
cycle. CPS1 is considered a turnover marker of mitochondrial damage 
(Crouser et al., 2006). CPS1 gene was found up-regulated in rectal cancer, 
indicating its role in poor response to chemotherapy by increasing glutamine 
metabolism, thus energy production (Lee et al., 2014). Glycerol-3-phosphate 
acyltransferase 1 is an outer mitochondrial membrane enzyme that catalyzes 
the conversion of saturated Acyl-CoA to lysophosphatidic acid, which in ER, 
changed into triacylglycerol and phospholipid. Glycerol-3-phosphate 
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acyltransferase 1 has a protective role against oxidative stress and up-
regulation in activity has been demonstrated in liver diseases including liver 
steatosis and fatty liver (Hammond et al., 2005, Lindén et al., 2006). Very long-
chain acyl-CoA synthetase is responsible for the transformation of long-chain 
fatty acid into fatty acyl-CoA and carnitine in the outer membrane of the 
mitochondrion. Fatty acyl-CoA then binds again to carnitine forming 
acylcarnitine allowing it to cross the outer mitochondrial membrane. In turn, 
carnitine O-palmitoyltransferase 2 (CPT2) is responsible for converting 
acylcarnitine within to inner mitochondrial membrane back to carnitine and 
fatty acyl for β-oxidation (Nsiah-Sefaa and McKenzie, 2016). Pyruvate 
carboxylase (PC) catalyses the conversion of pyruvate to oxaloacetate, the 
essential intermediate of metabolism, linking carbohydrate, lipid, amino acid, 
and nucleotide metabolism (Wexler et al., 1994, Adina-Zada et al., 2012). The 
PC level was associated with a low level of cellular energy to support 
increased glycogenesis, it was also linked to the proliferation of a various type 
of cancer such as breast and small lung cancer (Phannasil et al., 2015, Sellers 
et al., 2015).  
The cellular component, function distribution, and biological process of 
uniquely down- and up-regulated proteins by 5FU in Set A (95 proteins) and 
Set B (164 proteins) were examined, and then compared to a reference protein 
list to determine the highly enriched categories using BinGO software as 
illustrated in Sections 4.3.1 and 2.2.1.13.  
The cellular component analysis demonstrated that uniquely down-regulated 
proteins by 5FU of Set A (67 proteins) and Set B (113 proteins) were 
categorized into 16 cellular compartments. The analysis showed that both 
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datasets were significantly enriched in microsomal compartments including, 
mitochondrion, ER, and the ribosome. Consistently, the biological processes 
evaluation displayed proteins involved in metabolic processes, cellular 
processes, and transportation. However, proteins of Set B were uniquely 
down-regulated in programmed cell death processes including, cell 
recognition, cell-cell signaling, cell communication, cell cycle, cellular 
hemostasis, DNA metabolism, and response to a stimulus.  
On another hand, 28 and 51 proteins were uniquely up-regulated proteins by 
5FU of Set A and Set B, respectively. The cellular component categories 
proteins into 12 groups, where most of them belonged to microsomal 
compartments. However, nucleus-related proteins were only identified in Set 
A. whilst, ribosome, lysosome, and endosome compartments were determined 
exceptionally in Set B. Similarly, the analysis showed that up-regulated 
proteins were significantly involved in lipid, amino acid and carbohydrate 
metabolisms and generation of precursor metabolites and energy. However, 
cellular process-related proteins such as cell-cell signaling, cell proliferation, 
cell cycle and cell death were identified uniquely for Set B in both down- and 
up-regulated proteins, which pointed a significant bias towards a specific 
group of proteins compared to Set A. 
4.3.5 Functional characteristics of the proteins detected in the 
datasets   
A number of differentially expressed proteins were chosen for further 
investigation of the proteomics data based on their significant ratios or their 
relevance to liver microsomes abundance and function.  
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Major urinary proteins (MUPs) were found to have significant differences (> 6 
fold in DOX-treatment) in expression between Set A-treated and control liver 
microsomes. Interestingly, their expressions were asymmetrical in Set B, 
making them interesting to be investigated further since the key objective of 
this chapter is to identify potential biomarkers for treated liver microsomes by 
major anti-cancer drugs. CYP450 isoforms were also included because of: 1) 
their essential role in metabolizing anti-cancer drugs, and 2) their remarkable 
abundance in liver microsomes.  
Due to the higher degree of homology within MUPs and CYP450s, two unique 
peptides with MASCOT score > 28 or one unique peptide with at least two 
spectra (MASCOT score > 28) were required for protein identification and 
quantification (section 2.2.1.10) 
Confirming the existence of unique peptides for each isoform was performed 
using Skyline software (Skyline 3.5-64 bit) and the multiple sequence 
alignment tools (Clustal Omega 1.2.1) (section 2.2.1.13). The different 
sequences of MUP isoforms and their unique peptides are shown in Figure 
4.8. 
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Figure 4-8. Multiple sequence alignment of mouse MUP isoforms showing the high 
degree of homology. The red peptides represent the unique peptides for each MUP 
isoform that were identified in Sets A and B.  
 
Based on the aforementioned criteria, four MUP isoforms (MUP1, 2, 3 and 6) 
and two (MUP1 and 6) were unambiguously identified by Set A and Set B, 
respectively (Table 4.9). Quantitatively for Set A, 5FU and CIS resulted 
significantly in up-regulation of three MUP isoforms (MUP1, 2 and 6), where 
DOX was up-regulated the four isoforms (MUP1, 2, 3 and 6). Neither MUP1 
nor MUP6 was significantly affected by 5FU administration to mice in Set B, 
where MUP6 was significantly down-regulated only by PAX, oppositely 
TCPOBOP was up-regulated both MUP1 and MUP6 (Table 4.9). 
Accession Protein name Sequences
sp|P04939|MUP3_MOUSE      MKLLLPLLLLLCLELTLVCIHAEESSSMERNFNVEQISGYWFSIAEASYEREKIEEHGSM
sp|P11589|MUP2_MOUSE      ----MKMLLLLCLGLTLVCVHAEEASSTGRNFNVEKINGEWHTIILASDKREKIEDNGNF
sp|P11588|MUP1_MOUSE      ----MKMLLLLCLGLTLVCVHAEEASSTGRNFNVEKINGEWHTIILASDKREKIEDNGNF
sp|P02762|MUP6_MOUSE      ----MKMLLLLCLGLTLVCVHAEEASSTGRNFNVEKINGEWHTIILASDKREKIEDNGNF
sp|P11590|MUP4_MOUSE      ------MKLLLCLGLTLVCIHAEEATSKGQNLNVEKINGEWFSILLASDKREKIEEHGSM
sp|P11591|MUP5_MOUSE      ----MKLLLLLCLELTLVYVHAEEASSEGQNLNVEKINGKWFSILLASDKREKIEEHGTM
sp|P04939|MUP3_MOUSE      RAFVENITVLENSLVFKFHLIVNEECTEMTAIGEQTEKAGIYYMNYDGFNTFSILKTDYD
sp|P11589|MUP2_MOUSE      RLFLEQIHVLEKSLVLKFHTVRDEECSELSMVADKTEKAGEYSVTYDGFNTFTIPKTDYD
sp|P11588|MUP1_MOUSE      RLFLEQIHVLENSLVLKFHTVRDEECSELSMVADKTEKAGEYSVTYDGFNTFTIPKTDYD
sp|P02762|MUP6_MOUSE      RLFLEQIHVLENSLVLKFHTVRDEECSELSMVADKTEKAGEYSVTYDGFNTFTIPKTDYD
sp|P11590|MUP4_MOUSE      RVFVEHIHVLENSLAFKFHTVIDGECSEIFLVADKTEKAGEYSVMYDGFNTFTILKTDYD
sp|P11591|MUP5_MOUSE      RVFVEHIDVLENSLAFKFHTVIDEECTEIYLVADKTEKAGEYSVTYDGFNTFTILKTDYD
sp|P04939|MUP3_MOUSE      NYIMIHLINKKDGKTFQLMELYGREPDLSLDIKEKFAKLCEEHGIIRENIIDLTNVNRCL EARE
sp|P11589|MUP2_MOUSE      NFLMAHLINEKDGETFQLMGLYGREPDLSSDIKERFAKLCEEHGILRENIIDLSNANRCL QARE
sp|P11588|MUP1_MOUSE      NFLMAHLINEKDGETFQLMGLYGREPDLSSDIKERFAQLCEKHGILRENIIDLSNANRCL QARE
sp|P02762|MUP6_MOUSE      NFLMAHLINEKDGETFQLMGLYGREPDLSSDIKERFAQLCEEHGILRENIIDLSNANRCL QARE
sp|P11590|MUP4_MOUSE      NYIMFHLINEKDGKTFQLMELYGRKADLNSDIKEKFVKLCEEHGIIKENIIDLTKTNRCL KARE
sp|P11591|MUP5_MOUSE      NYIMFHLINKKDEENFQLMELFGREPDLSSDIKEKFAKLCEEHGIVRENIIDLSNANRCL QARE
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Table 4-9. Major urinary proteins unambiguously identified in the Sets A and B. Mean iTRAQ ratios with their standard deviations (SD) 
were used for significance determination (p-value). MUP considers up- or down-regulated if its mean iTRAQ ratio was higher than (1+SD) 
or less than (1/1+SD) respectively and the p-value < 0.05. The directions of arrow indicate whether MUP was up- or down-regulated.  
The table shows details of identified MUPs including, their molecular weight (M.Wt), isoelectric point (pI), the average 
MASCOT score and the percent of sequence coverage (S.C %). (*) indicated permutated p-value which has been 
computed following the permutation test.
Protein 
name 
SwissProt/ 
UniProt 
accession 
number 
M.Wt 
(kDa) 
pI 
MASCOT 
score 
S.C 
% 
Total 
peptides 
assigned 
to the 
protein 
Unique 
peptides 
assigned 
to the 
protein 
Number 
of spectra 
for unique 
peptide 
iTRAQ 
value 
p-
value* 
SD 
iTRAQ 
value 
p-
value* 
SD 
iTRAQ 
value 
p-
value* 
SD 
Set A 
5FU CIS DOX 
MUP1 P11588 20.6 4.9 784 61.7 13 2 2 2.18 ↑ 0.02 0.06 2.47 ↑ 2×10-2 0.86 6.27 ↑ 2×10-4 1.75 
MUP2 P11589 20.7 4.9 891 66.1 13 2 5 1.81 ↑ 9×10-3 0.34 2.04 ↑ 4×10-3 0.61 2.78 ↑ 1×10-4 0.51 
MUP3 P04939 21.5 4.6 112 10.9 2 2 4 1.25 0.48 0.22 1.19 0.66 0.12 2.05 ↑ 9×10-3 0.17 
MUP6 P02762 20.6 4.7 792 61.7 12 1 2 1.74 ↑ 0.03 0.24 2.21 ↑ 0.03 0.74 3.34 ↑ 3×10-3 1.31 
 Set B 
 5FU PAX TCPOBOP 
MUP1 P11588 20.7 4.9 437 58.9 9 1 5 1.07 0.68 0.12 1.06 0.72 0.13 1.52 ↑ 2×10-3 0.52 
MUP6 P02762 20.6 4.7 485 68.3 10 1 2 0.89 0.25 0.12 0.70 ↓ 9×10-3 0.09 1.63 ↑ 5×10-3 0.47 
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Based on the criteria mentioned above, a total of 26 and 34 CYP450s were 
confidently identified and quantified in Set A and Set B, respectively (Table 
4.10). The results showed that Set B recovered a number of CYP540 than Set 
A with higher MASCOT scores, total peptides, and unique peptides, a further 
indication of the more effective extraction method using combined cryo-
pulverization and sonication compared to sonication alone.  
Changes in CYP450 expression in response to different drugs of Set A and 
Set B are shown in (Table. 4.11) and (Figure 4.9). In Set A, two CYP450s 
(CYP2b9 and CYP2j5) were down-regulated by 5FU and none were up-
regulated. While in CIS treatment, one CYP450 (CYP2c70) was down-
regulated and one (CYP8b1) was up-regulated. Lastly, in Set A, two CYP450s 
(CYP2c50 and CYP2e1) and one CYP450 (CYP4a12a) were down- and up-
regulated, respectively in DOX-treated mice. In Set B, 5FU, PAX and 
TCPOBOP resulted in down-regulation of five CYP450s (CYP 2a4, 2b10, 
2c29, 2c50, and 3a11), fourteen CYP (CYP2a4, 2a5, 2b9, 2b10, 2c29, 2c37, 
2c39, 2c50, 2c54, 2c55, 2c70, 2d10, 2f2, and 4f14) and two CYP450s 
(CYP2a4 and 3a16), respectively. On the other hand, one (CYP4a10) and four 
(CYP2c37, CYP2c39, CYP2c55, and CYP3a11) CYP450 enzyme were up-
regulated by PAX and TCOPBOP, respectively. Nevertheless, none by 5FU.  
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Table 4-10. Cytochrome P450 enzymes unambiguously identified in Sets A and B. The average MASCOT score and a number of common 
and unique peptides (plus times of observation of unique peptides) are shown. CYP isoforms were defined by at least one unique peptide 
with significant MASCOT score.  
Protein 
name 
SwissProt/ 
UniProt 
accession 
number 
M.Wt 
(kDa) 
pI 
Set A Set B 
MASCOT 
score 
S.C % 
Total peptides 
assigned to the 
protein 
Unique peptides 
assigned to the 
protein 
Number of 
spectra for 
unique peptide 
MASCOT 
score 
S.C % 
Total peptides 
assigned to the 
protein 
Unique peptides 
assigned to the 
protein 
Number of 
spectra for 
unique peptide 
CYP 1a2 P00186 58.1 9.6 763 26.1 12 9 15 763 30.4 15 10 14 
CYP 2a4 P15392 
56.7 
7 
9.6 ND ND ND ND ND 1448 50.2 34 8 38 
CYP 2a5 P20852 56.7 9.7 347 17.8 8 2 2 1598 55.5 36 8 27 
CYP 2a12 P56593 56.1 9.7 347 17.8 12 11 15 1104 40.7 23 18 42 
CYP 2b9 P12790 55.7 8 282 9.4 5 3 3 668 24.8 13 9 21 
CYP 2b10 P12791 56.7 7.9 429 13.6 6 5 8 904 32.4 18 14 43 
CYP 2c29 Q64458 55.7 9.4 1298 40.4 24 10 23 2092 49.4 36 12 44 
CYP 2c37 P56654 55.6 6.8 739 23.9 12 2 2 1150 39.8 22 5 12 
CYP 2c38 P56655 56.2 9.5 ND ND ND ND ND 695 31.0 16 4 5 
CYP 2c39 P56656 55.8 9.1 815 22.2 12 3 8 1150 43.7 21 7 35 
CYP 2c40 P56657 55.7 7.9 311 13.8 7 6 8 689 25.1 14 12 28 
CYP 2c50 Q91X77 55.7 9.1 977 32.4 18 2 2 1875 42.0 31 4 13 
CYP 2c54 Q6XVG2 55.8 7.9 899 28.8 16 4 8 1691 45.7 32 8 35 
CYP 2c55 Q9D816 65.1 6.6 ND ND ND ND ND 278 17.1 6 4 7 
CYP 2c70 Q91W64 56 9.1 694 27.4 12 9 21 1049 36.4 19 16 57 
CYP 2d9 P11714 56.9 5.8 597 17.7 10 6 21 676 23.4 13 7 18 
CYP 2d10 P24456 57.2 6.2 890 25.4 15 7 18 1362 32.3 22 10 42 
CYP 2d11 P24457 57 5.8 ND ND ND ND ND 729 23.4 14 3 5 
CYP 2d26 Q8CIM7 56.9 6.2 1175 34.4 19 13 31 1543 42.0 24 18 51 
CYP 2e1 Q05421 56.8 9.3 1083 32.3 20 20 41 1412 44.8 30 25 82 
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CYP 2f2 P33267 55.9 8.8 637 26.7 12 8 14 1086 36.0 20 13 32 
CYP 2j5 O54749 57.7 9.6 277 8.8 5 2 2 411 20.4 10 4 4 
CYP 3a11 Q64459 57.8 9.5 496 16.9 10 6 18 893 32.5 21 10 53 
CYP 3a13 Q64464 57.5 9.4 141 7.0 3 2 3 606 24.9 13 12 26 
CYP 3a16 Q64481 57.8 7.7 ND ND ND ND ND 252 15.1 5 2 3 
CYP 3a25 O09158 58.1 9.5 408 16.9 9 8 16 303 18.3 5 5 5 
CYP 3a41 Q9JMA7 57.9 8.5 ND ND ND ND ND 867 27.6 16 7 58 
CYP 4a10 O88833 58.3 9.5 ND ND ND ND ND 263 21.4 6 5 6 
CYP 
4a12a 
Q91WL5 58.3 9.9 256 11.0 5 3 4 ND ND ND ND ND 
CYP 4f3 Q99N16 59.8 9.7 74 4.0 2 2 2 112 9.7 3 2 2 
CYP 4f14 Q9EP75 59.8 6.4 181 10.1 5 5 5 325 24.2 8 7 10 
CYP 8b1 O88962 57.7 9.7 193 10.8 7 5 5 67 4.6 2 2 2 
CYP 20a1 Q8BKE6 52.1 6.5 ND ND ND ND ND 128 11.5 2 2 3 
CYP 27a1 Q9DBG1 60.7 9.7 696 25.9 12 9 17 693 34.5 14 12 19 
CYP 51a1 Q8K0C4 56.7 9.3 ND ND ND ND ND 271 14.5 6 2 2 
ND indicated not detected in referring set. pI, isoelectric point; S.C%, sequence coverage percent 
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Table 4-11. iTRAQ ratios of identified cytochrome P450 isoforms in Sets A and B. Mean ratios of unique peptides with their standard 
deviations (SD) were used for significance determination (p-value). (*) indicated the permutated p-value for CYP which has been 
computed following permutation test. ND indicated; Not Detected 
Protein 
name 
SwissProt/ 
UniProt 
accession 
number 
Set A Set B 
5FU CIS DOX 5FU PAX TCPOBOP 
iTRAQ 
value 
SD 
p-
value* 
iTRAQ 
value 
SD 
p-
value* 
iTRAQ 
value 
SD 
p-
value* 
iTRAQ 
value 
SD 
p-
value* 
iTRAQ 
value 
SD 
p-
value* 
iTRAQ 
value 
SD 
p-
value* 
CYP 1a2 P00186 1.19 0.51 0.44 0.97 0.60 0.46 1.09 0.57 0.89 1.04 0.17 0.87 0.88 0.19 4×10-4 0.85 0.18 5×10-4 
CYP 2a4 P15392 ND ND ND ND ND ND ND ND ND 0.82 0.14 1×10-4 0.71 0.17 1×10-4 0.67 0.22 1×10-4 
CYP 2a5 P20852 1.27 0.33 0.35 0.97 0.19 0.58 1.07 0.27 0.98 0.97 0.18 0.22 0.74 0.17 1×10-4 0.83 0.21 3×10-4 
CYP 2a12 P56593 1.30 0.22 0.15 1.12 0.69 0.81 1.20 0.68 0.45 1.05 0.16 0.71 1.00 0.13 0.56 0.93 0.17 0.09 
CYP 2b9 P12790 0.58 0.26 0.01 0.92 0.39 0.51 0.67 0.49 0.08 0.93 0.22 0.07 0.82 0.15 3×10-4 0.97 0.20 0.48 
CYP 2b10 P12791 0.86 0.29 0.15 1.32 0.30 0.28 0.84 0.48 0.19 0.80 0.21 1×10-4 0.68 0.23 1×10-4 1.01 0.25 0.97 
CYP 2c29 Q64458 1.33 0.57 0.06 1.25 0.27 0.27 1.24 0.37 0.29 0.82 0.27 1×10-4 0.66 0.26 1×10-4 0.82 0.19 1×10-4 
CYP 2c37 P56654 0.89 0.08 0.45 0.94 0.12 0.62 0.72 0.06 0.22 1.03 0.27 0.96 0.67 0.10 1×10-4 1.36 0.20 3×10-4 
CYP 2c38 P56655 ND ND ND ND ND ND ND ND ND 1.24 0.19 0.08 0.99 0.11 0.67 1.07 0.11 0.61 
CYP 2c39 P56656 1.20 0.29 0.54 1.20 0.42 0.56 0.95 0.25 0.54 0.94 0.25 0.06 0.84 0.23 1×10-4 1.32 0.21 1×10-4 
CYP 2c40 P56657 1.25 0.36 0.37 0.91 0.26 0.32 1.26 0.66 0.36 1.03 0.20 0.99 0.89 0.15 2×10-3 0.88 0.18 0.01 
CYP 2c50 Q91X77 1.27 0.35 0.55 1.02 0.30 0.83 0.48 0.04 0.02 0.86 0.15 8×10-3 0.75 0.16 1×10-4 0.82 0.12 6×10-3 
CYP 2c54 Q6XVG2 1.19 0.73 0.57 0.84 0.51 0.15 0.91 0.64 0.39 0.93 0.16 0.03 0.85 0.15 1×10-4 0.89 0.18 0.01 
CYP 2c55 Q9D816 ND ND ND ND ND ND ND ND ND 0.95 0.10 0.35 0.56 0.17 1×10-4 1.29 0.32 0.01 
CYP 2c70 Q91W64 1.08 0.34 0.97 0.65 0.25 1×10-4 1.22 0.80 0.38 0.97 0.14 0.16 0.80 0.14 1×10-4 0.89 0.17 1×10-3 
CYP 2d9 P11714 1.20 0.54 0.40 1.08 0.37 0.99 1.05 0.49 0.94 0.93 0.16 0.08 0.88 0.15 5×10-3 1.08 0.21 0.35 
CYP 2d10 P24456 1.22 0.53 0.33 0.87 0.37 0.12 0.99 0.47 0.62 1.01 0.27 0.71 0.86 0.09 2×10-4 1.01 0.19 0.96 
CYP 2d11 P24457 ND ND ND ND ND ND ND ND ND 0.97 0.14 0.55 0.93 0.11 0.32 1.02 0.09 0.95 
CYP 2d26 Q8CIM7 0.95 0.41 0.21 0.82 0.29 8×10-3 0.76 0.42 8×10-4 1.11 0.17 0.04 0.91 0.19 2×10-3 0.89 0.15 3×10-3 
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CYP 2e1 Q05421 0.99 0.25 0.43 0.93 0.46 0.21 0.69 0.34 1×10-4 1.06 0.18 0.51 1.07 0.19 0.23 1.04 0.33 0.52 
CYP 2f2 P33267 1.27 0.35 0.24 0.94 0.36 0.37 1.26 0.52 0.31 1.01 0.26 0.78 0.84 0.21 1×10-4 0.95 0.27 0.24 
CYP 2j5 O54749 0.57 0.21 2×10-3 0.77 0.33 0.10 0.81 0.48 0.21 1.01 0.12 0.80 0.94 0.09 0.15 0.97 0.21 0.53 
CYP 3a11 Q64459 1.07 0.30 0.93 1.02 0.21 0.68 1.03 0.27 0.85 0.64 0.21 1×10-4 0.90 0.17 4×10-4 1.24 0.22 1×10-4 
CYP 3a13 Q64464 1.09 0.09 0.99 1.65 0.68 0.11 1.12 0.25 0.85 1.03 0.22 0.96 0.94 0.17 0.07 1.04 0.18 0.70 
CYP 3a16 Q64481 ND ND ND ND ND ND ND ND ND 1.05 0.11 0.87 0.93 0.29 0.38 0.60 0.38 2×10-3 
CYP 3a25 O09158 1.19 0.51 0.48 1.12 0.36 0.79 1.23 0.41 0.37 1.01 0.14 0.82 0.93 0.13 0.31 0.90 0.20 0.29 
CYP 3a41 Q9JMA7 ND ND ND ND ND ND ND ND ND 1.09 0.23 0.11 0.92 0.15 4×10-3 0.94 0.22 0.11 
CYP 4a10 O88833 ND ND ND ND ND ND ND ND ND 0.91 0.17 0.87 0.88 0.19 4×10-4 0.85 0.18 5×10-4 
CYP 4a12a Q91WL5 0.91 0.29 0.89 1.23 0.63 0.50 2.12 0.45 2×10-3 ND ND ND ND ND ND ND ND ND 
CYP 4f3 Q99N16 1.06 0.02 0.55 0.73 0.34 0.20 0.78 0.02 0.33 1.06 0.18 0.15 1.36 0.16 2×10-3 0.91 0.26 0.27 
CYP 4f14 Q9EP75 1.01 0.60 0.10 0.72 0.26 0.06 0.74 0.47 0.11 1.01 0.01 0.81 0.93 0.19 0.45 0.90 0.20 0.45 
CYP 8b1 O88962 1.07 0.30 0.97 1.74 0.56 0.03 1.07 0.39 0.99 1.07 0.22 0.84 0.83 0.11 6×10-3 0.83 0.17 0.02 
CYP 20a1 Q8BKE6 ND ND ND ND ND ND ND ND ND 1.04 0.39 0.78 1.01 0.18 0.88 1.01 0.14 0.97 
CYP 27a1 Q9DBG1 0.97 0.27 0.34 0.98 0.36 0.49 1.24 0.92 0.32 1.14 0.11 0.90 1.15 0.11 0.30 1.15 0.22 0.34 
CYP 51a1 Q8K0C4 ND ND ND ND ND ND ND ND ND 0.90 0.21 0.06 1.02 0.14 0.95 1.07 0.32 0.42 
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Figure 4-9. Cluster analysis for the relative expression in treated/control for all CYP 
isoforms identified in Sets A and B. CYP isoforms were significantly up- or down-
regulated if their p-value was <0.05 and had Log2 iTRAQ ratio > +1SD or <-1SD for up-
regulating and down-regulating, respectively. 
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4.4 Discussion 
Liver microsomes are mainly membrane fragments from the ER and represent 
an enriched source of many of the most important enzymes responsible for 
the modification of xenobiotic compounds including drugs. A recent attempt by 
Zgoda and his colleagues to profile liver microsomes from mouse, rat, and 
human in a comprehensive proteomics analysis demonstrated that a high 
proportion of identified microsomal proteins (up to 25%) belonged to integral 
membrane proteins (IMPs), where other compartment-related proteins were 
determined including proteins from cytosolic, mitochondrial, and Golgi 
apparatus (Golizeh et al., 2015). However, this is the first time the effect of 
anti-cancer drugs as well as CYP inducer drug (TCPOBOP) on liver 
expression has been investigated. 
4.4.1 Identified proteins from Set A and Set B analysis 
Comparing the number of proteins identified in Sets A and B showed that 34% 
more proteins were identified in the latter, and of these, 6% more 
hydrophobic/membrane proteins were detected. This is most likely due to the 
improved method of proteins extraction using a combination of cryo-
pulverization and sonication as deduced in Chapter 3. However, analysing 
particular cellular fraction raises the challenge in studying the possible 
pathways using an available tool such as Kyoto Encyclopedia of Genes and 
Genomes (KEGG), due to the possible bias in cellular location and biological 
processes of identified proteins. 
Non-microsomal proteins were identified in Sets A and B probably due to the 
challenges of removing contaminants using the only ultracentrifugation for 
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organelle enrichment (Zanetti and Catala, 1990, Friso and Wikström, 1999, 
Stan et al., 2005). ER marker proteins (calnexin precursor and protein disulfide 
isomerase), demonstrated that both datasets were enriched with ER-related 
proteins (Table 4.12). In addition, more membrane-associated ER enzymes 
(e.g. CYP450s) were identified in Set B than Set A, which highlights the 
improvement of CP+S extraction method. 
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Table 4-12. ER-identified subfamilies with their isoform numbers in Sets A and B. 
Protein families and accession were extracted from UniProt (Consortium, 2014).  
Protein class name location 
Number of Isoforms 
Set A Set B 
Protein production and modification 
endoplasmic reticulum resident protein 
(ERP) 
ER lumen 2 
P57759 
Q9D1Q6 
2 
P57759 
Q9D1Q6 
Endoplasmin (ENPL) ER 1 P08113 1 P08113 
Nucleoside diphosphate kinase (NDK) ER 2 
P15532 
Q01768 
2 
P15532 
Q01768 
Protein disulfide-isomerase (PDI) ER 5 
P09103 
P27773 
P08003 
Q921X9 
Q922R8 
5 
P09103 
P27773 
P08003 
Q921X9 
Q922R8 
Thioredoxin domain-containing proteins 
(TXND) 
ER 1 Q91W90 3 
Q9CQU0 
Q6P6J9 
Q91W90 
Thioredoxin (THIO) ER 1 P10639 1 P10639 
Elongation factors (EF) ER 5 
P10126 
P57776 
Q9D8N0 
P58252 
Q8BFR5 
7 
P10126 
O70251 
P57776 
Q9D8N0 
P58252 
Q8C0D5 
Q8BFR5 
Heat shock cognate 71 kDa protein 
(HSP7C) 
ER 1 P63017 1 P63017 
Leucine-rich repeat-containing protein 
(LRC) 
ER integral to 
membrane 
2 
Q505F5 
Q922Q8 
2 
Q505F5 
Q922Q8 
UDP-glucose 6-dehydrogenase (UGDH) ER 1 O70475 1 O70475 
ER to Golgi vesicle mediated-transport 
Transitional endoplasmic reticulum 
ATPase (TERA) 
ER 1 Q01853 1 Q01853 
Microsomal triglyceride transfer protein 
large subunit (MTP) 
ER 1 O08601 1 O08601 
Steroid biosynthesis 
3 beta-hydroxysteroid dehydrogenase 
(3BHS) 
ER integral to 
membrane 
3 
P26150 
Q61694 
Q9EQC1 
1 Q9EQC1 
Lipid and cholesterol biosynthesis 
Acetyl-coenzyme A acyltransferase (THIL) ER 1 Q8QZT1 1 Q8QZT1 
glyceraldehyde-3-phosphate 
dehydrogenase (G3P) 
ER 1 P16858 1 P16858 
Alpha-2-macroglobulin receptor-associated 
protein (AMRP) 
ER 1 P55302 1 P55302 
Fatty aldehyde dehydrogenase (AL3A2) 
ER, membrane 
bounded 
1 P47740 1 P47740 
calcium sequestering 
Sarcoplasmic/endoplasmic reticulum 
calcium ATPase (AT2A) 
ER integral to 
membrane 
2 
Q8R429 
O55143 
1 O55143 
Calnexin precursor (CALX) 
ER, integral to 
membrane 
1 P35564 1 P35564 
Glucose metabolism 
GDH/6PGL endoplasmic bifunctional 
protein (G6PE) 
ER lumen 1 Q8CFX1 1 Q8CFX1 
78 kDa glucose-regulated protein (GRP87) ER 1 P20029 1 P20029 
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Table 4-12. continued 
Xenobiotic metabolizing enzymes 
UDP-glucuronosyltransferase (UD) ER 6 
Q63886 
Q64435 
Q62452 
Q8BWQ1 
Q8JZZ0 
P17717 
7 
Q63886 
Q64435 
Q62452 
Q8BWQ1 
P17717 
Q3UP75 
Q8JZZ0 
Glutathione S-transferase (GST) ER 10 
P30115 
P24472 
Q9DCM2 
P10649 
P15626 
O09131 
P19157 
P46425 
Q64471 
Q91VS7 
10 
P30115 
P24472 
Q9DCM2 
P10649 
P15626 
O35660 
O09131 
P19157 
Q64471 
Q91VS7 
NADH-cytochrome b5 reductase (NB5R3) 
ER, membrane 
bounded 
1 Q9DCN2 1 Q9DCN2 
Cytochrome P450 (CYP450) 
ER, membrane 
bounded 
26 
P00186 
P20852 
P56593 
P12790 
P12791 
Q64458 
P56654 
P56656 
P56657 
Q91X77 
Q6XVG2 
Q91W64 
P11714 
P24456 
Q8CIM7 
Q05421 
P33267 
O54749 
Q64459 
Q64464 
O09158 
O88833 
Q91WL5 
Q99N16 
Q9EP75 
O88962 
Q8BKE6 
Q9DBG1 
 
34 
P00186 
P15392 
P20852 
P56593 
P12790 
P12791 
Q64458 
P56654 
P56655 
P56656 
P56657 
Q91X77 
Q6XVG2 
Q9D816 
Q91W64 
P11714 
P24456 
P24457 
Q8CIM7 
Q05421 
P33267 
O54749 
Q64459 
Q64464 
Q64481 
O09158 
Q9JMA7 
O88833 
Q99N16 
Q9EP75 
O88962 
Q8BKE6 
Q9DBG1 
Q8K0C4 
Glutathione peroxidase (GPX1) ER 1 P11352 1 P11352 
Carboxylesterase (EST) ER lumen 6 
Q8VCT4 
Q8VCC2 
Q64176 
Q63880 
Q8VCU1 
Q6AW46 
6 
P23953 
Q8VCT4 
Q64176 
Q63880 
Q8VCU1 
Q8VCC2 
Retinal dehydrogenase (AL1A1) 
ER, membrane 
bounded 
1 P24549 1 P24549 
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Selected ER proteins were compared to previous proteomics studies of liver 
microsomes (Table 4.13). The comparison demonstrated that the datasets 
from the current project identified a significant proportion of microsomal 
proteins with respect to the total number identified. Peng et al used alkaline 
carbonate to wash microsomal fractions to remove non-microsomal proteins  
(Peng et al., 2010). The membrane proteins were enriched in the extract 
because of depletion of approximately 70% of the non-microsomal proteins. 
Hence, among 428 proteins identified, 41% were membrane-associated, 
compared to 24% of 259 total proteins without sodium carbonate wash (Peng 
et al., 2010, Peng et al., 2012). However, previous work on liver microsomes 
conducted in our lab involved alkaline carbonate for microsomal enrichment 
demonstrated a large reduction in the total number of identified proteins 
including those of microsomal origin (data not shown).
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Table 4-13. Comparison of experimental conditions and selected proteins between current study (Sets A and B) and literature data. ND; 
not determined 
Previous works 
(Peng et al., 
2010) 
(Peng et al., 
2012) 
(Zgoda et al., 
2009) 
(Sutton et al., 
2010) 
(Mathias et al., 
2011) 
(Golizeh et 
al., 2015) 
Set A Set B 
Species Mouse Mouse Mouse Mouse Mouse Mouse Mouse Mouse 
Sex Male Male Male Male and female Male Male Male Female 
Pre-treatment None None phenobarbital None  None None 
5FU, 
DOX, CIS 
5FU. PAX, 
TCPOPBOP 
Sample preparation 
Differential centrifugation for 
fractionation, followed by sucrose 
gradient centrifugation and alkaline 
carbonate treatment 
Differential 
centrifugation for 
fractionation 
Differential 
centrifugation for 
fractionation 
Differential 
centrifugation for 
fractionation, 
followed by alkaline 
carbonate and Triton 
X-114 treatment 
Differential centrifugation for fractionation 
Protein digestion 
In-solution 
digestion 
In-gel digestion In-solution digestion 
Protein separation 2D-LC 2DE/1DE-SDS 
1DE-SDS, 2D-LC, 
3D-LC 
1DE-SDS 1D-SDS 2D-LC 
Protein identification 
LTQ-MS 
(MS/MS) 
Q-TOF-MS 
(MS/MS) 
Ion trap-MS 
(MS/MS) 
MALDI TOF-TOF 
MS (MS/MS) 
LTQ-Orbitrap-MS 
(MS/MS) 
Triple TOF-MS 
(MS/MS) 
MALDI TOF-TOF MS 
(MS/MS) 
Total identified proteins 428 259 4142 302 1212 1582 1146 1743 
% of Membrane 
proteins 
41% 24% 
1DE:27% 
2D-LC:21% 
3D-LC:18% 
59% 56% 18.9% 37% 34% 
Selected protein superfamily 
CYP450 family 
members 
25 10 29 27 35 29 26 34 
UDP-
glucuronosyltransferase 
9 6 8 4 7 8 6 7 
Protein disulfide 
isomerase 
3 2 4 5 4 5 5 5 
Superoxide dismutase I 1 0 1 ND 2 2 2 2 
Major Urinary protein 3 2 1 ND 2 4 4 2 
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As the main aim of this project is to investigate the influence of anti-cancer 
drugs on liver microsomes, there was a greater focus on DMEs. A previous 
comparative proteomics study by Patterson et al, (Patterson et al., 2007), used 
in-gel digestion approach resulted in the identification of 17 CYP450 isoforms 
from a mouse treated with TCPOBOP. Recent studies, which used shotgun 
proteomics approach (SDS-PAGE free), successfully identified 27 CYP450 
enzymes with a high degree of similarity, such CYP 3A, 2C and 4F subfamilies 
using ionic liquid-BMIM-BF4 for microsomes proteins solubilisation (Sun et al., 
2012). Isotope-coded affinity tagging using ICAT reagents have been used for 
relative quantification of cysteine-containing peptides resulting in the 
identification of 11 isoforms, but poor discrimination between closely related 
isoforms (e.g. CYP2a4/2a5) (Jenkins et al., 2006).  Another comprehensive 
analysis of rat, mouse and human liver S9 and microsomal fractions 
demonstrated 29 CYP450 isoforms identified in mouse liver microsomes 
(Golizeh et al., 2015). Furthermore, Mathias and his co-workers solubilised the 
carbonate-washed microsome fraction in detergent (Triton X-114), 
demonstrated so far the highest proportion of identified membranous proteins 
(54% of total microsomal proteome) and a number of CYP450 isoforms (35 
CYP450s) (Mathias et al., 2011). By using “shotgun” proteomics approaches, 
incorporating OG for first dimension separation in datasets A and B, we 
identified 26 and 34 CYP450 enzymes, respectively, which was close to that 
of Mathias et al. Furthermore, our results differentiated isoforms with very 
strong homology, for example, CYP2a4/5/12 in Set B compared to CYP2a5 in 
Mathias’ results and CYP2c38/39 in Set B compared to CYP2c39 Mathias’ 
results. In addition Set B contained 7 isoforms of UDP-
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glucuronosyltransferase compared to 8 from Mathias’ results (Mathias et al., 
2011). To sum up, these results provided a large amount of high quality of data 
identifying microsomal proteins by Set A and Set B for studying the influence 
of anti-cancer drugs on mouse liver microsomes. 
4.4.2 Analysis of 5FU as inter-experimental control 
Analysis of the two datasets A and B identified 925 common proteins, which 
represent 84.4% of Set A and 53.6% of Set B. As 5FU was used in both 
experiments, the shared proteins and their associated 5FU/untreated iTRAQ 
ratios (unchanged, up- or down-regulated) were compared to determine if 
protein changes were replicated. 
Comparison the two datasets showed very little overlap in the protein 
responses, with only four proteins down- and seven up-regulated in both. 
Whilst it was not considered significant during experimental design, this lack 
of correlation may have been due to the use of male mice in experiment A and 
female mice in experiment B. Hence, some proteins and their response to drug 
or toxicity may be specific to one sex. Thus, applying a statistical comparison 
using for example, principle component analysis (PCA) between the two 
datasets was not relatively useful in this situation. Previous studies have 
demonstrated that the expression of more than 1000 hepatic genes is sex-
dependent, including DMEs, e.g., CYP450s, sulfotransferases, glutathione 
transferases, and UDP-glucuronosyltransferase (Waxman and Holloway, 
2009, Conforto and Waxman, 2012, Buckley and Klaassen, 2007). An 
example of sex variation in Phase I metabolism is CYP450, a comprehensive 
study investigated the mRNA level of 78 CYP in different mouse tissues 
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including liver in male and female mice, showed that 24 and 5 CYP isoforms 
were predominantly expressed in female and male mice, respectively (Renaud 
et al., 2011). These results were consistent with our findings, where five 
CYP450s (CYP2a4, 2c38, 2c55, 3a16, 3a41) were exclusively identified in the 
female mouse experiment (Set B), whereas CYP4a12a was identified uniquely 
in the male mouse experiment (Set A). The Phase II DME, glutathione S-
transferases (GSTP1/2) also exhibited sex variation, where GSTP1 and 2 
were male predominant enzymes, but were weakly expressed in female liver 
(Knight et al., 2007). Consistently, our research identified both isoforms in Set 
A, where GSTP1 was only identified in Set B. Another example, are the solute 
carrier transporters (SLC), SLC22 and SLC35, whose expressions are higher 
in female compared to male mice (VanWert et al., 2007). Three and five 
isoforms of SLC were identified in Set A and Set B, respectively, among them, 
SLC22 and 35 were uniquely identified in the latter.  
MUPs are principally synthesized in the liver and, due to their small molecular 
weight (19-21kDa), escape the glomerular filtration step leading to excretion 
in urine. Moreover, MUPs account for approximately 99% of the protein found 
in male mouse urine (Flower, 1996). MUPs are expressed predominantly in 
male mice (typically for laboratory mice 10-20 mg/ml of protein per day) 
compared to female mice which excreting much less (approximately 2-10 
mg/ml protein per day) (Cheetham et al., 2009). Furthermore, some MUP 
isoforms are male-specific isoforms, e.g., MUP11 and darcin (Phelan et al., 
2014). The expression pattern of MUPs in both datasets revealed more MUP 
isoforms identified in Set A (MUP1, 2, 3, and 6) compared to Set B (MUP1 and 
6), which correlated with expected sex variation. MUP expression was much 
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higher in Set A compared to Set B based on the number of peptides and 
Mascot scores. This variation needs further investigation to exclude inter-
experimental variables such as sex and control used in each Set. Therefore, 
the expression of MUP in treated and untreated male and female mice, for sex 
variation, will be investigated thoroughly in Chapter 5.  
4.4.3 Assessment the influence of 5FU, CIS, DOX, PAX, and 
TCPOBOP on liver microsome expression 
4.4.3.1 5-flourouracil 
5FU has shown essential effect on RNA metabolism that contributes 
significantly to its toxicity (Fang et al., 2004). Previous studies showed that the 
levels of 28 ribosomal RNA (rRNA) were reduced to 0.19-fold by 25μm 5FU 
(Burger et al., 2010). The study proposed that 5FU incorporates into RNA to 
result in inhibition of rRNA processing. Consistently, 16 translational 
machinery proteins were down-regulated in our findings. Sun and his co-
workers, suggested down-regulation of ribosomal genes prevents Mdm2 
inactivation and p53 stabilization in 5-FU-treated cells (Sun et al., 2007) 
Endoplasmic reticulum stress: Several proteins involved in protein processing 
in ER were down-regulated in response to 5FU, including protein disulphide 
isomerase (PDIs) 1a, 3a, and 4a, calreticulin and calnexin. For example, PDIs 
are ER stress proteins that play a crucial role in cell survival under stress 
condition (Zhou et al., 2008). Suppression of these proteins suggested that 
5FU-induced ER stress by accumulating the unfolded proteins inside ER 
lumen (Yadunandam et al., 2012).  
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Drug metabolizing enzymes: 5FU is metabolised in the liver by CYP450s for 
Phase I and glutathione S-transferase (GST) for Phase II. In total, six 
CYP450s were down-regulated (CYP2a4, 2b9, 2b10, 2c29, 2j5, and 3a11) and 
none were up-regulated in responses to 5FU. Several studies demonstrated 
suppression of hepatic CYP2c and 2j subfamilies in rat and mice, potentiated 
fatty liver disease-associated hepatic inflammation and injury (Schuck et al., 
2014, Anwar-mohamed et al., 2010, Li-Masters and Morgan, 2001). Therefore, 
modulation of CYP2c29 and CYP2j5 may be considered indicators of liver 
injury. Most 5FU studies have investigated CYP450 mRNA levels or enzyme 
activity (Giunta, 2006). A previous attempt showed that 5FU has been 
implicated in down-regulating the synthesis of CYP2C9 and to a lesser extent 
CYP3A4 (Daly and King, 2003). Another study by Afsar et al (Afsar et al., 
1996), exhibited significant suppression in CYP2C11 and 3A content and 
catalytic activity in rat liver microsomes treated with one high dose (120 mg/kg, 
IP) of 5FU, which is very close to our experiment (100 mg/kg). Although the 
expression of CYP3A4 fluctuated within the duration of the experiment (14 
days), the authors concluded that 5FU suppressed the expression and activity 
of CYP2C11 and CYP3A (Afsar et al., 1996). Our results indicate that mouse 
CYP3a11, which is believed to be homologous to human CYP3A4, was down-
regulated. In contrast with previous observations, an alternative study used rat 
liver microsomes, displayed that single high dose of 5FU (120 mg/kg) did not 
show any changes in CYP450 expression (Stupans et al., 1995). However, 
they have noticed significant down-regulation in CYP2C11 and CYP3A 
isoforms with a consecutive low dose of 5FU (24 mg/kg/day for 5 days), 
suggesting that 5FU might inhibit their expressions (Stupans et al., 1995). Park 
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et al have used human liver microsomes to evaluate the alteration in CYP450s 
demonstrated no inhibitory effect of 5FU on these CYP isoforms, although 
there was a slight inhibition in CYP2C9 activity (Park and Kim, 2003). 
Accordingly, only CYP1A2 isoform was common with our finding. Recently, 
new cases have been reported on the interaction between capecitabine and 
phenytoin with 5FU confirming the inhibitory effect of 5FU on CYP isoforms 
(particularly CYP2C9) (Tanaka et al., 2014, Taguchi et al., 2015).        
Oxidative stress and mitochondrial dysfunction: A previous study investigated 
the effect of 5FU on A549 cells demonstrated that it produced a significant 
amount of ROS. Moreover, the author showed that mitochondrial dysfunction 
is a pathway of 5FU to induce apoptosis (Su et al., 2014). The mitochondrial 
antioxidant, superoxide dismutase 1 (CuSOD), alongside with microsomal 
glutathione transferase 1 (mGST1) and thioredoxin domain-containing protein 
5 and 15 (TXNDC5 and 15) were down-regulated by 5FU in our results, which 
may correlate with an increased redox imbalance. For instance, depletion of 
mGST1 is a hallmark to endogenous and chemically-induced oxidative stress 
(Lee et al., 2008, Ott et al., 2007). Further, a recent study evaluated 
systemically the toxic effects of 5FU and DOX on the activity of SOD1 reported 
down-regulation in SOD1 (Aikemu et al., 2016).  
TCA cycle and β-oxidation pathway: several hepatic enzymes involved in 
tricarboxylic acid cycle (TCA cycle) and mitochondrial β-oxidation pathway 
were induced in response to 5FU, including: citrate synthase, malate 
dehydrogenase, and pyruvate carboxylase for TCA and (3-hydroxyacyl-CoA 
dehydrogenase type-2, long chain acyl-CoA dehydrogenase, trifunctional 
enzyme subunit alpha and beta and fatty acid synthase (FAS) for β-oxidation 
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pathway (Figure 4.10). These up-regulations suggested an accumulation of 
free fatty acids (FFAs) in hepatocyte (Smith et al., 2003). In addition, the fatty 
acid transporter, FABP which has been induced in the previous study in 
response to 5FU was up-regulated in our findings, suggested an instance 
increase cytoplasmic FFAs (Coe and Bernlohr, 1998).   
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Figure 4-10. Schematic representation of the mitochondrial pathways in fatty acid, 
glucose, and ketone body’s metabolism. The rate of Acetyl-CoA formation is 
controlled by fatty acid degradation through β- oxidation, TCA cycle, glycolysis, and 
ketogenesis. The presence of LCFA in high amount in the cytosol stimulates their 
degradation in mitochondria, where LCFAD is responsible for activating LCFA into 
LCFA-CoA that only form able to enter the mitochondria. Transporters including CPT 
1, 2 were involved in the transport of Acyl-CoA onto an inner membrane for β- 
oxidation. Produced Acetyl-CoA can go further for ketone body synthesis or enter 
TCA cycle for energy generation. An excess amount of Acetyl-CoA leads citrate, a 
component of TCA cycle, to export to the cytosol for lipid synthesis and storage. 
LCFA; long chain fatty acid, LCFAD; long chain fatty acid dehydrogenase, CPT1 and 
2; carnitine acyltransferase I and II, HADH; Hydroxyacyl-coenzyme A dehydrogenase, 
TCA; tricarboxylic acid, HMG-CoA; 3-hydroxy-3-methyl-glutaryl-coenzyme A, ACC; 
Acetyl-CoA carboxylase, FAS; fatty acid synthase.      
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4.4.3.2 Cisplatin 
A previous proteomics study for evaluating the liver toxicity of CIS was 
performed by Cho and his workers (Cho et al., 2012a). A single dose (IC20, 
282.37 µM for 24 hours) was used to evaluate the hepatotoxicity of CIS on 
primary hepatocytes from rat liver. This study was similar to the current study 
of this project in point of dose of CIS (at low concentration), duration of 
treatment, organ (with respect to different models) and the analytical approach 
(i.e. shotgun proteomics). However, Cho et al, also performed transcriptional 
genomics analysis of regulated genes as a complement approach for 
proteomics.  
Oxidative stress and mitochondrial dysfunction: Edwards et al, proved that CIS 
has been accumulated in mitochondria, which indicates that mitochondria as 
an organelle is the main target for CIS (Sharma and Edwards, 1983, Tacka et 
al., 2004). Study done by Garrido and his workers, revealed that CIS binds 
mtDNA, thus inhibition mtDNA and mtRNA synthesis and consequently 
caused mitochondrial damage by induction ROS (Garrido et al., 2008) 
The level of antioxidants, catalase (CAT) and thioredoxin reductase 1 
(TRXR1), were suppressed, which are consistent with previous studies  (Bentli 
et al., 2013, Iraz et al., 2006). Earlier studies demonstrated that inhibiting 
TRXR1 by CIS is a mechanistic process, which leads to increase ROS, thus 
resulting in DNA damage and subsequently cell death (Saitoh et al., 1998, Sun 
and Rigas, 2008). Heat shock protein 70 (HSP70) which has antioxidant 
activity was up-regulated in CIS. A recent study demonstrated an elevation in 
HSPs including HSP70 have associated with formation fatty liver in mice 
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(Wheeler and Gekakis, 2014). Altogether, results are indicative of induction in 
ROS generation that proposed mitochondrial dysfunction.   
Drug metabolizing enzymes: one CYP isoform was significantly down-
regulated (CYP2c70) and one was up-regulated (CYP8b1) in this project. In 
rat hepatocytes, Cho et al identified three up-regulated proteins (CYP2D1, 
CYP2C13, and CYP2D5) but none were down-regulated in response to CIS 
(Cho et al., 2012a). Hence, the role of differential expression of CYP isoforms 
may explain toxic metabolism of cisplatin in hepatocytes. 
β-oxidation pathway and TCA cycle FABP1 which has been up-regulated 
commonly in Set A was consistently up-regulated in a previous study (Cho et 
al., 2012a). Remarkably, our results showed up-regulation in AACS and 
enzymes linked to fatty acid β-oxidation and TCA pathways such as 
dihydrolipoyl dehydrogenase, DlD and dihydrolipoamide S-
succinyltransferase, DLST. 
DlD and DLST are subunits of 2-oxoglutarate dehydrogenase complex 
(KGDH), which is a component of TCA cycle. The decrease in KGDH level has 
been linked to excess ROS generated within mitochondria, due to its 
antioxidant property (McLain et al., 2011). In agreement with TCA 
suppression, the glucose transporter (Solute Carrier Family 2 Member 2, 
SLC2a2) was down-regulated. SLC2a2, known by Glut2, facilitates 
hepatocellular glucose uptake thereby regulating the expression of following 
enzymes involved in glucose homeostasis in liver (Meugnier et al., 2007). 
Urea cycle: Three of urea cycle enzymes (Figure 4.11) were significantly 
down-regulated (arginase isoform 1, ARG1, argininosuccinate, ASS1, 
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carbamoyl-phosphate synthase, CPSM). Reduction in ASS1 has been 
observed previously in HepG2 cell line treated with CIS, suggesting its role in 
cellular sensitivity to CIS (McAlpine et al., 2014b).  
 
Figure 4-11. Schematic representation of the relationship Urea cycle and TCA cycle. 
Urea formation from ammonia starts inside mitochondrial matrix, which includes 
three steps. However, other three steps are taken place in the cytosol. The fumarate is 
a product of argininosuccinate lyase reaction can also be an intermediate of TCA 
cycle. CA3; carbonic anhydrase, CPSM; carbamoyl phosphate synthase 1, OTC; 
ornithine transcarbamoylase, ASS1; argininosuccinate synthase1, ASL; 
argininosuccinate lyase, ARG1; arginase 1, ORNT1; mitochondrial ornithine carrier 
isoform 1, AST; aspartate transaminase. Adapted from (Ersoy Tunalı et al., 2014).  
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4.4.3.3 Doxorubicin 
DOX accumulates mainly in the nucleus, however, notable traces of DOX were 
found to accumulate in the mitochondria. Alongside with the known 
mechanism of DOX in interfering apoptosis and survival pathways during its 
cytotoxic action, DOX has shown an intensive modulation in mitochondrial 
functions by inducing mtDNA mutations that lead to leakage of cytochrome c 
and the opening of mitochondrial permeability transition pores (Green and 
Leeuwenburgh, 2002) 
Endoplasmic reticulum stress: Chaperones, PDIa1 and Calreticulin were 
significantly down-regulated, which indicated accumulation of unfolded 
proteins and thus ER dysfunction as demonstrated earlier in 5FU. In 
agreement with Hammer et al (Hammer et al., 2010), cytoskeleton proteins, 
cytokeratin 8 and 18 (K8/K18), profilin-1, decorin and myosin were up-
regulated. These proteins have role in hepatocyte integrity in response to 
mechanical stress (Loranger et al., 1997) 
Drug metabolizing enzymes: In this study, two CYP450s (CYP2c50 and 
CYP2e1) were down-regulated, where CYP4a12a was up-regulated by DOX. 
Zordoky and his colleagues have reported significantly two down-regulated 
proteins (CYP2B1 and CYP2C11) and two up-regulated (CYP1B1 and 
CYP4A) in rat livers treated with 15mg/kg of DOX (Zordoky et al., 2011). 
Overexpression in CYP4A was consistence with our results (up-regulation of 
CYP4A21a); however, CYP2B1 and 2B2 did not identify in the current project. 
Another study has been done using human liver microsomes displayed 
inhibitory effect for DOX on CYP3A4 (Baumhäkel et al., 2001). Di Re et al, 
investigated the capability of a pharmacological therapeutic dose of DOX 
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(10µM) to modulate CYP450s in rat liver microsomes, the results did not show 
any alteration (Re et al., 1999). CYP2E1, which involves the formation of ROS 
was significantly down-expressed by DOX, indicate a cytoprotective role of 
liver. Zordoky et al demonstrated a slight decrease in CYP2E1 expression 
level but not significant (Zordoky and El-Kadi, 2008).  
β-oxidation pathway and TCA cycle: Mitra et al have revealed that rats fed with 
high-fat dietary lead to sensitise cardiotoxicity induced by DOX (Mitra et al., 
2008). It has been suggested that lipid peroxidation in consequence to a high 
level of ROS have considered as a possible mechanism of DOX induced-
steatosis (Šimůnek et al., 2009, Kim et al., 0000, Fu et al., 2010, Rashid et al., 
2013). A change in the expression of fatty acid metabolism was noticed in the 
present analysis. For instance, down-regulation of apolipoprotein E, prolow-
density lipoprotein receptor-related protein 1, which have shown role in 
protecting liver formation steatosis (Ding et al., 2016).     
Alongside with commonly up-regulated proteins with 5FU and CIS, acyl-CoA 
dehydrogenase and non-specific lipid transfer protein were uniquely over-
expressed by DOX. These proteins that are involved in β-oxidation were found 
up-regulated previously in response to DOX (Hammer et al., 2010). (Figure 
4.10).  
Urea cycle: It has been known that anti-cancer drugs such DOX can affect 
urea cycle enzymes (El-Sayyad et al., 2009). In the present study, ASS and 
mitochondrial ornithine transporter 1, ORNT1, were down-regulated, where 
ARG1, CPS1, and carbonic anhydrase 3, CA3, were up-regulated (Figure 
4.11). This disagreement in proteins alterations can be correlated to the 
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deleterious effect of DOX or the role of each protein in response to induced 
stress. For example, ARG1 was over-expressed in inflammation and high level 
of ROS, it has a role in activating macrophages preventing excessive nitric 
oxide (NO) production (Ricardo et al., 2008).  
4.4.3.4 Paclitaxel 
PAX is known to induce different cytotoxicity including, GI disorders, cardiac 
and skeletal muscle toxicity, myelosuppression, neurotoxicity, and acute liver 
injury (mostly hepatic cytolysis) (Foufelle and Fromenty, 2016). A recent case 
report showed that PAX can induce hepatic necrosis after acute dose 
(Mandaliya et al., 2015).   
Oxidative stress and mitochondrial dysfunction: The exact mechanism by 
which PAX induced liver toxicity is not clear, it has been reported that PAX 
produces cytotoxicity by generating ROS (Tanimukai et al., 2013, Ryu et al., 
2006, Xiong et al., 2014). Mitochondrial antioxidant proteins were down-
regulated by PAX including, TXNDC5 and 15, catalase, GPX1. Moreover, two 
isoforms of GSH (omega and P1) were down-regulated. Similar to 5FU, down-
regulation of these proteins indicated exaggeration in the oxidative stress. 
Previous studies showed that the increase in the cellular content of H2O2 is 
the target of PAX in inducing toxic effects on cancer cells (Hadzic et al., 2010, 
Alexandre et al., 2007).  
Numerous studies investigated the expression and activity of different 
antioxidant enzymes such as, SOD, catalase, GSH, and GPX in response to 
PAX (Pieniążek et al., 2013, Altintas et al., 2015). In agreement with our 
observations, these enzymes were suppressed in response to PAX.  
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A recent work investigated the ability of PAX-solvent (CrEL) to induce oxidative 
stress in liver. Results showed that both PAX and CrEL were able to alter the 
expression of plasma lipid peroxidation, SOD and catalase activities, (GSH) 
levels, thus both of them induced oxidative stress (Campos et al., 2014).        
Endoplasmic reticulum stress: In the current research, the expressions of 
several ER-marker proteins were reduced in response to PAX, including PDI 
family (PDI1a1, PDIa3, PDI4a, and PDIa6), calreticulin, calumenin, and 
calnexin. These proteins work as chaperone to regulate protein folding, 
cellular responses to stress and intracellular calcium (Ca2+) levels (Liao et al., 
2008). Down-regulation of these proteins may lead to aggregation of unfolded 
proteins and intracellular Ca2+ homeostasis alteration, thus resulted eventually 
in ER stress and cellular apoptosis (Ermak and Davies, 2002). It has not been 
reported the role of ER in PAX in toxicity (Liao et al., 2008). Such these 
proteins may suggest this role.    
β-oxidation pathway: It has been reported previously in minor cases that PAX 
may induce fatty liver (Harries et al., 2004). Our findings showed slight 
alterations in fatty acid metabolism pathway. This is including up-regulation in 
very long-chain specific acyl-CoA dehydrogenase (ACADV1), acyl-coenzyme 
A oxidase 1 (ACOX1), and 3-ketoacyl-CoA thiolase B (ACAA1b). These 
enzymes have role in lipid degradation (Figure 4.10), which may have 
suggested a slight increase in cytoplasmic FFAs content in response to either 
PAX or CrEL. However, the latter is a fatty acid esters of polyethylene glycol, 
which metabolises in the liver to produce FFAs that increase the content of 
hepatic lipids.  
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Drug metabolizing enzymes: Surprisingly, PAX had suppressed the 
expression of 13 CYP450s (CYP2a4, 2a5, 2b9, 2b10, 2c29, 2c37, 2c39, 2c50, 
2c54, 2c55, 2c70, 2d10, 2f2, and 4f14). These changes have never been 
reported before in literature. However, PAX is metabolised primarily in the liver 
via CYP2C8, 3A4, and 3A5, in addition, it is believed that PAX modulate the 
expression of these isoforms in mouse (Nallani et al., 2003). Thought, PAX 
solvent (CrEL) has shown the ability to modulate several hepatic enzymes 
such as CYP3A and CYP2C9 (Christiansen et al., 2011). It has been 
suggested that produced FFAs such as stearate from CrEL modulated 
CYP450s (Zhu et al., 2009). Furthermore, CrEL is known as organic anion 
transporting polypeptides (OATP) 1A2, 2B1, 1B1, and 1B3 inducer (Engel et 
al., 2012). In our result, OATP2B1 was up-regulated. In summary, these 
changes required further investigation to confirm whether the alterations were 
due to PAX or CrEL. 
4.4.3.5 TCPOBOP  
TCPOBOP is a CAR agonist that has been used commonly to induce CYP 
enzymes (Wei et al., 2000, Kelley et al., 1985). In addition to induction of 
CYP450s, TCPOBOP has shown a hepatoprotective mechanism by inducing 
pivotal enzymes at the gene level, for example, those involved in β-oxidation 
and peroxisome fatty acid oxidation, thus ameliorating hepatic steatosis 
induced by xenobiotics (Baskin-Bey et al., 2007). Several studies confirmed 
the effect of TCPOBOP on CYP450 at gene and protein level (Baskin-Bey et 
al., 2007). Edwina et al displayed significant up-regulation in the expression of 
CYP2b and CYP3a11 using mice treated with 3mg/day of TCPOBOP for 3 
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days. Another study on mRNA level demonstrated up-regulation in Cyp1a1, 
2b10, and 39a1 and down-regulation Cyp2c38, Cyp2u1, Cyp4v3, and 
Cyp17a1 by using 3mg/kg/day of TCPOBOP to treat mice for two days. 
Additionally, a comparative proteomics study performed by Lane and her 
workers (Lane et al., 2007), identified 17 CYP450s in mice treated with 
TCPOBOP as a single dose (3mg/kg) and sacrificed after 4 days of treatment, 
among these isoforms. The expression of nine CYP450s (CYP1a2, 2a4/5, 
2b10, 2b20, 2c29, 2c37, 2c38, 3a11 and 39a1) were significantly up-regulated, 
and CYP2c40, 2e1, 3a41 and 27a1 were significantly down-regulated.  
In our findings, a single dose (3mg/kg for 24 hours) of TCPOBOP was used 
as a CYP inducer. Of regulated CYP isoforms, the expression of CYP2a4 and 
CYP3a16 were significantly suppressed. Oppositely, four isoforms (CYP2c37, 
2c39, 2c50 and 3a11) were up-regulated. Results to some extent are with an 
agreement with previous studies.  
Although the present work has used the similar route of administration and 
dose of TCPOBOP (3mg/kg) similar to previous studies, the duration of 
treatment was not consistent. This may explain the lesser number of induced 
CYP450s than expected. Likewise, proteins for instance involved in β-
oxidation pathway were not induced in this research as observed previously 
by Baskin and co-workers (Baskin-Bey et al., 2007). 
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Chapter five: Investigating the influence of sex and 
selective anticancer drugs on the expression of 
signature proteins in mouse liver 
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5 Investigating the influence of sex and selective 
anticancer drugs on the expression of signature 
proteins in mouse liver 
5.1 Introduction  
Verification of the biomarkers identified by proteomics technologies has 
emerged as an important step to building a reliable pipeline in biomarkers 
development. The verification step acts as a bridge between the biomarkers 
identification step and qualification for clinical trials. Western blotting is widely 
technique used prior proteomics studies for qualitative and quantitative 
validation. 
A retrospective review of the literature indicates that sex variation in drug 
efficiency and toxicity profiles has previously been reported (Gandhi et al., 
2004, Franconi et al., 2007, Mennecozzi et al., 2015). In fact, male and female 
differ beyond their reproductive systems, and this difference extends to include 
all the physiological systems, such cardiovascular, immunological, 
neurological systems, metabolic function of the liver, etc. (Wizemann and 
Pardue, 2001). It has been reported from different studies in mouse and rat 
liver model that the expression of more than 1000 genes is sex dependent. A 
study has been undertaken using male and female mice to examine if the 
possible ameliorative effect of riboflavin on cisplatin-induced liver toxicity is 
sex dependent showed it to be more significant in the latter (Naseem et al., 
2015). However, the emerging picture from the literature has indicated that 
less than 50% of the research studies published have reported sex as a 
biological variable in their experimental animals, and only 20-28% of the 
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studies on cell lines stated the sex of the original primary cells used (Taylor et 
al., 2011). The sex bias is a noteworthy problem in scientific research as it 
might result in serious consequences in response and toxicity of drugs on both 
sexes (Check, 2010). 
Therefore, we explore the impact of sex variation in pharmacoproteomics in 
this chapter, by analysing two target protein families, Major urinary protein 
(MUP) and cytochrome P450 (CYP), in both, male and female mice treated 
with selected anticancer drugs. 
Major urinary proteins (MUPs) are a subgroup of proteins, of approximately 
10-15 discrete species in wild mice and 5-7 species in genetically 
homogeneous inbred laboratory mice, which all belong to a superfamily called 
lipocalins (Armstrong et al., 2005, Böcskei et al., 1992). Despite being also 
expressed in different glandular tissues such as salivary, nasal and mammary 
glands (Shahan et al., 1987b, Shahan et al., 1987a, Utsumi et al., 1999), 
MUPs are mainly produced in mouse liver. They are secreted by liver cells into 
the bloodstream to be filtered in the kidney and excreted in urine (Armstrong 
et al., 2005). 
MUPs consist of eight-stranded β-sheets with additional β-meander 
connections, which together form a conserved β-barrel with hydrogen bonds 
connecting the β-sheets. The barrel is open at one end with a secondary 
structure consisting of a C-terminal α-helix, which bundles outside the barrel 
(Figure 5.1). The β-barrel in MUPs is a predominantly hydrophobic cavity, 
which is capable of binding to lipophilic ligands (Sharrow et al., 2002).  
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Figure 5-1. Structure of major urinary proteins (Timm et al., 2001). The structure 
illustrates the eight stranded anti-parallel beta sheets and beta meander sheet (a-i) 
forming the eight stranded beta-barrel structure. The carboxyl and amino termini are 
shown as C and N, respectively. The yellow compound represents a lipophilic ligand 
that binds to the hydrophobic cavity of the barrel.  
  
MUPs have been reported to play a key role in pheromonal communication 
between mice males and females. Both male and female mice deposit a range 
of volatile and non-volatile compounds with urine (Taylor et al., 1984), which 
indicate the reproductive and health status and thus, evoke sex attractiveness 
and communication (Zala et al., 2004, Kavaliers et al., 2005, Mossman and 
Drickamer, 1996). The β-barrel in MUPs is believed to bind to the volatile 
pheromones, slowing their degradation and increasing the chance for these 
compounds to be delivered to the olfactory system of the recipient. Also, it has 
been proven that MUPs can delay the release of volatile pheromones from 
mice scent marks, prolonging their lifetime and educing an appropriate mice 
behavioural response (HURST et al., 1998, Armstrong et al., 2005). MUPs 
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have been found to have a role not only in general attractiveness but also in 
mate preference by females, serving as sexually selected signals that make 
the female prefer a particular male over another (Kumar et al., 2014). On the 
other hand, MUPs can present as circulating protein in the body. These 
circulating MUPs have been demonstrated to have a crucial role in regulating 
some physiological processes, such as lipid and glucose metabolism (Zhou et 
al., 2009).  
The expression of MUP in mouse liver is under multi-hormonal control (Knopf 
et al., 1983). Testosterone, growth hormone and thyroxine have been found 
to affect the mRNA of MUPs in the liver resulting in different isoforms (Knopf 
et al., 1983). For example, mice treated with testosterone have shown higher 
levels and more variable proportions of MUPs in urine. For instance, the 
authors have observed that the untreated mice that excrete MUP1 but not 
MUP2 appeared to excrete both isoforms after testosterone treatment, in 
addition to significantly induced levels of MUP1 in these mice (Szoka and 
Paigen, 1978). Some isoforms of MUPs are present exclusively or in 
significantly higher levels in males than in females (Armstrong et al., 2005). It 
has been reported that males’ average MUP production is three to four times 
higher than in females (Beynon and Hurst, 2004). Furthermore, MUPs 
expression has been found to be influenced by health status, such as infection 
and immune activation (Litvinova et al., 2005, Isseroff et al., 1986), as well as 
the diet of the mouse (Giller et al., 2013). MUPs are encoded by different 
genes which are highly polymorphic and this extensive heterogeneity results 
in a high number of MUPs isoforms and differential ligand affinities between 
MUPs species (Beynon et al., 2002, Darwish Marie et al., 2001, Sharrow et 
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al., 2002). Accordingly, inter-individual and intra-individual variations in mice 
MUPs levels have been investigated and the results have shown variant and 
dynamic MUPs profiles, however, more proteomics studies are required to 
understand their significance (Thoß et al., 2015, Cheetham et al., 2009).  
Cytochrome P450 (CYP450) is a group of heme-containing proteins that play 
a key role in phase I metabolism of drugs and xenobiotics. Sex variation in the 
expression of hepatic drug metabolizing enzymes, in general, is well reviewed 
and documented (Waxman and Holloway, 2009, Shapiro et al., 1995). In fact, 
CYP expression is known to be regulated by growth hormone released by the 
pituitary gland, which significantly shows sex variation (Shapiro et al., 1995, 
Cotreau et al., 2005, Kennedy, 2008). More specifically, it has been found that 
the expression of CYPs is influenced by the different rhythms of growth 
hormone secretion between males and females. For instance, growth 
hormone is secreted every 3.5-4 hours in males with no detectable levels 
between the peaks, whereas its secretion is continuous in females. This 
ultradian rhythm difference in growth hormone secretion between males and 
females has been found to be responsible for 3-5 folds difference in drug 
metabolism (Shapiro et al., 1995). 
The superfamily P450 consists of a number of different families, which are 
more than 40% identical in their primary structure. The families are subdivided 
into subfamilies whose primary structure is more than 55% identical (Nelson 
et al., 1993, Gonzalez, 1988). CYP1A subfamily consists of two members in 
both mouse and human, CYP1A1 and CYP1A2. The two members differ in the 
main site and level of expression in mouse and human. CYP1A1 is an extra-
hepatic enzyme that is expressed mainly in intestine, placenta, kidney and 
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lung (Guengerich, 1997, Baron and Voigt, 1993, Stejskalova and Pavek, 2011, 
Hakkola et al., 1996, Meyer et al., 2002, Cheung et al., 1999, Renaud et al., 
2011). Its levels of expression are very low in human and mouse liver. In 
contrast, CYP1A2 is predominantly expressed in the liver with very little extra-
hepatic expression levels in both mouse and human (Renaud et al., 2011). 
Interestingly, it has been found that CYP1A2 regulates the expression of 
CYP1A1 (Jiang et al., 2010, Schweikl et al., 1993). CYP1A2 is a major 
metabolizing enzyme in the liver, representing about 13% of liver CYP P450 
content (Shimada et al., 1994).  
In cancer, CYP1A enzymes have been shown to play a crucial role in 
susceptibility to cancer. They are responsible for detoxification and activation 
of polycyclic aromatic hydrocarbons (PAHs) and aromatic and heterocyclic 
amines, such as the compounds present in cigarettes, participating in pro-
carcinogens activation (Rodriguez-Antona and Ingelman-Sundberg, 2006).  
CYP1A2, in particular, metabolises 4% of all drugs (Zuber et al., 2002) and 
consequently been shown to indirectly play a major role in breast and lung 
cancer. Any alteration in its expression and activity can be directly associated 
with increased susceptibility to cancer (Ayari et al., 2013, Seow et al., 2001). 
CYP1A2 activity is greatly regulated by genetic factors and, environmental 
factors as well as drugs and xenobiotics (Härtter et al., 2003). For example, 
Chloroxoquinoline (CXL), a novel anticancer drug, has been found to 
significantly increase the mRNA levels of CYP1A2 in hepatic cell line a dose 
of 10, 50 and 100 μmol/L, which in turn decreases CXL efficacy after long-term 
exposure (Li et al., 2015b). Similarly, a new anticancer drug TSU-68 has 
shown an auto-induction of its hydroxylation (i.e. its metabolism) by increasing 
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CYP1A2 expression (Kitamura et al., 2008). CYP1A2 expression exhibits sex 
variation, with significantly higher levels of CYP1a2 protein expression in 
males compared to females in mice (Hersman and Bumpus, 2014). On the 
other hand, a female-bias was observed in the mRNA expression of CYP1A2 
in human liver (Zhang et al., 2011). Based on previous observations (Chapter 
4), an alteration in CYP1a2 expression has been found in response to PAX 
and TCPOBOP in the female set. Therefore, it was a point of interest to 
investigate whether this observation was due to the administration of the drugs 
or due to a sex variation CYP1a2 might show. 
CYP2E1 is a P450 enzyme that is present in both human and mouse with 80% 
homologous identity in the mouse to human. CYP2E1 is expressed in different 
tissue such as liver, lung, and nose (Martignoni et al., 2006). In fact, it is mainly 
expressed in liver accounting for around 6% of the total CYP450 content in the 
liver (Martignoni et al., 2006, Bieche et al., 2007). Despite having an activity in 
some extrahepatic tissues, the activity of CYP2E1 is considered to be most 
fundamental in the liver as it comprises around  50% of hepatic mRNA (Bieche 
et al., 2007)   
The high interest in studying CYP2E1 revolves around its essential role in 
metabolizing and activating a number of xenobiotics (e.g. ethanol)  and 2% of 
all drugs (e.g. chlorzoxazone) (Rodriguez-Antona and Ingelman-Sundberg, 
2006, Tanaka et al., 2000, Zuber et al., 2002). This enzyme is implicated in 
the conjugation of the drugs and xenobiotics by introducing the sites or 
unmasking them for subsequent elimination (Porubsky et al., 2008). 
Furthermore, CYP2E1 has a physiological role in starvation by metabolizing 
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the fatty acids and converting ketones to glucose, relating its function to 
diabetes and obesity (Lieber, 1997, Hong et al., 1987) 
However, in the process of metabolism, toxic and carcinogenic products might 
be produced leading to liver toxicity and cancer. Interestingly, CYP2E1 has 
been found to be more prone to form ROS compared to other CYP P450 
enzymes (Ioannides, 1996, Bell and Guengerich, 1997). This high propensity 
was suggested to be due to the unstable nature of CYP2E1 and the weak 
connection of the active site with other parts of the protein, which makes the 
substrate easy to dissociate (Porubsky et al., 2008).  
The high tendency to form ROS has resulted in CYP2E1 having a critical role 
in determining the susceptibility of individuals to cancer and toxicity (Porubsky 
et al., 2008). Moreover, the special attributes of CYP2E1 are also highlighted 
by its high conservation among species and the absence polymorphisms 
which affect its expression and activity (Porubsky et al., 2008). Therefore, 
environmental factors and drugs that may induce the expression of CYP2E1 
have grown to be of high importance, playing a major role in inter-individual 
variation in cancer susceptibility in reactions catalysed by this enzyme. 
CYP2e1 has shown significant changes in expression in the previous data 
(Chapter 4) in response to DOX in the male set. Such observation and the 
emerging picture from the literature regarding the crucial role that CYP2e1 
plays in cancer drew us to shed the light on it and extensively explore the 
changes in its expression in response to drugs taking sex variation into 
consideration. 
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Sex variation in the expression of hepatic CYP2E1 in general, and at the 
protein level in particular, has not been extensively studied. Previously, 
hepatic CYP2e1 mRNA expression has been found to be higher in female 
mice than in males, and the female sex hormones have been found to induce 
the expression of CYP2e1 (Konstandi et al., 2013). However, when studying 
the expression of hepatic CYP2e1 at the protein level in mice, a previous study 
has shown no difference between males and females (Hersman and Bumpus, 
2014).  
Among CYP450, CYP3A subfamily is the most important drug metabolizing 
enzyme in human, accounting for 30% of CYP450 total content in human liver 
and responsible for metabolizing more than 50% of drugs (Martignoni et al., 
2006, Zuber et al., 2002). CYP3A consists of four isoforms, 3A4, 3A5, 3A7, 
and 3A43 in human. CYP3A4 is the most abundant in human liver and, to a 
lower extent, in the intestine (Nelson et al., 2004). In previous comparison 
study employed six different species, mouse was proposed as the most similar 
to humans with respect to catalytic activities of the CYP3A subfamily 
(Bogaards et al., 2000). In mouse, there are six isoforms of CYP3a, CYP3a11, 
CYP3a13, CYP3a16, CYP3a25, CYP3a41 and CYP3a44. Where CYP3a11 is 
the most homologous to human sharing 76% of the amino acids of CYP3A4 
(Yanagimoto et al., 1992).  
The expression of CYP3A4 has been reported to display a high inter-individual 
variation and this variation has been mainly attributed to genetic factors 
(Özdemir et al., 2000). However, in the previous data (Chapter 4), five CYP3a 
isoforms have been identified in females, while only 3 have been identified in 
males. Moreover, the changes in the expression in response to drugs were 
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primarily observed in females. Sex variation has been shown to contribute to 
5.69% variation of CYP3A4 mRNA expression in human liver (Lamba et al., 
2010). While some studies have shown higher mRNA expression of CYP3A4 
in human liver of females than in males (Wolbold et al., 2003, Gorski et al., 
1998), other studies have not found such difference (Schmucker et al., 1990, 
George et al., 1995a). In regard to CYP3a11 in mouse, no significant effect 
has been found at mRNA level in response to continuous growth hormone 
treatment, suggesting a sex-independent pattern in hepatic CYP3a expression 
(Cheung et al., 2006). Therefore, the previous data and studies have led 
CYP3a to be of high interest. 
A particular challenge for studying mouse CYPs using Western blotting 
techniques is the virtual absence of commercially available anti-mouse CYP 
antibodies. An exception is anti-mouse CYP2e1, but for CYP1a2 and CYP3a, 
anti-human equivalent CYPs will be tested for their ability to detect mouse 
CYPs. 
5.1.1 Aims of the chapter 
One of the variables of the proteomics discovery work was that Set A was 
performed on male mice, whilst Set B was performed on female mice (Chapter 
4). In the original experimental design, sex was not expected to be a significant 
factor affecting protein expression when testing anti-cancer drugs.  Moreover, 
in order to state the real causes of the significant alteration in MUP 
expressions in Chapter 4. This project employs new Sets of male and female 
mice treated with DOX and PAX. 
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The first part of this chapter aimed to use liver microsomes from datasets, A 
and B, to verify the changes in MUP expression observed in the previous 
Chapter (Chapter 4) by western blotting technique. 
The second part intended to employ new Sets of untreated and treated (DOX 
and PAX) liver microsomes from male and female mice, which will be used 
further to: 
a. Determine whether antibodies against human CYPs 1A2 and 3A4 can 
be used to detect equivalent mouse CYP isoforms 
b. Investigate sex variation in MUP and CYP450 (CYP1a2, 2e1, and 3a) 
expressions, which will help us understand some of the physiological 
processes in both male and female. 
c. Investigate the effect of DOX and PAX on the expression of MUP, 
CYP1a2, and 2e1.  
d. Evaluate the sex variation in MUP, CYP1a2, and 2e1 in response to 
PAX and DOX treatments. 
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5.2 Material and Method 
5.2.1 Animals maintenance  
Male and female BALB\cOLaHsd –Foxn1nu immunodeficient nude mice 
(Harlan Laboratories, UK) aged 10 weeks were used for both untreated and 
treated experiments. All mice were kept and maintained as mentioned in 
Section 3.2.1. 
5.2.2 Cell lines 
Human colon adenocarcinoma (DLD-1) cell line was used to induce tumour in 
treated mice (Section 4.2.2.2).   
5.2.3 Tumour system 
Tumours were induced only in mice intended to be treated with either DOX or 
PAX as described previously in Section 4.2.2.3. 
5.2.4 Chemotherapy treatment and experimental design  
For the first part of this Chapter, prepared samples of Sets A and B in the 
previous chapter (section 4.2.2.4) were used. In the second part of this 
Chapter, new sets of sample were prepared as follow; a group of male and 
female mice were divided into three groups for each sex; the first group was 
received no treatment (NT), the second group was treated with DOX and its 
solvent (Normal saline - NS), and the third group was treated with PAX and its 
solvent (CrEL, DMSO and Arachis oil - PS) (Table 5.1). 
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For treated groups, mice were treated in two separate experiments; Female 
Mice Set (FMS) and Male Mice Set (MMS), then sacrificed 24 hours after 
treatment. Animals’ treatment and tissues collection were done by Home 
Office-certified expert Tricia Cooper, at the Institute of Cancer Therapeutics, 
University of Bradford. Heart, lung, liver, kidney, and tumour are recovered 
and stored at -80°C. 
Table 5-1. Conditions of mice treatment, type of drugs and tumors used. NA indicates 
not applicable 
Set Sex Drug 
Tumour 
type 
Dose 
(mg/k
g) 
No. of 
mice 
Route of drug 
administration 
Duration 
(hr.) 
No 
treatment 
mice set 
(NT) 
NT-Female 
NA NA NA 
3 
NA NA 
NT-Male 3 
Female 
mice set 
(FMS) 
FMS-DOX 
DOX DLD-1 10 3 IP 24 
NS DLD-1 -- 2 IP 24 
FMS-PAX 
PAX DLD-1 20 3 IP 24 
PS DLD-1 -- 3 IP 24 
Male mice 
set (MMS) 
MMS-DOX 
DOX DLD-1 10 3 IP 24 
NS DLD-1 -- 3 IP 24 
MMS-PAX 
PAX DLD-1 20 3 IP 24 
PS DLD-1 -- 3 IP 24 
 
5.2.5 Sample preparation  
5.2.5.1 Protein extraction from mouse liver by cryo-pulverization and 
microsomes preparation 
Whole liver extracts (S9 fraction) were prepared following the optimised 
method; cryo-pulverization and sonication extraction (CP+S) method as 
described previously in Section 3.2.2.1.2. Subsequently, microsomal fractions 
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were prepared from the S9 fraction by means of ultracentrifugation method 
(section 2.2.1.1). (Figure 5.2). 
 
Figure 5-2. Flow diagram showing the steps of validating signature proteins by 
Western blot technique. After drug treatment in two independent sets (FMS and MMS), 
proteins were extracted by the optimized method (CP+S). Then equal amounts of 
proteins (40µg) were prepared for SDS-PAGE separation. Protein expression was 
determined via Western blot technique and band intensity analyser. 
 
5.2.6 Western blotting  
Defined amount of microsomal proteins were used for Western blotting 
analysis as illustrated in Section (2.2.2). The conditions and concentrations of 
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primary and secondary antibodies that have used to validate the expression 
of MUP, CYP1a2, CYP2e1, CYP3a, and β-actin were demonstrated in Section 
2.2.2.5.    
5.2.7 Data analysis  
Statistical differences in protein quantity between two groups were determined 
with an unpaired two-tailed Students’ t-test (GraphPad Prism 7.0 software). 
For more than two group statistical comparisons, ANOVA was used. Data are 
presented as means ± standard deviation (S.D.). A p-value of ≤ 0.05 was 
regarded as significantly different from control values and is shown in Figures 
with an asterisk. 
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5.3 Results 
5.3.1 Optimisation of MUP1 antibody 
Serial dilution of recombinant MUP1 protein (10, 5, 2.5, 1.25, 0.625µg) was 
used to evaluate the efficiency of MUP1 antibody, as well as for liver MUP 
quantification purpose (Figure 5.3). 
 
Figure 5-3. Western blot analysis using serial dilutions of MUP1 recombinant protein. 
Band intensity was measured via ImageJ software for each concentration and 
represented in barograph.   
  
In accordance with MUP1 antibody supplier (Santa Cruz), and due to the high 
homology within MUP isoforms, this antibody has cross-reactivity among other 
isoforms of MUP. Therefore, the term MUP will represent all the possible MUP 
isoforms that may be detected, not just MUP1.   
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5.3.2 Validation MUP as a potential biomarker from quantitative 
proteomics datasets A and B 
Qualitative assessment was performed first to evaluate the consistency of 
sample preparation and protein quantification using SDS-PAGE gel (stained 
with Coomassie blue) approach for liver microsomes from Sets A and B 
(Chapter 4) (Figure 5.4) 
 
Figure 5-4. SDS-PAGE analysis stained with Coomassie blue. Gel shows the 
efficiency of microsomal proteins preparation from sets A and B. Loading amount 
was 40µg proteins per lane. Lane M, Molecular weight marker 
 
The stained gel demonstrated good quality and reproducible lysates for Set B 
which has been prepared recently for this project. In contrast, Set A which has 
been prepared before and kept at -20°C till used at this time has shown 
evidence of degradation due to lack of clearly defined bands, although the 
amount of loaded proteins was increased to double (data not shown). 
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Nevertheless, a preliminary experiment was performed on Set A along with 
Set B to determine if these samples could be used for MUP expression by 
Western blot analysis (Figure 5.5).  
 
Figure 5-5. Effect of drugs from sets A and B on the expression of MUP in liver 
microsomes. Western blotting analysis in duplicate (A). β-actin in the same 
microsomal extract was used as an internal reference. Optical density reading values 
of the MUP protein was normalized using the expression of β-actin, then represented 
as a fold in MUP expression in compared to corresponding control (B). Number of 
analyses = 3. P-value was calculated following Students’ t-test by comparing each 
treated drug with its control. 
 
Taking into account the possible activity of MUP1-antibody against other close 
homology MUP isoforms, Western blot analysis showed good agreement with 
iTRAQ proteomics analysis (Chapter 4). Statistical analysis showed that the 
induction of MUP expression was significant (p-value <0.05) in Set A (5FU, 
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CIS, and DOX) and Set B (TCPOBOP). For Set A, male mice, liver treated 
with DOX showed the greatest induction in MUP expression (7.2-fold 
increases compared to control) followed by CIS (2.3-fold) then 5FU (1.3-fold). 
In Set B, female mice, TCPOBOP (2.5-fold) has significantly induced MUP 
expression. Moreover, consistent with proteomics data, 5FU and PAX did not 
induce MUP expression.   
5.3.3 Assessing the influence of sex variation on MUP and CYP 
expression 
5.3.3.1 Sex variation and MUP expression 
A new set of untreated (NT) male and female livers were employed to 
investigate the differences in MUP expression. Initially, a stained gel with 
Coomassie blue was performed to assess the overall preparation method for 
untreated samples (Figure 5.6). 
 
Figure 5-6. Coomassie blue stained SDS-PAGE gel showing the efficiency of 
microsomal proteins extraction from no treatment (NT). Three mice were used for 
each sex. Loading volume was 20µg proteins per lane. Lane M, Molecular weight 
marker 
M 
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The stained gel showed good qualitative separation based on clearly defined 
bands, enabled used the samples for MUP expression evaluation (Figure 5.7). 
 
Figure 5-7. Comparison of MUP expression between no treatment – NT, male (n=3) 
and female (n=3) sets in triplicate. Western blotting analysis (A). β-actin in the same 
liver extract was used as an internal reference. Optical density reading values of the 
MUP protein was normalised using the expression of β-actin, then represented as a 
normalised ratio of MUP expression (B). P-value was calculated following Students’ t-
test by comparing untreated male mice with untreated female mice. +ve control 
indicates MUP1 recombinant protein (1.25µg) included as positive standard. 
 
Comparing MUP expression between male and female mice received no 
treatment, indicated a significant increase (> 3 fold) in the male mice with 
greater consistency amongst the three mice (SD=0.1) compared to female 
mice (SD=0.32). This indicates that MUP is chiefly expressed in male mice 
compared to female mice.  
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5.3.3.2 Sex variation and CYP450 expression 
CYP isoforms (CYP1a2, CYP2e1, and CYP3a) were selected to assess sex-
based variation, which consequently will be used to investigate the capability 
of two anti-cancer drugs (DOX and PAX) to modulate their expressions. At the 
same time, this was an opportunity to determine if anti-human CYP antibodies 
could be used to detect mouse equivalent enzymes. The expression profiles 
of CYP1a2, 2e1, and 3a were evaluated in the liver of NT-female and -male 
mice (Figure 5.8)    
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Figure 5-8. Comparison of CYP1a2, CYP2e1, and CYP3a expressions between 
untreated (NT) male and female. Three mice of each sex were used in Western blotting 
analysis in duplicate (A). β-actin in the same liver extract was used as an internal 
reference. Optical density reading values of the CYP isoform was normalized using 
the expression of β-actin, then represented as a normalised ratio of CYP expression 
(B). P-value was calculated following Students’ t-test by comparing untreated male 
mice with untreated female mice for each CYP enzyme. 
 
Western blotting analysis exhibited a significant decrease in CYP1a2 
expression in NT-female (p-value, 0.042) compared to male one. For CYP2e1 
and CYP3a, the analysis did not show any significant sex dimorphism. 
However, CYP2e1 expression in NT-female was lower but not significant (p-
value, 0.258) compared to the NT-male set.  
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5.3.4 Assessing the influence of selected drugs on MUP and 
CYP450 expression 
5.3.4.1 Sex effect of treated mice with DOX on MUP expression 
DOX exhibited the highest effect on MUP induction in the proteomics dataset 
A. Initially, SDS-PAGE was prepared first for male and female sets to ensure 
the quality of microsomal proteins preparation and quantification prior Western 
blot analysis (Figure 5.9).  
 
Figure 5-9. SDS-PAGE analysis for DOX-treated female mice (FMS-DOX, gel A) and 
male mice (MMS-DOX, gel B). 20µg of protein was loaded into each lane, then 
separated proteins were stained using Coomassie blue stain. For both gels (A and B), 
Lane M, Molecular weight marker; Lane 1, DOX mouse-1; Lane 2, DOX mouse-2; Lane 
3, DOX mouse-3; Lane 4, NS mouse-1; Lane 5, NS mouse-2; Lane 6, NS mouse-3 (gel 
B only).     
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MUP expression was evaluated using Western blot analysis (Figure 5.10). In 
FMS-DOX and similar to the NT-female set, the amount of MUP in samples 
treated with DOX exhibited inconsistency in MUP expression relative to beta-
actin. For samples treated with DOX-solvent (i.e. normal saline – N.S), the 
level of MUP was more consistent between the two mice. However, comparing 
the average amount of MUP for DOX-treated samples and NS-treated 
samples with NT samples did not show any significant variation in MUP 
expression. These results indicated that the expression of MUP in female mice 
is very low, where a slight variation in MUP expression within samples can be 
exaggerated statistically making it challenging to observe the effect of the 
drug.   
In contrast, male treated mice with DOX, NS, and NT showed more 
consistency in MUP expression and a statistically significant up-regulation of 
MUP expression in DOX-treated mice (p-value, 0.0478) compared to NT, 
which was in agreement with the previous result in Chapter 4 (Set A). 
Moreover, there was no significant difference in MUP between solvent (NS) 
and NT, confirming that this up-regulation is in response to DOX-treatment.   
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Figure 5-10. Comparison of MUP expression between FMS-DOX and MMS-DOX. 
Samples were treated with; DOX (3 mice for each set), NS (2 and 3 mice for female and 
male sets, respectively), and NT (3 mice for each set) in triplicate for western blotting 
analysis (I). β-actin in the same liver extract was used as an internal reference for 
relative expression. Optical density reading values of the MUP protein was normalized 
using the expression of β-actin, then represented as a normalised ratio of MUP 
expression (II). P-value was calculated following Students’ t-test by comparing treated 
samples with their corresponding control (NT), for female Set (A) and male Set (B). 
+ve is indicated an MUP recombinant protein that was included as positive standard. 
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5.3.4.2 Sex effect of treated mice with DOX on CYP450 
The effects of DOX on CYP1a2 and CYP2e1 from both sexes were 
investigated by Western blotting approach (Figure 5.11). 
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Figure 5-11. Comparison of CYP1a2 and CYP2e1 expressions between FMS-DOX and 
MMS-DOX. Samples were treated with; DOX (3 mice for each set), NS (2 and 3 mice for 
female and male sets, respectively), and NT (3 mice for each set) in duplicate for 
western blotting analysis (A). β-actin in the same liver extract was used as an internal 
reference. Optical density reading values of the CYP protein was normalized using the 
expression of β-actin, then represented as a normalised ratio of CYP1a2 (B) and 
CYP2e1 (C) expressions. P-value was calculated following Students’ t-test by 
comparing treated samples (DOX or NS) with their corresponding control (NT). 
 
The results demonstrated that DOX did not modulate either CYP1a2 or 
CYP2e1 expression. Moreover, the expression of both CYP isoforms was 
similar in DOX-treated samples from FMS and MMS. 
5.3.4.3 Sex effect of treated mice with PAX on MUP 
The effect of PAX was only observed in the proteomics treated (Set B), where 
the expression of MUP1 in response to PAX was significantly down-regulated. 
In this analysis, the effect of PAX and its solvent (CrEL, DMSO, and Arachis 
oil) on MUP expression from female (FMS-PAX) and male (MMS-PAX) mice 
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will be investigated thoroughly. Stained SDS-PAGE gels showed high quality 
of protein preparation and quantification in both sets (Figure 5.12) 
 
Figure 5-12. SDS-PAGE analysis for PAX-treated female mice (FMS-PAX, gel A) and 
male mice (MMS-PAX, gel B). 20µg of protein was loaded in each lane, then separated 
proteins were stained using Coomassie blue stain. For both gels (A and B), Lane M, 
Molecular weight marker; Lane 1, PAX mouse-1; Lane 2, PAX mouse-2; Lane 3, PAX 
mouse-3; Lane 4, PS mouse-1; Lane 5, PS mouse-2; Lane 6, PS mouse-3.     
 
Further, gels were processed for Western blot analysis to evaluate MUP 
expression in response to PAX and its solvents (PS) (Figure 5.13). Treatment 
with PAX for three female mice displayed high discrepancy, where mouse 
number 1 and 3 presented a very low amount of MUP compare to mouse 
number 2 which showed a relatively high amount. For mice treated with PAX-
solvent (PS), the amount of MUP was elevated and consistent. In this 
experiment, one untreated female mouse (NT number 3) was replaced with 
MUP positive control.  
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 Figure 5-13. Comparison of MUP expression between FMS-PAX and MMS-PAX. 
Samples were treated with; PAX (n=3), PS (n=3), and N.T (n=2 for female and n=3 for 
male) in triplicate for western blotting analysis (I). β-actin in the same liver extract was 
used as an internal reference. Optical density reading values of the MUP protein was 
normalized using the expression of β-actin, then represented as a normalised ratio of 
MUP expression (II). P-value was calculated following Students’ t-test by comparing 
treated samples with their corresponding control (N.T), for female Set (A) and male 
Set (B). +ve control is MUP1 recombinant protein included as a positive standard. 
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The expression of MUP in NT-female mice was also consistent and in low 
amount. On the other hand, male mice treated with PAX and its solvent (PS) 
showed greater consistency, with exception of PAX mouse 1, where the 
amount of MUP was unexpectedly low. However, these results highlight the 
occurrence of individual variation in MUP expression. 
Additionally, there was no significant variation between PAX or PS -treated 
mice and NT, in male and female sets.          
5.3.4.4 Sex effect of treated mice with PAX on CYP 
Similar to DOX, PAX was used to investigate whether it has the ability to 
modulate the expression of CYP1a2 and CYP2e1 in male and female mice 
(Figure 5.14). PAX exhibited no significant differential expression for either 
CYP1a2 or CYP2e1.  
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Figure 5-14. Comparison of CYP1a2 and CYP2e1 expressions between FMS-PAX and 
MMS-PAX. Samples were treated with; PAX (3 mice for each set), PS (3 mice for each 
set), and NT (3 mice for each set) in duplicate for western blotting analysis (A). β-actin 
in the same liver extract was used as an internal reference. Optical density reading 
values of the CYP protein was normalized using the expression of β-actin, then 
represented as a normalised ratio of CYP1a2 (B) and CYP2e1 (C) expressions. P-value 
was calculated following Students’ t-test by comparing treated samples (PAX or PS) 
with their corresponding control (NT). 
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5.4 Discussion 
5.4.1 Validation MUP as a potential biomarker from quantitative 
proteomics datasets A and B   
Liver microsomes from datasets A and B (Chapter 4) were used in the first part 
of this Chapter to confirm the observed changes in MUP expression via 
Western blotting techniques. In spite of partial degradation in liver samples of 
Set A, quantitative comparison between proteomics iTRAQ ratios and Western 
blotting band intensities showed strong agreement and reproducible data 
(Table 5.2). Furthermore, statistically, significant up- and down-regulated 
isoforms were consistent between proteomics and Western blotting data for 
both datasets. Based on the supplier, the MUP1 antibody may bind other 
isoforms of MUP, especially MUP2, which participate 98% of amino acid 
sequence with MUP1. The fold changes in MUP of liver treated with DOX 
compared to control (7.2) is slightly higher than the relative iTRAQ ratio of 
MUP1 (6.27), which may prove that MUP antibody binds more than one 
isoforms with different affinity.  
As indicated in the previous chapter, we believe that some factors have 
affected the results of MUP from Sets A and B. The variation in the proteomics 
results may have been due to one or more experimental variables; 1) using 
different controls since the control of Set A has not been injected with normal 
saline as in Set B, 2) the sex variation effect, 3) drug solvent effect, and 4) 
inter-individual variation.  
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Table 5-2. Comparison MUP expression (Set A and B) between quantitative 
proteomics iTRAQ data and Western blotting data. Fold changes based on the iTRAQ 
ratio is representing the amount of particular MUP in treated sample to a 
corresponding control. Fold changes in Western blotting data is the optical density of 
total MUP in treated band to corresponding control band. ND; not detected, (*) 
indicates significantly up-regulated, (**) indicates significantly down-regulated.  
 Proteomics data Western blotting data 
MUP 
isoforms 
Fold Changes – iTRAQ ratio Fold Changes – intensity ratio 
Set A Set B Set A Set B 
5FU CIS DOX 5FU PAX 
TCPOB
OP 
5FU CIS DOX 5FU PAX TCPOBOP 
MUP1 2.18* 2.47* 6.27* 1.07 1.06 1.52* 
1.3* 2.3* 7.2* 1.2 0.96 2.5* 
MUP2 
1.81* 2.04* 2.78* ND ND ND 
MUP3 
1.25 1.19 2.05* ND ND ND 
MUP6 
1.74* 2.21* 3.34* 0.89 0.70** 1.63* 
 
Accordingly, we have verified the expression of MUP and CYP450 enzymes, 
CYP1a2, CYP2e1, and CYP3a, in new sets of male and female mice. 
Importantly, we have demonstrated that anti-human CYP1A2 and anti-
CYP3A4 antibodies can be used to detect equivalent mouse isoforms. In the 
latter case, we cannot be definitive about the mouse isoforms detected as four 
mouse CYP3a isoforms were detected by proteomics analysis (Chapter 4, 
Table 4.10), including CYP3a11, which has greatest sequence homology to 
CYP3A4. 
In order to exclude the factors of variation in drug effect on proteins, we have 
studied the sex-effect on each of the protein of interest alone and then this 
effect on the proteins upon DOX and PAX administration. In addition, we have 
taken the possible effect of drug solvent into consideration.    
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5.4.2 Sex effect on protein expression of MUP, CYP1A2, CYP2E1, 
and CYP3A  
Major urinary proteins (MUPs) are a subfamily of proteins that descends from 
a superfamily called lipocalines. Our study has revealed a noteworthy sex 
variation in the expression of MUP in untreated males and females, having 3:1 
ratio of males to females. This result is in line with previous studies that 
demonstrated higher male levels of MUP from both laboratory-bred strains and 
wild caught strains (Beynon and Hurst, 2004, Finlayson et al., 1963, Payne et 
al., 2001), and supports the data of a previous study that testosterone has an 
effect on the levels of MUP (Szoka and Paigen, 1978). However, the previous 
studies showed that the levels of MUP correlate to its concentration in urine, 
while our study has compared the levels of protein expression in the liver, 
which helps to avoid some factors that may be related to dilution following its 
expression from the liver via the bloodstream to the kidney.  
Regarding hepatic CYP450s, sex variation in expression is highly important 
due to its major impact on drugs and xenobiotics metabolism. In general, sex 
dimorphism has been observed and reviewed by previous studies but remains 
controversial (Waxman and Holloway, 2009, Shapiro et al., 1995). The current 
study has investigated such dimorphism in the protein levels of three 
CYP450s, CYP1a2, CYP2e1, and CYP3a, which have a well-known role in 
cancer etiology and drugs metabolism.  
Our results have shown a significant sex difference in protein expression of 
CYP1a2 (p<0.05), being higher in males than in females. This result is 
consistent with a recent study that demonstrated a male-bias in the CYP1a2 
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in murine liver microsomes using Multiple Reaction Monitoring (MRM)-MS-
based quantitation technique (Hersman and Bumpus, 2014). However, a 
previous study (Zhang et al., 2011), contradicts our results by observing higher 
levels in women. This discrepancy might be attributed to use of a microarray 
to measure the gene expression on the mRNA level, while we have used 
Western blotting to measure the enzyme expression at protein level. 
Moreover, the tissue the authors used was a human tissue from patients who 
have primary liver tumours removed. Also, the liver tumour  might have added 
confounders affecting their results, especially that CYP1A2 has been 
previously found to be the most affected by liver diseases (George et al., 
1995b).  
In regard to CYP2e1, no significant difference has been found in the levels of 
CYP2e1 in female mice compared to males though there was inter-individual 
variation in females. Our results are in agreement with a previous proteomics 
study, which found no sex difference in protein level using MRM-MS technique 
(Hersman and Bumpus, 2014). Similarly, a previous study has observed no 
difference in CYP2E1 mRNA and protein levels between male and female 
mice. However, their data did reveal a fluctuation in the CYP2e1 levels in 
females based on the phase of the female estrous cycle, with the highest 
expression of CYP2e1 at the estrous phase and lowest at metestrus 
(Konstandi et al., 2013) and may explain the  inter-individuality we observed. 
Our study has found no significant sex-related variation in the protein 
expression of CYP3a. These findings are consistent with those observed by 
another previous study, which demonstrated sex-independent and GH-
unresponsive hepatic pattern in murine CYP3a11 mRNA expression, the most 
  232 
homologous isoform in the mouse to human CYP3A4, an attribute verified by 
our use of an anti-3A4 antibody to analyse mouse samples (Cheung et al., 
2006). Previous attempt to investigate the effect of 3-methylcholanthrene on 
mouse hepatic CYP3A expression showed that CYP3A4 antibody produced in 
the rat is primarily bound CYP3a11 (Lee et al., 2013a).   
Furthermore, no sex dimorphism has been found in another previous study 
when investigating mRNA expression in either CYP3A11, CYP3A13, 
CYP3A25, and  CYP3A57 isoforms (Renaud et al., 2011). However, in 
contrast to our results, a previous study indicated differential expression of the 
CYP3A4 protein in human liver microsomes at mRNA and protein levels 
(Wolbold et al., 2003). However, inter-individual variation in human CYP3A4 
is highly prevalent, and 90% is attributable to genetic factors (Özdemir et al., 
2000). 
5.4.3 Effect of DOX and PAX on MUP 
To the best of our knowledge, we are the first study to observe the acute effect 
of DOX on MUP and show a significant induction of protein expression in male 
mice. However, this induction has not been observed in female mice. Previous 
studies have found that other drugs, Phenobarbital (PB), 3-methylcholantrene 
(3-MC) and N-nitrosomorpholine (NNM) alter MUP expression (Zgoda et al., 
2006, Glückmann et al., 2007). The authors suggested that MUPs may have 
a role in the binding of PB and 3-MC or their oxidation products, as well as 
participating in their corresponding complexes excretion. 
Circulating MUP is reported to have a physiological role in regulating glucose 
and lipid levels and markedly reduces hyperglycaemia in mouse liver (Zhou et 
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al., 2009). On the other side, DOX has been found to cause insulin resistance 
and a tremendous increase in serum glucose (Arunachalam et al., 2013), as 
well as accumulation of fatty acids (Hammer et al., 2010).   Interestingly, DOX 
has caused an up-regulation of FABP in our results. Taken together, the 
regulatory role of MUP in glucose and lipid levels and the effect of DOX on 
glucose and fatty acids may be related.   
DOX has been shown to activate aryl hydrocarbon receptor (AhR) (Volkova et 
al., 2011). 3-MC which also activates AhR (Pansoy et al., 2010), whose 
activation was found to increase lipids, glucose levels, and hepatic oxidative 
stress, has also been found to increase MUP expression (Biljes et al., 2015, 
Minami et al., 2008, Lee et al., 2010). Moreover, administration of NNM, which 
causes a decrease in glucose levels (Nehrbass et al., 1998), has shown a 
down-regulation in MUPs (Glückmann et al., 2007).  
PAX effect has also been investigated on MUP protein expression in males 
and females, with a remarkable inter-individual variation in the treated mice. 
Overall, our results have revealed no significant effect of PAX on both males 
and females MUP expression. 
5.4.4 Effect of DOX and PAX on CYP1A2 and CYP2E1 
DOX has been reported to cause cardiotoxicity which is suggested to be 
associated with CYP450 enzymes. Previous studies have investigated such 
association at mRNA levels. However, the effect of DOX has not been 
extensively studied at the protein level. Our study demonstrated that DOX (10 
mg/kg, IP, 24 hours) had no significant effect on CYP1a2 and CYP2e1 
expression in either sex. A previous study (Zordoky et al., 2011) also found 
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no altered regulation in hepatic CYP2e1 expression at both gene and protein 
level by DOX (15 mg/kg, IP, 24 hours) using RT-PCR and Western blotting 
techniques in male mice. In contrast to our study, a previous study has 
observed an induction in both CYP1A2 and CYP2E1 mRNA expressions in a 
human cardiac cell line, H9c2 (Zordoky and El-Kadi, 2008). Likewise, PAX had 
no significant effect on CYP1a2 and CYP2e1 in our results. The comparison 
between proteomics data (Chapter 4) and Western blotting data (Chapter 5) 
regarding CYP1a2 and CYP2e1 is illustrated in Table 5-3. 
Table 5-3. Comparison CYP1a2 and CYP2e1 expressions between quantitative 
proteomics iTRAQ data (Set A and Set B) and western blotting data (FMS and MMS). 
Fold changes based on the iTRAQ ratio is representing the amount of particular CYP 
isoform in treated sample to a corresponding control. Fold changes in Western 
blotting data is the optical density of total CYP isoform in treated band to 
corresponding control band. (*) indicates significantly altered protein. 
 Proteomics data Western blotting data 
CYP isoform 
Fold Changes – iTRAQ ratio Fold Changes – intensity ratio 
Set A Set B FMS MMS 
DOX PAX DOX NS PAX PS DOX NS PAX PS 
CYP1a2 1.09 0.88 1.03 0.98 1.27 0.94 1.02 0.97 0.83 0.98 
CYP2e1 0.69* 1.07 0.83 0.92 1.07 0.89 1.11 0.96 0.92 1.09 
 
Results from either DOX (Set A, male mice) or PAX (Set B, female mice) of 
proteomics experiments were in agreement with data obtained from Western 
blotting analysis. Moreover, the latter technique involved the solvent of each 
drug to ensure that the observed changes were because of drugs, not their 
solvents. However, an exception is CYP2e1 in response to DOX treatment, 
which was significantly down-regulated in proteomics analysis but not in 
Western blotting analysis. Even though, the expression of DOX in FMS was 
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slightly reduced (0.83-fold change) but not in MMS. This result might highlight 
the short duration of treatment, alongside weather CYP2e1 antibody has 
cross-reactivity with other mouse CYP isoforms. 
In conclusion, we suggest that MUP altered-regulation only occurs in response 
to a physiological function alteration, and we can propose MUP as a candidate 
biomarker for hepatotoxicity in male mice. Our study has presented an 
investigation assay that will enable further exploration of the impact of different 
drugs on MUP and some CYP450, taking sex effects into consideration. We 
suggest further investigation in regard to DOX and PAX effect, over a longer 
time course, on MUP to verify its function in response to drugs, as well as on 
CYP1a2 and CYP2e1 enzymes due to their significant role in metabolizing 
drugs and cancer etiology. 
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Chapter Six: Investigating the influence of DOX 
and PAX on the activity of cytochrome P450s in 
mouse liver microsomes using VIVID assay 
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6 Investigating the influence of Doxorubicin and 
Paclitaxel on the activity of cytochrome P450s in 
mouse liver microsomes using VIVID 
6.1 Introduction:  
As the mRNA levels vary, the proteins also vary, and so does the activity of 
these proteins. The post-translational modifications that the proteins might 
undergo to regulate their activity, localization or interaction with other cellular 
molecules, result in protein functional diversity and this has brought 
meaningful insights toward studying the activity of the enzyme in addition to 
its gene and protein expressions (Karve and Cheema, 2011). Moreover, 
changes in protein expression do not necessarily reflect changes in activity, 
as the protein expression is more stable and easily analyzed compared to 
activity assessment (Myers et al., 2012). Understanding the changes in the 
activity of proteins in addition to their expression will accelerate the process of 
understanding the mechanistic basis of human disease and developing 
clinically effective drugs. 
As described earlier, the mechanism by which CYP450s exert their function in 
phase I metabolism revolves around using molecular oxygen (O2) to give the 
substrate (i.e. drug) an oxygen atom through what is called mono-oxygenase 
cycle, which requires some cofactors, including NADPH oxidoreductase 
enzyme and cytochromeb5 and specific conditions to be accomplished (Rang 
et al., 2014). Therefore, assessing the enzyme activity in vitro is considered a 
challenge as all the components of the CYP kinetic cycle (Figure 1.3) should 
be available in appropriate amounts, in addition to the pH and temperature 
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that should be optimized carefully in order to obtain the maximum activity of 
the enzyme. Also, care is required during the mechanical destruction of the 
cells for proteins extraction, so as to maintain the enzyme active (Wienkers 
and Heath, 2005, van Eunen and Bakker, 2014, Scopes, 2002).  
CYP450 enzyme activity is evaluated based on the rate of forming a marker 
metabolites, which can be detected by one of these approaches; 
luminescence, fluorescence, radioactivity, photometric or mass spectrometric 
assays (Paul et al., 2012). The fluorescence method is the most used method 
for CYP450 activity evaluation and is based on the incubation of an 
appropriate non-fluorescent substrate with a specific CYP450 enzyme 
converting it into a fluorescent metabolite. The rate of changes in fluorescence 
intensity represents the quantitative measure of the fluorescent metabolite 
formed, hence the measure of enzyme activity. 
Each method has its own advantages and limitations. For instance,  
photometric and fluorometric assays are considered superior over the 
radiometric that they are continuous, accurate with high throughput, and less 
hazard and cost (Paul et al., 2012, Liao et al., 2015). Meanwhile, the 
fluorometric assay is considered more sensitive and reproducible than 
photometric and lower amounts of both substrate and enzyme are needed, 
accordingly (Chen et al., 2005). Nevertheless, photometric and fluorometric 
assays are not applicable in the case of non-chromogenic or non-fluorogenic 
substrates which are still a challenge for chemists to synthesize (Paul et al., 
2012). On the other hand, the mass spectrometric assay is used for those 
substrates that lack chromophore or fluorophore, but unfortunately, it is a 
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discontinuous method and requires high costly equipment (Paul et al., 2012, 
Wu et al., 1997).  
The VIVID assay is sensitive, homogeneous, cost effective fluorometric 
method with a high throughput (Trubetskoy et al., 2005b). VIVID fluorogenic 
substrates are metabolised by CYP450s into highly fluorescent products in the 
visible light spectrum with minimal interference from background fluorescence 
(Figure 6.1), which reflects the concentration of the metabolite and thus, 
enzyme activity (Trubetskoy et al., 2005b).    
 
Figure 6-1. Schematic representation of metabolizing fluorogenic VIVID substrate by a 
cytochrome P450 enzyme from “blocked” dye into a fluorescent metabolite. The 
arrows indicate the two potential P450 cleavage sites. Oxidative cleavage at either site 
releases the highly fluorescent product. 
 
VIVID assay was originally designed for evaluating the power of various 
compounds in inhibiting human CYP450 isoforms; by incubating microsomes 
from baculovirus-infected cells co-expressing CYP450 isoform (i.e. 
baculosome CYP450) contains reductase cofactors (NADPH-cytochrome 
P450 reductase and cytochromeb5) provided by Invitrogen with an 
experimental inhibitor, then measure the inhibition percent for this compound. 
However, we modified this assay by replacing the baculosome CYP450 
enzyme with mouse liver microsomes to be able to measure the activity of 
particular microsomal CYP450 enzyme. 
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In the modified workflow, a master pre-mix is prepared by mixing a defined 
amount of liver microsomes proteins with NADPH regeneration system 
(glucose-6-phosphate and glucose-6-phosphate dehydrogenase), which 
converts NADP+ into NADPH, and thus required to start the CYP450 reaction. 
Then the pre-mix is mixed with VIVID fluorogenic substrate and as 
demonstrated in Figure 6.2. The feature of using the regeneration system is to 
minimise the fluorescence background of NADPH, which is the main 
component of the mono-oxygenase cycle.  
 
Figure 6-2. A schematic representation of a kinetic Vivid® CYP450 Assay. In the first 
step, a master pre-mix is prepared by combining liver microsomes with regeneration 
system (consisting of glucose-6-phosphate and glucose-6-phosphate 
dehydrogenase). Next, the master pre-mix is mixed in step 2 with the corresponding 
VIVID substrate and NADP+ to initiate the reaction. Finally, in step 3, fluorescence 
readings are continuously measured over time for kinetics-related calculations.  
 
Two examples of VIVID substrates are ethoxymethyloxy-3-cyanocoumarin 
(EOMCC) and 7-benzyloxymethyloxy-3-cyanocoumarin (BOMCC). They 
possess a high aqueous solubility, which allows using a lower concentration 
of the organic solvents such as acetonitrile and DMSO (Trubetskoy et al., 
2005b). This feature is of a high importance as the organic solvents are well 
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known to affect the metabolism by CYP450 (Easterbrook et al., 2001). A 
further advantage of the VIVID assay substrates is their emission and 
excitation wavelengths. As opposed to many other fluorophores, the emitted 
wavelengths lie further away from the wavelengths of NADPH. Although, the 
VIVID substrates EOMCC and BOMCC are used to assay CYP1A2 and 
CYP3A4, respectively, they have limited specificity, which is an inherent 
challenge of analysing CYPs. For example, BOMCC has cross-reactivity with 
other isoforms including, CYP2B6, CYP2C9, and CYP3A5, and EMOCC 
towards CYP2C19, CYP2D6, and CYP2E1. 
The VIVID assay has been applied to assess the capacity of several chemical 
and herbal compounds in inhibiting CYP450 enzymes activity by previous 
studies. Trubetskoy et al have investigated the effect of a CYP inducer, 
rifampicin, on CYP3A4 activity in DPX-2 cell line (Trubetskoy et al., 2005a), 
Marks et al investigated the metabolism and inhibition of CYP2E1 by known 
CYP2E1 inhibitors such as propofol and ketoconazole (Marks et al., 2002) 
Another study evaluated the effect of short term and long term exposure of an 
herbal supplement on oral bioavailability of nevirapine (Minocha et al., 2011) 
using the VIVID assay. Furthermore, novel CYP450 inhibitors have been 
evaluated by our group using the high throughput VIVID assay (Sellars et al., 
2016). The VIVID assay has also been applied on the human liver microsomes 
to assess the effect of some haplotypes in cytochrome P450 oxidoreductase 
(CYPOR) gene on the activity of CYP3A4 (Moutinho et al., 2012). Hence, the 
VIVID assay provides a robust tool to understand the mechanism behind drug-
drug interaction, drug resistance, drug response and toxicity. Furthermore, it 
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is considered a high throughput and sensitive step in drug development 
studies.  
Liver microsomes are the most widely used amongst in vitro technologies in 
metabolizing enzymes activity profiling (Fasinu et al., 2012), but has not 
previously been studied using the VIVID assay.  
In order to measure enzyme activity from liver microsomes, VIVID assays were 
slightly modified. Microsomal proteins were enriched via centrifugation and 
ultracentrifugation to get rid of the majority of proteins that might interfere with 
the enzyme activity assessment.  
6.1.1 Aims of the chapter 
Since the alteration in expression does not necessarily reflect alteration in 
enzyme activity and as we are using liver microsomes extracted from mouse 
liver, the first aims of this chapter is:  
a. To determine if the VIVID assay could be used to measure CYP1a2 
and CYP3a activity in mouse liver microsomes 
b.  To test and optimise the ability to use VIVID substrates in measuring 
the endogenous CYP450s activities.     
c. To evaluate and correlate the observed changes, particularly in 
CYP450 isoforms (CYP1a2 and 3a), in previous chapters (Chapter 4 
and 5) by using the VIVID assay  
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6.2 Material and Method 
Materials and methods used in the VIVID assay were described in detail in 
Sections 2.1.3 and 2.2.1, respectively. Samples of liver microsomes from 
female (FMS) and male (MMS) mice treated with DOX and PAX, in addition to 
their solvents prepared in the previous chapter (section 5.2.1) were used for 
the VIVID assays (Figure 6.3).  
 
Figure 6-3. Flow diagram showing the steps of measuring the activity of CYP450 
enzymes using VIVID assay. No treatment – NT, treated female (FMS) and male (MMS) 
mice sets, were prepared in Chapter 5. Then the optimal amount of microsomal 
proteins was determined and used further for VIVID activity assay. 
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6.3 Results 
6.3.1 Determine whether the VIVID assays detect and enable the 
measurement of mouse liver CYPs 
6.3.1.1 Optimisation of mouse liver microsomes protein 
concentration 
Normal and treated mouse liver microsomes from both sexes were used to 
evaluate the activity of CYP1a2 and CYP3a. initially, recommended 
concentration of substrate (3µM EOMCC for CYP1a2 or 5µM BOMCC for 
CYP3a) was incubated with different amount of microsomal proteins (6.25 to 
120 mg/ml); thus normal untreated (NT) male samples (three mice) were used 
to determine the best concentration of microsomal proteins that can be used 
further for measuring the activity of CYP1a2 and CYP3a (Figure 6.4). 
Keeping the substrates concentrations constant in each reaction and 
increasing the concentration of the microsomal protein displayed a 
corresponding increase in enzyme activity. The rate (enzyme activity) of 
metabolite formation in the reaction of CYP1a2/CYP1A2 with the fluorogenic 
substrate (EOMCC) started to plateau at concentrations 40 mg/ml and above 
(Figure 6.4A). The rate of CYP3a/CYP3A4 activity exhibited similar properties 
but at different concentration (25 mg/ml) of liver microsomal proteins (Figure 
6.4B). The term “activity” will be expressed by rate, which is computed 
throughout this Chapter by taking the slope of relative fluorescence units 
(RFU) per minute within 10 – 20 minutes. 
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Figure 6-4. Determination of the optimal concentration of mouse liver microsomes. A 
serial dilution of microsomes was incubated with either 3µM EOMCC substrate for 
CYP1a2 (A) or 5µM BOMCC substrate for CYP3a (B). The VIVID assay was carried out 
twice and readings were taken every minute for 60 minutes as relative fluorescence 
unit (RFU). Recombinant human CYP1A2 (5nM) and CYP3A4 (5nM) baculosomes were 
included as standards 
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The maximum reaction velocity (Apparent Vmax) and Michaelis-Menten 
constant (Km), which would be the half of the concentration that would give 
Vmax were determined using the Michaelis-Menten’s equation (Figure 6.5, 
Table 6.1).  
 
 
Figure 6-5. The rates (RFU/min) of enzyme activity for CYP1a2 (A) and CYP3a (B) were 
calculated by taking the slope at 10-20 minutes (n=3), and then the rate was plotted 
versus corresponding protein concentration of liver microsomes to calculate Vmax and 
Km.      
 
For both activity assays, 25mg/ml was determined to be the optimal 
concentration to be used for mouse CYP activity assays.   
Table 6-1. The kinetic parameters Vmax and Km were calculated. GraphPad Prism was 
used to calculate best-fit values based on Michaelis-Menten equation  
Michaelis-Menten parameters CYP1a2 CYP3a 
Vmax (mmol/min/mmol) 0.187 ± 0.006 0.1533 ± 0.01 
Km (mg/ml) 22.99 ± 2.31 30.12 ± 5.63 
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6.3.1.2 Optimisation of the substrate concentration 
The optimized concentration of liver microsomes (25mg/ml) was used in order 
to determine the optimal concentration of EOMCC and BOMCC substrates 
and compare the rate of reactions to human CYP baculosome standards 
(Figure 6.6A and B). Each substrate, EOMCC (6 to 1.5µM) and BOMCC (10 
to 2.5µM), was titrated with a constant amount of mouse liver microsome 
(25mg/ml). 
In both cases, there was a linear increase in CYP activity with increasing 
substrate concentrations. Based on the kinetics calculation (Table 6.1) for the 
male set, the concentration 25mg/ml compared well to the recombinant human 
CYP1A2 or CYP3A4. 3µM and 10µM of substrate EOMCC and BOMCC, 
respectively, were chosen for screening activity assays using 25mg/ml of 
mouse liver microsome proteins. These optimised concentrations from male 
liver microsomes were used as well for female treated and treated samples.        
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Figure 6-6. Determination of the rate of CYP1a2 and 3a from male mouse microsomal 
protein (25mg/ml) and baculosome CYP1A2 and CYP3A4 using different 
concentrations of EOMCC substrate for CYP1a2/CYP1A2 activity (A) and BOMCC for 
CYP3a/CYP3A4 activity.  
 
Next, to show the best concentration of substrate that can detect a minimal 
activity for CYP450, Apparent Vmax and Michaelis-Menten constant (Km), were 
calculated for optimised amount of microsomal proteins (25 mg/ml) using serial 
dilution of BOMCC and EOMCC substrates (Table 6.2). 
Table 6-2. The kinetic parameters Vmax and Km were calculated based on serial dilution 
of substrates. GraphPad Prism was used to calculate best-fit values based on 
Michaelis-Menten equation  
Source of 
CYP450 
Michaelis-Menten 
parameters 
EOMCC BOMCC 
Baculosome 
CYP450 (5nM) 
Vmax (mmol/min/mmol) 0.086 ± 0.002 0.1533 ± 0.01 
Km (µM) 3.8 ± 0.34 0.34 ± 0.001 
Microsomal 
proteins 
(25mg/ml) 
Vmax (mmol/min/mmol) 0.072 ± 0.004 1.58 ± 0.11 
Km (µM) 3.60 ± 0.28 5.4 ± 0.18 
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6.3.2 Determination of sex-specific CYP1a2 and CYP3a activity 
In the present work, the activity of CYP1a2 and CYP3a isoforms in mouse liver 
over both sexes was determined. Three of untreated male and female mice 
were used to evaluate the variation (Figure 6.7).  
 
 
Figure 6-7. Comparison of the activity rates of untreated liver microsomal proteins 
from male (n=3) and female (n=3) mice in duplicate. A total of 25mg/ml was incubated 
with 3µM EOMCC substrate (A) for CYP1a2 activity and 10µM BOMCC substrate (B) 
for CYP3a activity. 
  250 
By using 25mg/ml of liver microsomes from untreated male and female 
samples, the rate of activity of CYP1a2 was significantly higher (p-value, 
0.0185) in male mice compared to female mice. The opposite was observed 
for CYP3a activity, where microsomal livers from female mice showed higher 
(p-value, 0.0427) level of activity than male mice    
6.3.3 Measurement of CYP activity in treated male and female sets 
In a similar, but expanded the experiment to the sex-specific study, 25mg/ml 
of mouse liver microsome proteins from anti-cancer drug treated mice (FMS 
and MMS), were analysed in the VIVID assay. The activity of CYP1a2 has 
decreased significantly to about 50% upon administration of PAX (p-value, 
0.034) and PS (p-value, 0.049) compared to untreated controls in male mice, 
whereas no significant effect has been observed in females (Figure 6.8). On 
the other hand, DOX has increased the activity of CYP1a2 in both male (p-
value, 0.414) and female (p-value, 0.095) mice but not to a significant level 
(Figure 6.8). 
Regarding CYP3a, there was a significant increase (p-value, 0.0068) in the 
activity of CYP3a in response to DOX in females. This inducing effect has been 
also observed in males with DOX; however, there was notable inter-individual 
variation (Figure 6.9). 
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Figure 6-8. The effect of drugs and their solvents on CYP1a2 activity rate for female 
and male liver microsomes. The rates were calculated using the slope for 10-20 
minutes. All treatments from both sexes had three mice (except NS in female had two 
mice). A total of 25mg/ml of each sample was incubated with 3µM EOMCC substrate. 
Each bar represents the average rate in triplicate with standard deviation.  
 
 
Figure 6-9. The effect of drugs and their solvents on CYP3a activity rate for female 
and male liver microsomes. The rates were calculated using the slope for 10-20 
minutes. All treatments from both sexes had three mice (except N.S in female had two 
mice). A total of 25mg/ml of each sample was incubated with 10µM BOMCC substrate. 
Each bar represents the average rate in triplicate with standard deviation.   
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6.4 DISCUSSION 
In this chapter, we aimed initially to establish a robust workflow that can be 
employed for measuring the activity of CYP450 from the biological complex 
mixture (i.e. liver microsomes) based on fluorescence assay. Then, we 
investigated and correlated (with previous results) the sex effect, as well as 
the anticancer drugs (DOX and PAX) effect on expression and activity of the 
mouse equivalents of CYP1a2 and CYP3a which play a major role in drugs 
metabolism and cancer susceptibility in humans.  
In the first instance, the VIVID assay was successfully applied to mouse liver 
microsome models, which had not previously been demonstrated. Comparing 
the kinetics parameters (Km and Vmax) for mouse CYP1a2 and CYP3a to 
human baculosome CYP1A2 and CYP3A4 exhibited (Table 6.2) a very close 
of maximum rate of reactions (Vmax) between human and mouse CYP1A2, 
indicating a high activity of mouse CYP1a2 by using 25 mg/ml of proteins that 
was equal to 5nM of baculosome CYP1A2. Using anti-CYP3A4 antibody for 
mouse liver microsomes measured the activity of multiple mouse CYP3a 
family members (CYP3a11, CYP3a16, CYP3a25 and CYP3a41), identified by 
proteomics (Chapter 4, Table 4.8). Because of the promiscuous nature of 
CYPs, activity from other mouse CYPs may also contribute to the observed 
activity.    
6.4.1 Sex variation in CYP1a2 and CYP3a activity  
In our results, the activity of CYP1a2 has been higher in untreated males than 
in females. This finding supports our results in the previous chapter, which 
revealed a significantly higher expression of CYP1a2 in untreated males 
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compared to females. Consistent with our findings, the previous study has 
found lower clearance of Clozapine, which is mainly metabolised by CYP1A2 
in women (Banov et al., 1993). Moreover, Gunes et al have found a higher 
activity of CYP1A2 in males than in females in Turkish population when 
investigating the metabolism of caffeine, a major substrate for CYP1A2 
(Gunes et al., 2009). Furthermore, and consistent with our study an in vitro 
study has demonstrated a higher metabolism of phenacetin O-deethylation, 
which is a marker for CYP1a2 activity, in the liver microsomes of the male mice 
than in females (Löfgren et al., 2004).  
In regard to CYP3a, our results have revealed a significantly higher activity in 
females compared to males. Correspondingly, proteomics data from Chapter 
4, resulted in the identification of five CYP450 isoforms (CYP3a11, CYP3a13, 
CYP3a16, CYP3a25, CYP3a41) out from six isoforms, which are believed to 
be homologue to human CYP3A4. Moreover, two of them (CYP3a16 and 
CYP3a41) have not been detected in Set A (Male mice), indicating them 
female-predominant isoforms that may a possible role of inducing the activity 
of CYP3a in female mice. Furthermore, the other possible isoforms rather than 
CYP3a that can metabolise BOMCC substrate were not detected in 
proteomics data of Sets A and B, indicating low amount expressed in mouse 
liver of both sexes.   
However, our finding is in line with the previous study that found higher N-
dealkylation of verapamil by CYP3A4 in human females (Wolbold et al., 2003). 
Moreover, an in vitro study (Schmidt et al., 2001) has demonstrated a higher 
activity of CYP3A4 in women when comparing the activity of the enzyme in 10 
male and 10 female human liver microsomes using high-sensitive HPLC/MS 
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and -UV detection methods. Also, Parkinson et al have found that the activity 
of CYP3A4 in human liver microsomes in females is twice as high as in men, 
which is consistent with our results (Parkinson et al., 2004).  
The sex difference in the expression of CYP3A might be attributed to the 
pregnancy-associated progesterone hormone, which is a ligand for the nuclear 
receptor, pregnane X receptor (PXR) (Timsit and Negishi, 2007), whose 
activation is known to induce CYP3A expression (Harmsen et al., 2007). 
Moreover, it has been found that growth hormone (GH) regulates the 
expression of CYP3A through enhancing the binding of the transcriptional 
factors to the CYP3A promoter, inducing its expression (Li et al., 2015a). Here, 
it is worth mentioning that the GH is known to be pulsatile in male mice while 
it is constant in females (Waxman and Holloway, 2009), which results in sex 
difference in CYP3a4 expression. Such findings have been supported by 
another study (Dhir et al., 2006) which has revealed an up-regulation of 
CYP3A4 mRNA expression with constant treatment with GH, whereas 
pulsatile GH treatment has shown a suppression of CYP3A4 mRNA 
expression in primary human hepatocytes.  
6.4.2 Effect of PAX and DOX on CYP1A2  
Regarding the activity of CYP1A2 in response to PAX, our results have shown 
a significantly reduced activity of CYP1A2 in PAX treated compared to the 
untreated mice in males but not in females. However, PS (CrEL, DMSO) has 
also shown a significant decrease in CYP1A2 activity and an approximately 
similar activity compared to PAX. This observation leads us to the assumption 
that the decrease in activity was due to the solvent rather than the drug 
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exposure. In agreement with our results, DMSO with the concentration 2% has 
been found to have an inhibitory effect on CYP1A2-mediated phenacetin O-
deethylation (Nirogi et al., 2011). Likewise, similar inhibition has been 
observed when investigating the effect of DMSO (1%) using caffeine N3-
demethylation as a probe reaction, which has revealed 30% decrease in 
CYP1A2 activity (Hickman et al., 1998). In good agreement, as a part of the 
previous study conducted in our lab to evaluate the inhibitory effect of novel 
CYP450 inhibitors, different solvents on CYP1A2 and CYP3A4 were 
evaluated, among them, 1% of DOMS has shown 28% inhibition in CYP1A2 
activity. So we suggest that the effect of DMSO on CYP1A2 may occur at the 
protein level rather than the activity, as we also observed a decrease in protein 
expression of CYP1a2 by Western blot (Chapter 5) in response to DMSO. In 
addition, PAX has exhibited a decrease in CYP1a2 protein level by proteomic 
profiling (iTRAQ ratio = 0.88) (Chapter 4).  
The sex difference that was observed by PS in males, but not in females, might 
be attributed to the higher levels of CYP1a2 expressed in males, so the 
inhibitory effect was more readily observed.  
DOX has increased CYP1a2, however high inter-individual variation affected 
the interpretation, making the difference insignificant. To the best of our 
knowledge, we are the first to study that investigates the effect of DOX on the 
activity of CYP1a2 in liver.  
6.4.3 Effect of PAX and DOX on CYP3a  
PAX increased the activity of CYP3a in both males and females; however, this 
increase was not significant due to the high inter-individual variation. DOX-
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treated mice showed a significant increase in the activity of CYP3a in females 
with no significant effect for the DOX solvent (NS). The effect of acute DOX 
administration on CYP3A4 activity has not been extensively studied, however, 
CYP3A4 mRNA has been found to be up-regulated in DOX-resistant MCF7 
cell line (AbuHammad and Zihlif, 2013).  
DOX is a major substrate of CYP3A4 (Rose, 2005) suggesting that mRNA 
expression of CYP3A4 may be induced in response to DOX administration to 
accelerate its metabolism and clearance, and thus develop DOX resistance. 
The mechanism by which CYP3A4 is induced in response to DOX has been 
proposed (Goldstein et al., 2012), in which DOX administration led to 
phosphorylation, and therefore activation of p53 in human liver cells. Such 
activation resulted in inducing CYP3A4 at both gene and activity levels.  
As for PAX and CYP1a2, observing sex difference in the effect of DOX on 
CYP3a can be explained by having higher levels of the enzyme in the females, 
making the difference more obvious. In addition, it is noteworthy that CYP3a 
activity has also been increased in male in response to DOX but not to a 
significant level. GH again, may play a role as continuous GH, observed in 
females, was also found to increase the activity of human CYP3A4, while a 
decrease in activity has been noticed with pulsatile GH, found in males (Jaffe 
et al., 2002).  
In conclusion, our results have shown that the activity of the enzymes CYP1A2 
and CYP3A shows differential extent with sex, and the anticancer drugs DOX 
and PAX can alter the activity of the metabolizing enzymes of interest. 
Moreover, these drugs have also shown a significant effect on CYPs in the 
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previous data (Chapter 4 and 5) at protein level. This emphasizes the 
importance of performing further studies in such context with more specific 
substrates, to better understand the levels of alteration and as the alteration in 
activity can affect drugs response and toxicity. 
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7 General discussion and future work 
7.1 General discussion 
During drug development stages, the high failure rate of new drug candidates 
in preclinical or clinical studies due to hepatotoxicity is considered as a 
substantial problem. Moreover, it became very clear that the unexpected 
hepatotoxicity is one of the major causes for the withdrawal of drugs from the 
market. Hence, an urgent need has emerged to develop reliable and robust 
approaches for predicting the susceptible toxicity and revealing the 
mechanism by which drug-induced hepatotoxicity develops.  
Several in vivo and in vitro hepatic models have been established and used to 
investigate the possible mechanisms of drug toxicity on liver. However, the 
former has provided more sensitive and reliable results, in addition affording 
insights into the molecular mechanism of drug-induced hepatotoxicity (Suter 
et al., 2011). In this study, we used the mouse as an animal model that 
Patterson et al, proposed as a highly controllable experimental system, which 
is extensively used for studying human disease. Moreover, models, in which 
carefully chosen human cell line xenografts are grown on immune-deficient 
mice, have been widely used to evaluate the response to a range of anti-
cancer drugs (Patterson et al., 2007). Before conducting any experiment on 
animals, several factors were taken into account in compliance with the 3R’s 
rules including, the dose of drug, duration of exposure, the number of animals, 
sex, control system, etc. (Parasuraman, 2011).  
In order to perform a large-scale analysis of a complex biological system (e.g. 
liver microsomes) to identify potential biomarkers in response to drugs, an 
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advanced technique such as quantitative proteomics is necessary. However, 
identification of low abundance and membranous proteins represent the main 
challenge for proteomics.  
Confirmation of the biomarkers identified by proteomics approach is a crucial 
step due to possible biological and technical variations (de Gramont et al., 
2015). Different approaches such as multiplex reaction monitoring (MRM), 
Western blotting and ELISA can be used based on the properties of identified 
biomarkers. Despite the low number of commercially available antibodies and 
low specificity of others, Western blotting is widely used in the proteomics 
studies for protein identification and quantification purposes.  
Therefore, downstream approach to confirm the change in expression of the 
particular protein is a key step to building a reliable pipeline in biomarkers 
development. Different approaches such as multiple reaction monitoring 
(MRM), Western blotting, enzyme assays and ELISA can be used to support 
proteomics analysis based on the properties of identified biomarkers. As there 
are a large number of commercially available antibodies (though frequently of 
poor specificity), Western blotting is widely used in proteomics studies for 
protein identification and quantification purposes. Western blotting of MUPs 
and CYPs, along with VIVID assays specific for selected CYPs has useful 
provided complementary information to support the proteomics data.  
VIVID assay is a high-throughput screening assay that has been designed for 
examining the inhibitory effect of various compounds on specific baculosomes 
or bactosomes CYP450 activity. The microtiter plate format that used in VIVID 
assay, allows analysis of multiple samples simultaneously, providing relatively 
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high throughput analysis. VIVID assay can monitor the fast conversion of the 
substrate to product on a fluorescence-based microtiter plate reader, allowing 
rate change monitoring every minute. Moreover, VIVID assay is relatively 
quick (30 minutes). However, substrates used in VIVID system are not 
absolutely specific for each CYP, therefore when analysing heterogeneous 
mixtures, a number of components could contribute in the assay. In this 
project, VIVID assay was modified to be used for measuring the activity of 
selected liver microsomal CYP450s. 
Being capable of identification, validation and measuring the activity of hepatic 
proteins such as CYP450 in this project, provided the opportunity to correlate 
the quantity of particular proteins with their activities, thus gaining a deeper 
insight in their response to drug toxicity. 
The eventual aim of this thesis was to investigate the effect of selected anti-
cancer drugs on liver microsomes through evaluating the alteration in 
microsomal proteins in response to these drugs and finding out more reliable 
and sensitive biomarkers of hepatotoxicity. Furthermore, to get a better 
understanding of the underlying mechanistic basis for chemotherapy-induced 
liver injury. Therefore, a single dose of the anti-cancer drug was used to treat 
mouse for 24 hours intraperitoneally, before being killed and organs were 
collected.  
The doses of drugs used in this project were determined in the separated 
experiment as the maximum tolerated dose by mouse (section 4.2.2.4), which 
is considered typical in acute toxicological studies. Moreover, it has been 
concluded that 24 hours of exposure is enough to reduce cell viability in 
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toxicological studies. Previous transcriptional and proteomics studies showed 
that 24 hours were enough to induce changes at gene and proteins level, 
respectively, after DOX administration (Hammer et al., 2010, Wang et al., 
2009).   
Nevertheless, applying these conditions of treatment was a main challenge in 
this project. For instance, none of the previous mentioned affected 
mitochondrial antioxidants by DOX (i.e. CAS, SOD, GSH-Px and TXNDC) was 
significantly affected in our result. Alshabanah et al, have demonstrated 
significant decreases in CAS, GSH-Px, GSH and SOD activities in rat livers 
treated with high cumulative dose (18mg/kg/10days) of DOX compared to 
(10mg/kg/24 hours), whilst, there were no significant changes at low and 
intermediate cumulative doses (i.e. 6 and 12 mg/kg/10days) (Alshabanah et 
al., 2010).  
Duration of treatment was also considered in TCPOBOP treatment, which has 
been designed to resemble phenobarbital in CYP induction via CAR activation 
(Kelley et al., 1985). In this thesis, the effect of TCPOBOP was evaluated and 
showed comparable results with previous proteomics study (Lane et al., 2007). 
However, the effect of TCPOBOP was to some extent limited and this might 
be due to short duration of treatment (3mg/kg/24 hours) compared to Lane et 
al, who used 3mg/kg/4 days (Lane et al., 2007). Moreover, this project 
highlighted the importance of considering sex variation in further experimental 
design. A result from 5FU, which has been included in both proteomics studies 
for reproducibility purpose, showed little overlapping in the number of 
regulated proteins between both datasets, suggesting the role of sex in 
different protein responses. Hence, some proteins and their response to drug 
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or toxicity may be specific to one sex and remain to be clarified. It has been 
reported in previous studies conducted on rat and mouse livers that the 
expression of about 1000 genes is sex-dependent (Waxman and Holloway, 
2009). For instance, in our results, 9 CYP450 isoforms were uniquely identified 
in female mice (Set B) and thought to be female-predominant enzymes, while 
one isoform was uniquely identified in male mice (Set A) (summarized in 
Figure 4.9). Several studies showed that the expression of human CYP3A4 
and its homolog in mouse, which is responsible for metabolizing almost 60% 
of commercially available drugs, shows sex dimorphism (Diczfalusy et al., 
2008, Sakuma et al., 2009, Parkinson et al., 2004). A study by Sakuma et al, 
demonstrated that three isoforms in mouse (CYP3a16, CYP3a41, and 
CYP3a44), homologous to human CYP3A4, are female-predominant. 
Consistently CYP3a16 and CYP3a41 were identified in our work and uniquely 
only in female mice. The authors proposed that the dimorphism in gene 
expression is not confined to DMEs only, other proteins such as lipoproteins, 
pheromone binding proteins and fatty acid homeostasis proteins have shown 
sex dimorphism. Therefore, our study also highlighted MUP, a pheromone 
binding protein, as a protein of interest. Four isoforms of MUP were identified 
in male mice compared to 2 identified in female mice, reflecting the naturally 
occurring higher levels in the former.  
As the main limitation of using proteomics is identifying the low abundant and 
membranous proteins, advances in MS-instrumentation and superior 
fractionation methodologies were able to enrich and target proteins of interest 
in the current study, thus overcoming these obstacles. The present project has 
succeeded in evaluating and optimizing a proteomics workflow that has been 
  264 
employed in investigating the influence of major anti-cancer drugs on liver 
microsomes. Moreover, to the best of our knowledge, this research has 
identified unambiguously the maximum number of CYP450 enzymes including 
highly homologous isoforms compared to the published literature by using the 
shotgun approach, making it a valuable approach for studying the influence of 
drugs on DMEs (particularly CYP450s).  
Moreover, MS-based proteomics approach is ideal to study the CYP450 
polymorphisms, where particular peptides that contain single nucleotide 
polymorphism (SNP) can be identified. CYP450s are a well characterised 
group of enzymes whose activity has been shown to be significantly affected 
by SNP variants. For example, CYP2D26 which is responsible of metabolism 
approximately 25% of current drugs showed a large inter-individual variation 
in the activity, thus variable drug metabolism and drug response (Koski et al., 
2007). The CYP2D6 activity ranges significantly within a population and 
includes ultra-rapid metabolizers (UMs), extensive metabolizers (EMs), 
intermediate metabolizers (IMs) and poor metabolizers (PMs) (Zhou, 2009). 
To address this polymorphism, the ProteoGenomics approach uses proteomic 
data to provide protein-level evidence of gene expression and to help refine 
gene models. It can help in confirming translated genes, identifying PTMS, 
and identifying splice variant, mutations, and/or polymorphism. Traditional 
identification approaches such as Western blotting and activity-based assays 
cannot define such alterations. However, this project did not correlate the 
sequence of identified CYP isoforms to their genes. Furthermore, little is 
known about CYP450 variant in mouse, particularly for cloned mouse. Further 
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studies concerning ProteoGenomics would be of a high importance applying 
the advantages of the new MS instruments (Orbitrap Fusion). 
The current study was effectively able to detect and quantify bands of CYP1a2 
and CYP3a isoforms by using anti-human CYP antibodies. Furthermore, and 
for the first time, it was able to measure the activity of CYP1a2 and CYP3a 
from a complex biological sample such as mouse liver microsomes, by the 
means of VIVID assay. 
Traditional proteomics approaches such 2D-DIGE has been used intensively 
before for evaluating the hepatotoxicity of numerous drugs and validating new 
biomarkers (Van Summeren et al., 2013, Hammer et al., 2010). However, 
despite the increasing interest in using the advanced proteomics approaches 
such as shotgun approach in drug assessment, minor studies were directed 
to investigate the mechanisms of drug-induced hepatotoxicity  
In accordance with previous studies conclusions and our observations, 
pharmacoproteomics is a powerful technique that can be involved in all 
aspects of drug development including, drug target discovery. New 
advancements in MS have increased the sensitivity of detection and resolution 
(Chapter 1, Table 1.5). However, attempt to identify interesting deregulated 
proteins in disease or treated tissues is fairly not a straightforward process and 
a number of obstacles may come across. Therefore, strong challenges in 
sample preparation, MS-instrumentation, database and statistical analysis 
need to be considered and handled prior to designing the experiment. One of 
the important challenges is heating production during proteins extraction for 
enzyme activity, thus an optimised method was used to overcome it. Another 
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challenge in pharmacoproteomics and particularly in the present study is the 
repeatability and reproducibility issue. Such issue is pivotal and considered 
one of the most critical parts of the biomarker discovery procedure. The costly 
materials and the long time that iTRAQ and MALDI-TOF MS approaches need 
were a remarkable obstacle in achieving the reproducibility in the current 
study.  
In conclusion, we propose that pharmacoproteomics is a valuable approach to 
be used in future toxicological studies and biochemical analysis, aiming to 
assess the hepatotoxic effect of new candidates as well as already established 
drugs.  
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7.2 Future work 
The data generated from the current study has provided strong evidence about 
the employment of shotgun proteomics in studying liver microsomes. In 
addition to giving a preliminary view about the effect of selected drugs on 
mouse liver, which encourages conducting further verification studies. The 
main limitations, which were not anticipated at the beginning of the project, 
were using control mice that were not absolutely mimicking the drug 
treatments and sex variation between Set A and Set B. However, these 
limitations were addressed in subsequent studies, where two drugs (DOX and 
PAX) were selected based on previous results to treat male and female mice 
with inclusion of solvents and untreated mice. As a comprehensive research 
conducted for the first time, a number of further experiments would be 
beneficial, including:  
a. Evaluating the effect of the time course of drug exposure on the 
regulated proteins, by giving a single dose of an anticancer drug and 
placebo and scarifying the animal after 24,48 and 96 hours. 
b. Confirming the absolute quantity of identified CYP450 isoforms using 
selected reaction monitoring (MRM) approach. 
c. Surface plasmon resonance or HPLC approach could be developed to 
determine if any drugs bind to MUPs, initially using recombinant form. 
d. Employing human cell lines enriched with drug metabolising enzymes, 
such as HepaRG2 cell line, to correlate the changes in CYPs in our 
observations with human tissue. 
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e. Considering other mouse organs, such as kidney, to determine 
pharmaco- and toxico-proteomics biomarkers, using analogous 
proteomics strategies to those used in this project.  
f. Validating other potential biomarkers for their cellular role in drug-
induced liver toxicity. 
g. Employing proteomics strategies to analyse the xenograft and the effect 
of anticancer drugs on it. 
  
  269 
8 Reference 
ABDALLAH, C., DUMAS-GAUDOT, E., RENAUT, J. & SERGEANT, K. 2012. 
Gel-based and gel-free quantitative proteomics approaches at a 
glance. International journal of plant genomics, 2012. 
ABUHAMMAD, S. & ZIHLIF, M. 2013. Gene expression alterations in 
doxorubicin resistant MCF7 breast cancer cell line. Genomics, 101, 
213-220. 
ADINA-ZADA, A., ZECZYCKI, T. N. & ATTWOOD, P. V. 2012. Regulation of 
the structure and activity of pyruvate carboxylase by acetyl CoA. 
Archives of biochemistry and biophysics, 519, 118-130. 
AFSAR, A., LEE, C. & RIDDICK, D. S. 1996. Modulation of the expression of 
constitutive rat hepatic cytochrome P450 isozymes by 5-fluorouracil. 
Canadian journal of physiology and pharmacology, 74, 150-156. 
AIKEMU, A., AMAT, N., YUSUP, A., SHAN, L., QI, X. & UPUR, H. 2016. 
Attenuation effect of Abnormal Savda Munziq on liver and heart toxicity 
caused by chemotherapy in mice. Experimental and Therapeutic 
Medicine, 12, 384-390. 
AKHDAR, H., LEGENDRE, C., ANINAT, C. & MORE, F. 2012. Anticancer drug 
metabolism: chemotherapy resistance and new therapeutic 
approaches. Topics on drug metabolism. InTech, Rijeka, 137-171. 
AKI, Z., KOTILOGLU, G. & ÖZYILKAN, Ö. 2000. A patient with a prolonged 
prothrombin time due to an adverse interaction between 5-fluorouracil 
and warfarin. The American journal of gastroenterology, 95, 1093. 
AL-ASMARI, A., AL-ZAHRANI, A., KHAN, A., AL-SHAHRANI, H. & AL AMRI, 
M. A. 2016a. Taurine ameliorates 5-flourouracil-induced intestinal 
mucositis, hepatorenal and reproductive organ damage in Wistar rats 
A biochemical and histological study. Human & experimental 
toxicology, 35, 10-20. 
AL-ASMARI, A., KHAN, A. & AL-MASRI, N. 2016b. Mitigation of 5-fluorouracil-
induced liver damage in rats by vitamin C via targeting redox-sensitive 
transcription factors. Human & experimental toxicology. 
ALBERTINI, S. & SUTER, L. 2000. Two-dimensional database of mouse liver 
proteins: changes in hepatic protein levels following treatment with 
acetaminophen or its nontoxic regioisomer 3-acetamidophenol. 
Electrophoresis, 21, 21482161Goldring. 
ALEXANDRE, J., HU, Y., LU, W., PELICANO, H. & HUANG, P. 2007. Novel 
action of paclitaxel against cancer cells: bystander effect mediated by 
reactive oxygen species. Cancer research, 67, 3512-3517. 
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